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Introduction: Despite intense research efforts and improvements to mortality rates, breast cancer remains 
the leading cause of premature cancer death for women.  Identifying women at highest risk is vitally 
important for screening decisions that may have a critical impact on diagnosis and prognosis.  A family 
history of breast cancer is a well-established risk factor, but it can be unreliable.  An easily measured and 
accurate biomarker of breast cancer risk would be a significant advancement to public health by allowing 
targeted screening of women who would benefit most. It may also reveal underlying molecular 
mechanism that could illuminate pathways to prevention. 
 
Incidence rates of breast cancer have remained unmoved owing to the lack of known modifiable risk 
factors.  This may be due in part because most breast cancer research has focused on behaviors and 
exposures in, or recalled from, adulthood.   The studies detailed in this dissertation seek to investigate the 
associations between oxidative stress and breast cancer risk in both adult women and adolescent girls with 
a family history of breast cancer. 
 
Methods: To determine the relationship between oxidative stress and breast cancer risk in adult women 
with a family history of breast cancer we measured and compared urinary levels of 8-OxodG and F2-
Isoprostane in a prospective matched case control study nested within the New York Breast Cancer 
Family Registry.  Cases (N=73) were individually matched with 2 controls on age, year of urine donation, 
menopausal status, and race.  Conditional logistic regression methods were used to determine the odds of 
breast cancer from oxidative stress controlling for other risk factors for breast cancer and potential 
confounders. 
 
To better understand how oxidative stress levels change during puberty in girls and if such change is 
modified by a family history of breast cancer, we measured and compared levels of those same urinary 
biomarkers of oxidative stress in adolescent girls with and without a family history of breast cancer from 
the New York site of the Lessons in Epidemiology and Genetics of Adult Cancer from Youth cohort 
(LEGACY).  Oxidative stress levels were measured both cross-sectionally at baseline and longitudinally 
every 6-months for up to 18-months.  Linear regression was used for the cross-sectional analysis and 
repeated measures analysis using mixed models was employed for the longitudinal analysis.  
 
In both studies, biomarker levels were measured using well-established ELISA methods and adjusted for 
hydration status using specific gravity. 
 
Results: In the case control study of adult women we found that both 8-OxodG and F2-Isoprostane levels 
were significantly associated with a reduced risk of breast cancer after adjusting for BRCA1/2 mutation 
status, time between menarche and parity or menopause, and BMI (8-OxodG: β10-unit= -0.14, OR=0.87, 
p=0.03; F2-Isoprostane: β10-unit = -0.53, OR=0.59 , p=0.03).  This inverse association was strongest among 
women under 50 and in women with a BMI below 25 for both biomarkers, and among women who 
reached menarche before age 14 for F2-Isoprostane.  Overall, women in the highest tertile of either 
oxidative stress biomarker had approximately 50% reduced odds of breast cancer diagnosis. 
 
In our cross-sectional study of adolescent girls, we found that there was no significant difference in either 
oxidative stress biomarker in girls based on their family history of breast cancer.  F2-Isoprostane levels 
were significantly associated with breast development measured by Tanner stage even after adjusting for 
age, age-specific BMI category and race (β=0.28, p=0.01).  8-OxodG levels were not significantly 
associated with age, BMI, race or Tanner stage at baseline but they were significantly associated with 
overweight/obese BMI but only among girls with a breast cancer family history (β=0.47, p=0.01).  
Change in 8-OxodG levels was significantly higher over the follow-up period in girls with a family 
 
history of breast cancer.  This result remained significant after categorical measures of age, BMI, Tanner 
breast stage and race were added to the longitudinal model.  F2-Isoprostane levels significantly increased 
in all girls over follow-up but this increase did not differ by family history of breast cancer, and the 
change was no longer significant our multivariate longitudinal analysis.    
 
Discussion:  In both adult women and adolescent girls we found significant associations between oxidative 
stress and breast cancer risk. In adult women, low levels of urinary biomarkers of oxidative stress may 
promote cancer progression.  During adolescence, girls with a family history of breast cancer may be 
exposed to higher rates of DNA oxidation that could result in genetic mutations. The relationships 
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Chapter I: Literature Review 
 
BREAST STRUCTURE AND DEVELOPMENT 
 
Breasts are an exceptional organ. Within a women’s lifetime her breasts will undergo multiple and 
distinct periods of growth, development, differentiation and involution.  Unlike most other tissue types, 
breast development occurs largely after birth.  The ostensible purpose of breasts is to provide milk for 
offspring.  Yet breasts, distinct from mammary parenchyma, are not needed for lactation.  The conical 
shape of the breast aids human infants in latching on for nursing without suffocating, and the evolution of 
a protruding breast, absent in most other mammals, is theorized to be a significant contributor to the 
ability of humans to walk upright (1, 2).    Within the breast, the parenchyma (referred to throughout as 
“mammary gland” or “mammary tissue”) is composed of 15-20 lobes that radiate out from the nipple and 
areola.  Each lobe is comprised of a tree-like structure of ducts that branch out into smaller and smaller 
ducts that terminate in milk-producing lobules.  Each lobule is comprised of milk-storing cavities known 
as alveoli that are lined with hundreds of milk secreting acini. The mammary gland is stimulated by 
oxytocin, produced during labor and delivery and in response to infant suckling, to release stored milk 
down from the alveoli, through the ducts and out through the nipple. Both ducts and lobules are composed 
of epithelial cells surrounded by a layer of contractile myoepithelial cells that contract in response to 
oxytocin stimulation (3).  Mammary epithelium is comprised of two main cell types: basal and luminal.  
The myoepithelial cells comprise the outer basal layer of the mammary gland along with a small 
population of stem cells.  The inner luminal layer of epithelial cells is defined by their hormone receptor 
status (4).  The mammary tissue is surrounded and supported by adipose and fibrous connective tissue (2) 
that makes up the majority (80%) of breast tissue by volume.  In other primates there is a relatively larger 
proportion of glandular to stromal tissue (5).  
 
Mammary gland development begins in utero during the first trimester of gestation, independent of 




functional and sometimes capable of lactation under the influence of maternal hormones.  But by 2 years 
of age the breast undergoes involution leaving only a rudimentary ductal system (6).  During childhood 
breast growth remains proportional to whole body growth and again is no different in males than females.   
 
Puberty in girls brings on massive growth and development in response to hormonal changes. Breast 
budding is the first sign of puberty; menarche is the last. Time from start to finish can range from 18 
months to 5 years (7).  Connective tissue proliferates and replaces fatty tissue.  Estrogen and EGF 
controls the growth and branching of the ducts, and progesterone controls the growth of the glandular 
buds (3, 4).  Most of the growth during puberty is stromal but there is significant glandular growth mostly 
in the elongation and branching of the ducts. Epithelial buds known as terminal end buds (TEB) form 
along existing ducts and canalize forming the basis of lobular units.  These lobular units are hormone 
sensitive and are precursors to the mammary gland and the origin of most breast cancers (8).   Progression 
of breast development is measured clinically by Tanner Stage, a classification system developed in the 
1960s by British pediatrician James M. Tanner.  Stage 1, is preadolescent and only the tip of the nipple is 
raised.  Stage 2 is when breast buds appear, the breast and the nipple are raised and the areola enlarges.  
Stage 3 signifies the presence of glandular breast tissue with the breast growing larger from stage 2.  At 
Stage 4 the areola and nipple become raised and form a second mound above the rest of the breast.    
Finally, Stage 5 is the mature adult breast which is rounded with only the nipple raised (9). 
 
 Post-puberty, glandular and stromal development ceases for a time but does respond monthly to cyclic 
menstrual changes in hormone levels.  Additional proliferation of the ducts occurs during the follicular 
phase and during the luteal phase the ductal system dilates as the alveolar cells prepare to differentiate 
into secretory cells (7).  Rates of mitosis peak in the luteal phase (10) and breasts change significantly in 





Although outwardly, the breasts post-puberty appear fully developed, it is not until the second trimester of 
a woman’s first pregnancy, where the lobuloaveolar compartment develops, that the breast attains full 
maturity (5, 6). During lactation, the number of alveolar buds per lobule increases to 80 from 11 post-
puberty (11).  Insulin, hydrocortisone, and prolactin act in concert to control the differentiation of 
secretory mammary epithelium (3). Pregnancy, childbirth, lactation, and weaning steer breast tissue 
through cycles of proliferation, differentiation and apoptosis and 4 corresponding stages of lobular 
development (12), while nulliparous breast tissue remains largely in an undifferentiated form (13). 
Weaning initiates involution, which removes the milk-producing epithelial cells.  After a prolonged 
period without nursing, the alveoli collapse and apoptose. Involution mimics wound healing and 
tumorigenesis and may create a microenvironment that promotes pre-neoplastic mammary growth which 
might contribute to the transient increase in breast cancer risk post-pregnancy.  Extensive tissue 
remodeling leaves only a simple ductal architecture similar to the pre-pregnancy state (4, 5). Postpartum, 
the basal myoepithelial layer is rarely seen (5). Menopausal involution is distinct from weaning 
involution, whereby in the former the glandular tissue is replaced by fat tissue.    
 
Breasts are a unique organ and human breasts are unique among primates.  Humans are the only primates 
to have permanent breasts from puberty onward (1).  Other primate species develop breasts during 
pregnancy and maintain them only for the duration of nursing their offspring.  There are abundant 
hypotheses as to why human breasts evolved differently—perhaps permanent breasts are an outward sign 
of fertility, higher milk production, better fat storage or proper hormone levels (14, 15).  Interestingly, 
most theories conclude that the value of breasts hinges on their attractiveness to males and not a potential 
benefit to the offspring.   But whatever it is about human breasts that confers a selective advantage during 
reproductive years, it may prove to be a liability for the female in the long run.  The ability of breast 
tissue to undergo multiple repeated cycles of proliferation, differentiation and apoptosis in a women’s 
lifetime indicates that there is a reserve of multipotent mammary stem cells, a theory that was confirmed 




of these stem cells is believed to be highest post-puberty (16).  Mouse studies have demonstrated that an 
entire mammary gland can be derived from a single stem cell (17).  Oncogenic changes in mammary stem 
cells may be the source of cancer stem cells capable of generating tumors.  An early oncogenic mutation 
in one stem cell can, over a lifetime, be passed on to thousands of differentiated mammary epithelial cells 
and multipotent daughter cells (18). Several risk factors for cancer, including early menarche, late 
menopause and nulliparity, are related to the long term presence of undifferentiated breast tissue, which 
are subjected to monthly proliferative hormonal fluctuations and environmental carcinogens, making 
breast tissue highly susceptible to oncogenic transformation (19).  
 
BREAST CANCER EPIDEMIOLOGY 
 
Breast cancer is the most commonly diagnosed cancer in women. Worldwide, 1.7 million women were 
diagnosed with invasive breast cancer in 2012 and breast cancer was responsible for 591,500 deaths (20).  
Breast cancer incidence in western countries increased by 30% between 1980 and the late 1990’s before 
leveling off.  This is largely believed to be a result of changing reproductive patterns--such as delaying 
childbirth, having fewer children, and reductions in breastfeeding--and increased mammography (20).  
While there was a significant 7% drop in breast cancer diagnoses in 2003, largely attributed to reduction 
in use of hormone replacement therapy (HRT) (21), the age-adjusted incidence rate has increased 
annually since then by about 0.2%.    
 
Women are most commonly diagnosed between the ages of 55 and 64. Still, 20% of new cases are in 
women under the age of 50 making breast cancer the leading cause of premature cancer death in women.  
Five year survival rates are lower for women under 40 than for women over 50 (22).  Among women 
aged 60-84, white women have the highest incident rate. However, for women under age 45, incidence 
rates are higher for African Americans than for whites, and African Americans have higher mortality rates 





Mortality and Prognosis 
The overall mortality rate from breast cancer in the US has decreased 34% since 1990 (22).  This is 
largely due to early detection of breast cancer by routine screening and advances in treatment therapies.  
Breast cancer prognosis largely depends on the stage of the tumor at diagnosis and its molecular sub-type.  
Staging refers to how much the cancer has grown and spread beyond its source tissue. In situ tumors are 
confined to the layer of cell from which they originated and are considered non-invasive.  Approximately 
20-50% of in situ tumors may progress to invasive breast cancer within 10 years so treatment is 
recommended.  Invasive tumors are classified by SEER as either local, regional or distal.  Tumors in the 
local stage are still confined to the breast and have the best prognosis with a five-year survival rate of 
99%. Regional breast cancers have spread to nearby lymph nodes or nearby tissue.  88% of women 
diagnosed at the distal stage will be alive five years later. Distal breast cancers have metastasized to 
lymph nodes above the collarbone or distant organs.  Breast cancers diagnosed at this stage have only a 
26% 5-year survival rate (23).   
 
Breast cancers are also classified by their molecular subtype which predicts which treatment will be 
effective and how aggressive the cancer may be.  Luminal A tumors express receptors for the hormones 
progesterone (PR) or estrogen (ER) but do not excessively express receptors for human epidermal growth 
factor 2 (HER2) and are the most common molecular subtype.  These tumors are responsive to hormone 
therapy and are generally less aggressive than other molecular subtypes.  Luminal B tumors also express 
hormone receptors but additionally have high levels of HER2 or Ki67, a marker of proliferation.  Triple 
negative breast cancers (often referred to as “basal-like”) do not express any hormone receptors or HER2 
which limits treatment options.  HER2 enriched tumors are also negative for hormone receptors but do 
express HER2.  This is the rarest molecular subtype, found in only 4% of breast cancers. Recent advances 






There are three methods currently used to screen for breast cancer.  Clinical breast exams (CBE) are a 
physical examination of the breast by a health care practitioner to feel for any lumps.  Magnetic resonance 
imaging (MRI) uses radio waves and magnets to make a computerized image of the breast.  MRI is better 
at finding tumors than other screening methods but it also has a higher rate of false-positives and is 
recommended only for women who are at highest risk.  A mammogram is an X-ray of the breast and is 
the most commonly used method of screening. Regular mammography has been found to reduce 
mortality from breast cancer (25).   A recent meta-analysis of randomized clinical trials (RCTs) and 
observational studies concluded that for women over 40 years of age and at average breast cancer risk, 
mammography decreased mortality by about 20%.  The magnitude of the benefit of regular 
mammography varies by age. The greatest reduction in mortality was found among women aged 60-69 
(>30% reduction in mortality in RCTs) while women aged 40-49 only had a 15% reduction in mortality 
(26).  CBE, with or without the addition of mammography showed increased risk of false positive results 
without any benefit in mortality reduction.   
 
Screening for breast cancer does have some risks (27).  Mammography can be uncomfortable and exposes 
the breast to radiation.   All methods of screening carry the risk of overdiagnosis and false positives.  
Overdiagnosis occurs when screening leads to treatment that does not benefit the patient either because 
the tumor is aggressive and resistant to treatment or because the tumor is so slow growing that it would 
not pose a threat to the patient in their lifetime.  False positives, an abnormal test result in a patient 
without breast cancer, lead to further invasive testing, and unnecessary anxiety.  Finally, even the best 
screening method may give a false negative results which may delay treatment. 
 
The frequency and the age at which women should begin screening for breast cancer has become a 
contentious issue in recent years.  The benefits of screening for any disease depend on the accuracy of the 




improve with early diagnosis.  These factors contribute to why mammography is less beneficial for 
younger women.  Breast tissue is denser in younger women where mammography is less effective in 
detecting tumors.  Both tumors and normal glandular breast tissue appear white on mammograms making 
it hard to distinguish the two.  Breast tumors in younger women tend to grow faster than in older women 
and annual or biennial screening may still fail to catch tumors at an earlier, treatable stage.  Finally, 
because breast cancer is much rarer in younger women they are more likely to have a false positive result 
than older women (28).   
 
Current Screening Recommendations 
The US Preventative Task Force Service (USPSTF) changed their breast cancer screening 
recommendations in 2009. Their previous recommendations were for mammography screening every 1 to 
2 years for all women beginning at age 40 (29).  Citing recent RCTs that showed only a 15% reduction in 
breast cancer mortality among women aged 39-49 who had regular mammograms (29), they determined 
that the high rate of mammographic false positives and resulting adverse effects, combined with the low 
incidence of breast cancer in younger women, largely outweighed any benefits.  They dropped their 
recommendation for routine mammography for women under 50.  They currently recommend biennial 
mammographic screening for women without strong genetic or environmental risk factors for cancer 
beginning at age 50. The task force leaves screening decisions for women 40-49 up to the individual 
based on their perceived potential for benefit and tolerance of risk of overdiagnosis (30).    
 
These recommendations have not been universally adopted.  The National Comprehensive Cancer 
Network and Memorial Sloan Kettering Cancer Center still recommend annual screening for women 
starting at age 40 (31) and the American Cancer Society (ACS) recommends all women 45 and older have 
annual mammograms and they dropped their recommendation for CBE in 2015 (32).  The USPSTF 




screening among women under 50 immediately after the new guidelines were announced, two years later 
mammography rates for women aged 40-49 had increased above 2008 levels (33). 
 
Prevention 
Women at increased risk of breast cancer have few options for prevention.  Most of the strongest risk 
factors such as age, gender, breast tissue density, age at parity, menarche, and menopause, are, for the 
most part, unmodifiable.  Tamoxifan and Raloxifene, estrogen receptor modulators, are efficacious for 
breast cancer prevention but as they can have serious side effects, should only be taken by those at highest 
risk (34). The lack of effective tools to identify these women who would benefit the most from these 
drugs is a critical barrier for clinicians (35).  Other preventive actions such as prophylactic mastectomy, 
while effective, are radical and irreversible, and should only be undertaken if increased risk is established 
with certainty. 
 
RISK FACTORS FOR BREAST CANCER 
 
Gender and age are two of the strongest risk factors for breast cancer.  The risk of breast cancer increases 
with age and doubles every 10 years until menopause, when the increase in incidence slows but does not 
plateau (MacPherson 2000). There are approximately 2600 cases of breast cancer in males in the US 
annually but breast cancer is approximately 100x more common in women than in men (36).  The 
differences in breast cancer risk between men and women are likely both structural and hormonal.  
Excessive estrogen exposure is a known risk factor for breast cancer.  Elevated blood levels of estrogen 
double the risk of breast cancer with the risk increasing in a dose-dependent manner 10-20% for every 
doubling of estrogen (37, 38).  Estrogen is believed to be one of the rare chemicals that can both initiate 
and promote cancer growth.  Initiation of cancer is believed to be caused by estrogen metabolism by 
cytochrome p450 enzymes to catechol estrogens and then to catechol estrogen quinones (39).  Estrogen 




radicals which can damage DNA biomolecules (40, 41).  Lactoperoxidase in human milk and mammary 
glands can also metabolize estradiol to its phenoxyl radical, propagating superoxide and H2O2 (42).  
Estrogen signaling through the estrogen receptor is a powerful mitogen, acting transcriptionally to alter 
gene expression in order to increase cell proliferation and decrease apoptosis (43). 
 
Genetics and Family History 
After gender and age, the strongest risks factors for breast cancer are genetic. Studies of hereditary breast 
cancer—defined as breast cancer with an autosomal dominant pattern of inheritance—have identified 
several genes that significantly increase the risk of breast cancer.  While these inherited genes greatly 
increase the risk of breast cancer among carriers of germline mutations, they are rare, and are only 
responsible for approximately 5-10% of all breast cancer cases (44).  These genes are important in 
understanding the specific pathways that lead to breast cancer and may be important in sporadic breast 
cancer.  In general, genes associated with hereditary breast cancer share in common participation in DNA 
repair and preservation of genomic integrity (45).   
 
BRCA1 and BRCA2 
Of the genes associated with hereditary breast cancer, mutations in BRCA1 and BRCA2 (collectively 
referred to as BRCA1/2) confer the highest penetrance, increasing the lifetime risk of breast cancer to as 
much as 80% (46) and are responsible for approximately 40-50% of hereditary breast cancers (47).  
BRCA1/2 is involved in homologous recombination and double strand break repair (DSBR). BRCA1 is 
also involved in cell-cycle checkpoint control, chromatin remodeling, transcription regulation, protein 
ubiquitination, and antioxidant regulation (45, 48, 49). In vitro studies have shown that BRCA1 and 
BRCA2 are involved in nucleotide excision repair via the transcription coupled repair of 8-OxodG lesions 





Germline loss of both copies of BRCA1/2 is embryonically lethal (51).  There is no obvious phenotypic 
difference between those with two functioning BRCA1/2 alleles and those with only one, other than the 
increased risk of breast and ovarian cancer (45).  Almost all tumors in BRCA1/2 mutation carriers have 
lost the functioning BRCA1/2 allele and additionally most have acquired mutations in TP53 or other cell 
cycle checkpoint control genes (47).  These additional mutations appear to be critical for BRCA1/2 related 
carcinogenesis.  Once cells acquire a mutation in the second BRCA1/2 allele they are unable to repair 
DNA damage from the next cell cycle and most will die (46).  Mutations in TP53 or other cell cycle 
regulating genes are likely critical for the survival of cells with, or prior to, the total loss of BRCA1/2 
function. P53 mutations are two to three times more frequent in BRCA1/2 breast cancers than in sporadic 
ones (47). Additionally, this evasion of apoptosis and continued proliferation despite BRCA1/2 defects 
appears limited to breast and ovarian cells.  It has been speculated that estrogen is responsible for the 
survival of BRCA1/2 null cells. Estrogen has anti-apoptotic properties (52, 53).  Estrogen blockage by 
Tamoxifan treatment reduces the risk of breast cancer in BRCA1/2 mutation carries as does prophylactic 
oophorectomy (45).  It is worth noting though, that approximately 80% BRCA1/2 related cancer are ER-
negative (54) and that BRCA1/2 mutations do not increase the risk of cancer in the endometrium, another 
tissue that is ER responsive (49).   
 
The role of BRCA1/2 in sporadic breast cancer is not as significant.  Although at least 50% of sporadic 
tumors have lost either a BRCA1 or BRCA2 allele (46), complete loss of heterozygosity is rare in sporadic 
breast tumors (55).    This suggests that the temporality of BRCA1/2 loss may be critical for breast cancer 
tumorigenesis.   However, alterations in BRCA1/2 expression due to epigenetic silencing (56) or 
mutations in upstream activating molecules may still be important in sporadic breast cancer.  
 
TP53 
Tumor protein 53 gene (TP53) encodes p53, a critical, if not the critical, tumor suppressor in multicellular 




the “master regulator” of cell cycle progression. Under normal cellular conditions, p53 is maintained at 
low levels via mouse double minute 2 (MDM2)-dependent proteolytic degradation. In response to cellular 
stressors that threaten genomic stability, MDM2 dissociates from p53 and allows p53 to orchestrate 
transcription of numerous effector genes that lead to either DNA repair, cell cycle arrest, senescence or 
apoptosis.  P53 can also act directly though protein-protein interactions, mainly with Bcl2, to induce 
apoptosis.  P53 also plays a critical role in regulation of and response to oxidative stress. P53 triggers 
expression of several genes that generate or respond to oxidative stress (57).   Cellular levels of p53 
appear to be a function of existing levels of cellular stress which includes oxidative stress conditions.  
Mouse studies have demonstrated that antioxidant treatment reduces expression of TP53 and increases 
tumor burden (58). Low levels of p53 activate antioxidants, allowing cells to repair damage and survive.  
High levels of p53 induce a pro-oxidant response triggering senescence or apoptosis (59, 60). The 
inactivation of TP53 has been found in a majority of tumor types.  Germline mutations in TP53 cause Li-
Fraumeni syndrome and predispose carriers to cancers, including breast cancer, at an early age (average 
age at onset of first tumor is 25). Germline TP53 mutations are very rare with a prevalence not higher 
than 1:5,000 to 1:20,000 (61).  80% of adult women with Li-Fraumeni Syndrome will develop breast 
cancer, and the remaining 20% will develop another sarcoma within their lifetime (62).   Germline TP53 
mutations account for less than 1% of breast cancer cases (63), but 20-40% of sporadic breast cancers 
harbor TP53 mutations (64). 
 
ATM 
Mutations in the ataxia-telangiectasia mutated (ATM) gene moderately increase the risk of breast cancer.  
Homozygous mutations result in the eponymous disease, ataxia telangiectasia, a rare condition that leads 
to neurological degeneration and immune system dysfunction.  Heterozygous carriers of ATM mutations 
are at increased risk of breast cancer.  The ATM protein is a serine/threonine kinase involved in double 
strand break repair (DSBR).  Double strand breaks, created as a result of gamma radiation, oxidative 




recruits ATM to the site of DNA damage which then sets off a signaling cascade via phosphorylation of 
p53, Chek2, and BRCA1 among others (66, 67).  The pleiotropic effects include initiation of G1/S, intra-S 
and G2/M cell cycle checkpoints, DNA repair, and if DNA repair is unsuccessful, activation of p53-
mediated apoptosis via upregulation of Noxa and Puma genes (68).   
 
Homozygous ATM mutations are found in approximately 1% of the US population and conveys an 
approximately two-fold increase in breast cancer risk.  However, only 15% of carriers will develop breast 
cancer in their lifetime.  What determines which carriers will develop the disease is not known (67). 
 
CHK2 
Checkpoint Kinase 2 gene (Chk2) encodes a serine threonine kinase which is activated by ATM in 
response to genotoxic events, and ultimately prevents cells from dividing (49).  Chk2 inactivates, via 
phosphorylation, downstream CDC25 phosphatases and prevents the cell from entering mitosis. Chk2 
also helps stabilize p53 leading to cell cycle arrest at G1 (69).  The best studied variant, 1100delC, 
produces a truncated protein that is unable to signal to its substrates which include BRCA1 and p53.   The 
1100delC variant increases breast cancer risk approximately two-fold in women and 10-fold in men.  This 
mutation has been found in approximately 5% of breast cancer patients and 1% of healthy individuals 
from North America and Western Europe (70).  Other Chk2 variants such as the I157T, convey a lower 
risk of breast cancer and are rarer in these populations.   
 
Family History as a Risk Factor 
A family history of breast cancer is one of the strongest risk factors for developing breast cancer, 
increasing the risk by 2-4-fold (71, 72).  Family history reflects a complex mix of shared genetics, 
lifestyle and environment. Which of these factors is driving increased risk varies between and even within 




the etiologic pathways driving familial risk remain ambiguous.  A family history of breast cancer may be 
classified as either hereditary or familial.  Hereditary breast cancers follow an autosomal dominant pattern 
of inheritance. Familial breast cancer has no single agreed upon definition but is generally accepted to 
include (i) at least three breast and/or ovarian cancer cases in a family; (ii) two breast cancer cases in 
close relatives, with at least case diagnosed before age 50; (iii) two breast cancer cases in a family 
diagnosed before 40 years of age; (iv) any male breast cancer with a family history of ovarian cancer or 
early onset female breast cancer; (v) Ashkenazi Jewish ancestry with breast cancer, particularly triple-
negative breast cancer diagnosed before age 60; or (vi) breast and ovarian cancer in the same patient (73).  
 
Environmental factors that may have increased the risk of breast cancer in one generation in some 
families, such as hormone replacement therapy (HRT) or diethylstilbestrol (DES) use, may not apply to 
others.  Variation in family size means that family history cannot be measured equally. Family history 
may be limited by a small number of first-degree relatives.  Even for women with several siblings, by the 
time they reach the age where cancer commonly manifests, opportunities for risk reduction may have 
been lost.  
 
Prevalence of Family History 
A 2003 Dutch study of 1 million women between the ages of 30-50 estimated that one third had a family 
history of breast cancer in a first or second degree relative.  80% of these were in a second degree relative.  
Overall only 6% of healthy women in the general population had 2 or more 2nd degree relatives with 
breast cancer and less than 1% had 2 or more first degree relatives with breast cancer or 1 first degree and 
2 or more second degree relatives with breast cancer.   These numbers may be an underestimation of the 
rate in the US where breast cancer is more prevalent (74).   The Nurse’s Health Study found 15% of 
women reported having a family history of breast cancer in a first degree relative, which is less than the 
20% the Dutch study found (72).  A “family history of breast cancer”, generally defined as having at least 




above.  Familial breast cancer is much rarer, estimated to be present in less than 0.7% of the US 
population (75). 
  
Reproductive or Hormonal Risk Factors 
It has been known since the early 1700s that reproductive factors play a role in breast cancer incidence.  
Nulliparous women have approximately 20-70% increased odds of breast cancer diagnosed after age 50.  
For earlier age at breast cancer diagnosis, parity seems to increase the risk likely because pregnancy 
hormones promote growth of precancerous lesions.   Having a full term pregnancy before the age of 20 
halves the risk of breast cancer compared to having a first live birth at age 30 (10, 12).  Women who have 
their first live birth at age 35 or older are at higher risk of breast cancer than nulliparous women (76) 
which again, is likely due to the transient increase in breast cancer risk after a pregnancy. 
 
Studies examining the relationship between breast feeding and breast cancer risk—especially those done 
in countries where long-term breast feeding is common—have demonstrated a protective effect for breast 
feeding longer than 1.5 years.  A large international study found the relative risk of breast cancer 
decreased by 4.3% (95% CI 2.9-5.8; p<0.0001) for every 12 months of breastfeeding in addition to a 
decrease of 7.0% (5.0-9.0; p<0.0001) for each birth (77).  This may also be related to a reduction in the 
number of menstrual cycles a women experiences in her lifetime since breast feeding suppresses 
ovulation.   
 
Women who have their first period at age 15 or older have 20% reduced odds of breast cancer than 
women who were under 12 at menarche. This may be because an earlier age at menarche exposes the 
breast to more years of monthly hormone fluctuations, or because early age at menarche is a result of 
higher levels of endogenous estrogen which also is a risk factor for breast cancer (10). Similarly, a late 
age at menopause (>55) confers a two-fold increase in risk relative to those who reached natural 




40 increases the risk of breast cancer.  Women with short menstrual cycles would experience more 
menstrual cycles over their lifetime, holding all other factors constant, and would spend more time in the 
luteal phase of the menstrual cycle where levels of estrogen and progesterone peak along with mitotic 
activity of mammary tissue (10).  Several of the hormonal risk factors highlight the potential vulnerability 
of breast tissue between menarche and parity or menopause.    
 
Breast Tissue Density 
Having dense breast tissue has been consistently identified as risk factor for breast cancer (78). Breast 
density refers to the ratio of epidermal and stromal tissue to fat tissue as it appears on a mammogram.  
The most common clinical tool use to assess breast density is the Breast Imaging Reporting and Data 
System (BI-RADS) which divides breast density into 4 density categories: 10% of women (D1, <25% 
glandular breast tissue) have almost completely fatty breasts, 40% of women (D2, 25-51% glandular) is 
scattered fibroglandular density, 40% of women have heterogeneously dense breasts (D3, 51-75% 
glandular) and an additional 10% of women have extremely dense breasts (D4, >75% glandular). Women 
in the upper two density categories, or those whose breasts are >49% glandular, are considered to have 
“dense breasts”.  Women with heterogeneously dense breasts have 20-50% greater risk of breast cancer, 
while women with extremely dense breasts have over twice the risk of breast cancer compared to women 
with scattered fibroglandular tissue.  Premenopausal women and women using HRT are at highest 
increased risk.  While an independent risk factor for breast cancer, breast density does decrease with age 
and BMI.  It also is influenced by parity, with parous women, especially those with an early age at parity, 
having less dense breasts later in life (79, 80).  In addition to increasing breast cancer risk, dense breast 
tissue reduces the accuracy of mammograms, making it difficult to detect tumors.  The sensitivity of 
mammograms decreases from 88% for women with mostly fatty breasts to 62% for women with 





MODIFIABLE/ENVIRONMENTAL RISK FACTORS 
 
A 2000 study of almost 45,000 Scandinavian twins found that hereditable factors are likely responsible 
for only an average of 27% of breast cancer risk (95% CI 4-41%) leaving the bulk of breast cancer risk 
due to potentially modifiable risk factors (82). Geographic studies of breast cancer show up to a five-fold 
difference in risk by country (76), while studies of immigrants from low risk countries demonstrated that 
breast cancer risk increased with time spent in the US (83) indicating a significant role for environmental 
factors.  While this information is a source of hope for women looking to reduce their risk, to date, most 
modifiable risk factors that have been identified only contribute a modest change in breast cancer risk. 
Some of the difficulty in identifying strong modifiable risk factors may be because their contribution to 
risk varies according to other risk factors already present (84), because their effect varies across the life 
course, or because of the specificity of risk factors for particular subtypes of breast cancer that are not 
accounted for in many studies.  For example, radiation exposure as a risk factor is strongest among 
women who were exposed in adolescence (85). BMI is a risk factor for postmenopausal breast cancer 
(86).  Among premenopausal women obesity is protective, particularly for ER+ tumors (87).  Other 
exposures, such as diethylstilbestrol (DES) or preeclampsia, may influence breast cancer risk during 
prenatal development (88-90).   
 
Alcohol 
Alcohol consumption is one of the few consistently identified modifiable risk factors for breast cancer.  A 
large prospective study of women in the Nurse’s Health Study found that women who consumed alcohol 
regularly, but not excessively, had a 50% higher risk of breast cancer than women who rarely drank.  
Women under age 55 at low absolute risk of breast cancer (due to an early pregnancy and no family or 
person history of breast cancer or benign breast disease), who consumed more than 1 alcoholic drink per 
day had 2.5 times the risk of breast cancer than similar women who did not consume alcohol (91).  




risk. Alcohol increases expression of estrogen and progesterone receptor on breast cells making them 
more responsive to hormone stimulation (92).  Alcohol may impair folate metabolism depending on 
polymorphic variations in enzymes involved in one-carbon metabolism.  Folate deficiency can lead to 
chromosomal instability, misincorporation of uracil, and impaired epigenetic regulation (93).  A 2010 
study of 160 breast tumor samples found that methylation profiles were associated with both alcohol 
consumption and dietary folate levels.  Alcohol intake was associated with hypomethylation, while there 
was increased methylation with increasing dietary folate (94).  Alcohol metabolism is known to produce 
DNA damaging free radicals and some studies have shown that breast cancer risk varies by 
polymorphisms in alcohol dehydrogenase genes (93).  Given that moderate alcohol consumption is quite 
common for women from many countries, the impact of alcohol on breast cancer risk is considerable.  
One study estimated that 5% of breast cancer cases in Europe can be attributed to alcohol consumption 
(93).  
 
Body Mass Index (BMI) 
The effect of BMI on breast cancer risk depends on menopausal status. Obesity increases the risk of 
breast cancer for post-menopausal women while it may convey a slight protective effect for 
premenopausal women.  The increased risk is likely because adipose tissue becomes a significant source 
of estrogen production among postmenopausal women.  Prior to menopause, the ovaries produce the 
majority of estrogen and the contribution from fat tissue is minor in comparison.  The increase in risk may 
also be limited to women who gained significant weight in adulthood and not for women who’ve been 
overweight for all their lives (95, 96). 
 
Radiation/Chest Radiation 
Studies of atomic bomb survivors show that radiation increased the risk of breast cancer (97).  Medical 




cancer.  Diagnostic chest X-rays for tuberculosis or pneumonia have been associated with a significant 
increase in breast cancer risk (OR=2.5) (98).  Radiotherapy treatment for a prior cancer was also found to 
increase risk (OR=3.6) (98). Regular mammography has shown to moderately increase the risk of breast 
cancer among younger, high risk women (OR=1.8) which is why MRI is often recommended for 
screening risk populations (99). 
 
Hormone Replacement Therapy (HRT) 
While endogenous sources of estrogen, other than through body fat, are unavoidable, exogenous sources 
are.  Results from the Million Women Study in Britain and the Women’s Health Initiative in the US 
provided strong evidence that the use of HRT increased the risk of breast cancer.  The Women’s Health 
Initiative enrolled over 15,000 women in a RCT and compared health outcomes between women 
randomized to receive either placebo or combined estrogen/progestin HRT.  The trial was stopped early 
after 5.2 years of follow-up when it became clear that the observed increased risks for breast cancer 
(HR=1.26), coronary heart disease (HR=1.29), and stroke (HR=1.41) in the HRT arm would outweigh 
any potential benefits (100).  The Million Women Study enrolled over 1 million British postmenopausal 
women in an observational cohort study from 1996 to 2001.   The risk of breast cancer for women using 
estrogen-only HRT preparations was elevated (RR=1.30) as was the risk for women using 
estrogen/progestin combination HRT therapy (RR=2.00).  The authors estimated that HRT use in the UK 
alone over the previous decade was responsible for 20,000 extra breast cancer cases (101). At the time 
these results came out approximately 10 million women in the US were using HRT.  In 2003 the FDA 
mandated safety warnings of health risks on all labels of products containing estrogen alone or combined 
with progestin for use in postmenopausal women (102).  As use of HRT dropped among American 
women, so did the incidence of breast cancer confirming what the Million Women Study found: that 5 
years from cessation of HRT use the risk of breast cancer was similar to non HRT users, indicating that 





Diet, Vitamins and Exercise 
Fruit and vegetable consumption is associated with health in general and fruits and vegetables contain 
antioxidants and fiber which can bind estrogens during enterohepatic circulation (103) giving rise to hope 
that it may be a means to reduce breast cancer risk.  However, evidence for an association between 
vegetable and/or fruit intake and breast cancer risk has been weak or inconclusive. A recent meta-analysis 
of 15 prospective studies that have examined the relationship found overall there was no significant 
association between vegetable intake and breast cancer risk and only an 8% reduction in risk with the 
highest levels of fruit consumption or 12% reduction for the highest consumption of fruits and vegetables 
combined (104).  Still, most institutional guidelines recommend “a healthy diet” in order to reduce breast 
cancer risk (105-107) and post-menopausally, maintaining a healthy weight through eating a healthy diet, 
might reduce the risk of breast cancer. 
 
Early Life Exposures 
Given the unique development of breast tissue, it is not surprising that early life exposures may be 
particularly influential in determining breast cancer risk.  A 2011 Institute of Medicine report urged 
researchers to examine risk factors of breast cancer during critical life stages of susceptibility.  Increased 
birth weight (>4,000g or 8.8lbs) has been associated with a 4-fold increase in risk of premenopausal 
breast cancer (108). Increased birth length is also associated with increased risk in breast cancer while 
longer gestational age and preeclampsia (for both mother and daughter) is inversely associated with breast 
cancer risk (109).  These risk factors may reflect maternal hormone levels which are positively associated 
with birth height, weight and length and inversely associated with pregnancy duration.  Conversely, 
increased weight during adolescence may be protective against breast cancer (although notably, studies 
were done among women who were not overweight during adolescence).  Studies of carcinogens and 
endocrine disruptors have also revealed early life as a critical period of susceptibility (110).  This is of 




women are exposed to chemicals such as polychlorinated biphenyls, organochlorine pesticides, 
perfluorinated compounds (PFCs), phenols, polybrominated diphenyl ethers (PBDEs), phthalates, 
polycyclic aromatic hydrocarbons, and perchlorate (111).  In a recent study, rhesus monkeys exposed in 
utero to BPA levels comparable to that found in human populations were born with mammary glands that 
were significantly more developmentally advanced and denser in mammary buds than unexposed 
monkeys, which may increase breast cancer risk (112). In rats, exposure to carcinogenic DMBA (a PAH 
found in tobacco smoke) produced 2 times more tumors when exposure occurred before terminal end 
buds had differentiated into alveolar buds (11).   
 
In human studies, exposure to DDT was found to increase the risk of premenopausal breast cancer only in 
women who were exposed before the age of 14 (113).  In utero exposure to DES, a synthetic estrogen, 
results in an up to 3 times greater risk of breast cancer (90).  Studies of atomic bomb survivors found 
women exposed before they were 20 years of age had the highest excess risk of breast cancer with a 13-
fold increased relative risk, while women who were over 35 had a 2-fold risk of breast cancer (85). 
Similarly, known risk factors for adults such as alcohol use or medical radiation, convey a stronger effect 
when the exposure occurs during adolescence or at least pre-parity (91, 114-117). 
 
OXIDATIVE STRESS 
Chemistry of Molecular Oxygen 
The ubiquitous generation of reactive oxygen species (ROS) is due to the unique chemical properties of 
oxygen.  Molecular oxygen (O2) has two unpaired electrons with the same spin quantum number. Unlike 
most other biomolecules which covalently bind electron pairs with opposite spins, O2 can only accept a 
pair of electrons with parallel spins.  This makes O2 more likely to undergo single electron reductions 
which produce ROS intermediates (118).  The superoxide radical (O2•-) is the first intermediate produced, 
from the addition of one electron (O2 + e- = O2•- ).  In hydrophobic environments such as membrane 




environments, superoxide reacts with itself, or dismutates, producing molecular oxygen and hydrogen 
peroxide (H2O2).  This process can be accelerated by superoxide dismutase (SOD) enzymes. Hydrogen 
peroxide is not a free radical, but is stable, can travel across membranes and, in the presence of free iron, 
can produce the hydroxyl radical (OH•) via the Fenton reaction (119).  Hydroxyl radicals are also 
produced as a result of ionizing radiation breaking down water molecules. The hydroxyl radical is highly 
reactive, with a very short half-life (10-9 sec) yet is capable of reacting with and damaging most types of 
biomolecules including amino acids, phospholipids, sugars and DNA (120).   
 
Mammalian cells have evolved numerous defense mechanisms to limit the production of ROS and 
mitigate any damage. Enzymatic defenses include catalase, glutathione peroxidase and superoxide 
dismutase. Catalase is found in peroxisomes and in the mitochondria and catalyzes the conversion of 
hydrogen peroxide to molecular oxygen and water.  Glutathione peroxidase catalyzes the reaction of 
hydrogen peroxide and monomeric glutathione (GSH) to produce water and glutathione disulfide 
(GSSG).   Superoxide dismutase catalyzes the reaction of superoxide to hydrogen peroxide and oxygen.  
There are distinct forms in the cytoplasm and in the mitochondrial matrix.  In addition to enzymatic 
defenses, the antioxidant glutathione scavenges hydroxyl radicals and singlet oxygen, donating an 
electron from the thiol group of its cysteine.  Reduced glutathione (GSH) can be regenerated from the 
oxidized form (GSSH) by the enzyme glutathione reductase.  The balance of the reduced to oxidized form 
of glutathione can be indicative of oxidative stress. Uric acid is the most abundant antioxidant and 
provides over half the total antioxidant capacity of human serum.  It is produced from xanthine as an 
intermediate of purine metabolism.  It reacts with the hydroxyl radical and hypochlorous acid and protects 
against activated granulocytes which produce free radicals to protect against microbes (121-123). 
 
Dietary antioxidants also help minimize cellular ROS level.  Lipid soluble antioxidants, such as β-
carotene (a precursor of vitamin A) and Vitamin E (the tocopherols) are incorporated into cell membranes 




include vitamin C, a non-specific radical scavenger capable of reducing singlet oxygen, peroxyl radicals, 
and hydroxyl radicals.  Water soluble antioxidants work in the cytosol and the blood (124-126). 
 
Genetic Effects 
Oxidative stress is thought to be a significant contributor to the creation of spontaneous mutations that 
can initiate or promote cancer (127).  The hydroxyl radical (OH) can oxidize DNA bases, creating 
lesions that reduce base pairing specificity, lead to misreading of adjacent pyrimidines, and can ultimately 
result in mutations if left unrepaired.  Guanine (G), as a result of its low redox potential is particularly 
susceptible to oxidative damage.  One product of oxidative damage to guanine is 8-oxo-7,8-dihydro-2’-
deoxyguanosine (8-OxodG) which mimics thymine (T) and leads to incorrect pairing with adenine (A) 




In addition to its mutagenic potential, oxidative lesions can have epigenetic effects. The substitution of 8-
OxodG for guanine in CpG islands can inhibit methylation of adjacent cytosines (129).  8-OxodG and 
other lesions can interfere with DNA methytransferease (DNMT) binding, leading to global 
hypomethylation (130).  Hypomethylation has been associated with increased breast cancer risk (131) and 
with a family history of breast cancer in young girls (132) .  Additionally, DNA lesions in the methyl-
CpG-binding protein (MBP) recognition sequence of DNA reduce MBPs binding affinity.  This inhibits 
MBP’s ability to block the access of transcriptional machinery to the promotor along hypermethylated 
regions (130).  Overall, these events can result in aberrant epigenetic control of gene expression, 






Role of Oxidative Stress in Physiology 
The production of ROS is a normal part of cellular respiration and production of ATP in the mitochondria 
where O2 accepts electrons and H+ before being reduced to water as part of the electron transport chain.  
Normally the vast majority of O2 is consumed but still about 1-2% of electrons are leaked out of the 
mitochondria producing O2-  (133, 134).  O2- is also produced in the endoplasmic reticulum as a part of 
oxidative protein folding  (135) in peroxisomes to break down fatty acids, and in phagocytic cells in order 
to destroy bacteria (136, 137).   
 
ROS are also an important part of cell signaling via redox (reduction/oxidation) regulation (138).   The 
redox state of the cell regulates its response in conjunction with extracellular stimuli. Redox regulation 
targets sulfhydryl groups (RSH) on cysteine residues which are oxidized to form disulfide bonds.  
Oxidants can activate protein tyrosine kinases (PTKs) that promote growth such as the epidermal growth 
factor receptor (EGFR), platelet derived growth factor (PDFR) and Src, and protein serine/threonine 
kinases including mitogen activated protein kinase (MAPK) and Akt (134).  
 
The cellular redox state also influences transcriptional regulation.  Several transcription factors have 
redox-sensitive cysteine residues at their DNA binding sites and oxidation of these residues inhibits their 
DNA-binding activities. Oxidative stress can interfere with stabilization of protein-protein interactions, 
including Nrf2-Keap1 and MDM2-p53, often dissociating the protein complex and freeing active 
functional proteins (139).     
 
The redox state and magnitude and duration of oxidative stress are critical in cell survival.  Low doses of 
ROS stimulate cell proliferation; moderate levels of oxidative stress induce cell cycle arrest and 
increasing levels shift mode of cell death from apoptosis to necrosis (134, 139).  p53, the “master 
regulator” of cell cycle regulation, is subject to complex redox regulation through its many cysteine 




exposure to oxidative stress triggers apoptosis through activation of several critical molecules.  Mild 
oxidative stress stimulates expression of the anti-apoptotic Bcl-2, and promotes cell survival.  Under 
oxidative stress conditions, Bcl-2 is inhibited, increasing mitochondrial membrane permeabilization.  
Mitochondrial permeabilization, in turn, promotes the release of cytochrome c into the cytosol where it 
forms a complex with caspase-9 activating the caspase apoptotic cascade (139, 141).  Release and 
activation of caspases leads to DNA fragmentation and loss of membrane integrity and is triggered by 
increased mitochondrial levels of ROS and redox-sensitive cysteine residues in its active site.  
Excessively high doses of H2O2 in vitro, conversely, cause inactivation of caspases, causing cells to 
undergo necrosis (139). 
 
Role in Disease 
Largely because of its mutagenic potential, oxidative stress has been implicated in the initiation of cancer 
(127, 142-144). Additionally, oxidative stress can alter epigenetic regulation, accelerate telomere 
shortening, increase microsatellite instability, and damage promotor sequences, all of which may 
contribute to tumorigenesis (145).  Numerous studies have demonstrated elevated biomarkers of oxidative 
stress in cancer tissue or in the plasma or urine of cancer patients (146).  Whether oxidative stress is a 
cause or a consequence of cancer has not been determined.  Cancer cells are known to have elevated 
levels of oxidative stress due to reduced DNA repair (147, 148), metabolic changes, increased production 
of ROS, and reduced antioxidant expression (149).  Cancer treatments including chemotherapy and 
radiation therapy can also increase oxidative stress levels in cancer patients.  To date, only a few studies 
have measured oxidative stress prospectively in order to clarify the role oxidative stress may play in the 
initiation or progression of cancer and results have been inconsistent (150-153). 
 
Oxidative stress is associated with numerous non-cancerous diseases (146, 154) including chronic 
inflammatory diseases such as lupus, rheumatoid arthritis, ulcerative colitis, and infection with 




leukocytes that release large amounts of ROS in order to combat infection, either real or perceived (155). 
Studies of neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease and Parkinson’s 
disease also implicate oxidative stress in their pathophysiology with protein and lipid peroxidation having 
a stronger association than DNA oxidation (154).  As not all diseases associated with chronically high 
levels of oxidative stress are associated with an increased risk of cancer (146), there is still doubt as to its 
role as a cause of cancer. 
  
F2-Isoprostanes 
Oxidative stress cannot be measured directly in vivo, therefore human studies rely on biomarkers of 
oxidative stress.  Two of the most well validated urinary biomarkers of oxidative stress are 15-F2t-
Isoprostanes and 8-oxo-2′-deoxyguanosine. 15-F2t-Isoprostanes (F2-Isoprostanes) are isomers of 
prostaglandins and are produced solely through the free radical oxidation of arachidonic acid, a 
ubiquitous polyunsaturated fatty acid.  They are sensitive and specific markers of lipid peroxidation.  
Unsaturated lipids have more double bonds and are more susceptible to free radical attack than saturated 
fats.  Most arachidonic acid is bound to phospholipids which are more readily oxidized than free 
arachidonic acid (156).  Free isoprostanes in body fluids are cleaved from phospholipids through 
hydrolysis by phospholipases.  Detectable levels are found in normal biological fluid including plasma, 
urine, CSF, and bile.  Its constant presence indicates that there is ongoing peroxidation of lipids that is 
never completely blocked by antioxidant defenses (157).  As a biomarker of oxidative stress, F2-
Isoprostanes are considered by some to be the “gold standard”.  In a multi-lab study of various oxidative 
stress biomarkers in urine and plasma, F2-Isoprostanes were the only one to consistently respond in a 
dose and time-dependent manner to oxidative stress induced by carbon tetrachloride exposure (158). 
Unlike markers oxidative DNA damage, levels of isoprostane are not confounded by repair mechanisms.  
F2-Isoprostane levels in body fluids are not affected by dietary lipid intake (159) but are rapidly 
metabolized and sufficient quantities are detected in the urine.  Urinary F2-Isoprostanes have an 




handling and storage of urine samples.  Finally, urinary F2-Isoprostane levels can be easily measured by 
ELISA without further extraction or purification (160).   
 
8-OxodG 
8-Oxo-2′-deoxyguanosine (8-OxodG) is the most commonly used marker of oxidative DNA damage.  
Guanine is more readily oxidized compared to adenine. 8-OxodG is stable in urine (161), easily and 
reliably measured by ELISA, and is known to lead to point mutations (162).  DNA polymerases alpha, 
gamma and epsilon have a tendency to pair A with 8-OxodG as it structurally mimics thymine (163). 
Urinary 8-OxodG is thought to be largely a result of DNA repair (164) and oxidative stress on the 
nucleotide pool (165) and reflects whole body oxidative stress.  Human 8-oxoGua DNA glycosylase 1 
(hOGG1), as a part of base excision repair machinery, removes 8-OxodG that is correctly paired with C, 
producing 8-oxo-7,8-dihydro-guanine (8-OxoGua).  The nucleobase of free 8-OxodG can be hydrolyzed 
by purine nucleotide phosphatases (PNP) also resulting in 8-OxoGua.  8-OxoGua can then be 
phosphorylated by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to 8-OxodGTP, which can 
then be reincorporated into DNA.   8-OxodGTP, if it’s not reincorporated into DNA, is degraded by 
human MutT homologue (hMTH1, also known as Nudix hydroxylase) to 8-OxodGMP which is subject to 
further degradation by 5’(3’)-nucleotidase activity, yielding 8-OxodG which is then excreted in urine 
(166, 167).  
 
Cell culture studies have shown that the nucleotide pool is also a major target of oxidative stress (165). 
The nucleotide pool is located in the cytoplasm and more vulnerable to attack by ROS than DNA which is 
sequestered in the nucleus and protected by histones (166). What proportion of 8-OxodG in the urine 
comes directly out of DNA rather than the nucleotide pool is not known.  OGG1 knockout mice excrete 
26% less 8-OxodG than wild-type mice (166) indicating there is a backup method for removing 8-OxodG 
in the DNA, perhaps via transcription coupled repair or another form of nucleotide excision repair (50). 




8-OxodG. Oxidative stress on the nucleotide pool can still contribute to DNA damage and resulting 
mutations and epigenetic misregulation.  Free 2’-deoxyquanosine 5’-triphosphate (dGTP) in the 
nucleotide pool can be oxidized by •OH radical producing oxidized 8-OxodGTP which can be 
reincorporated into DNA unless it is dephosphorylated by the Nudix hydroxylases, which prevents 
reincorporation into DNA.  Levels of 8-OxodG in urine or plasma are not pure markers of oxidative stress 
but partially reflect the balance of DNA repair and recycling to oxidative insult. 
 
Urinary levels of 8-OxodG are not significantly influenced by dietary sources or cell death (168).  
Mitochondrial DNA is also not a significant source of urinary 8-OxodG as mitochondrial DNA is only 
about 1% of cellular DNA and has a more efficient repair mechanism by OGG2a (169). Once in the 
circulation, 8-OxodG is excreted in the urine within a few hours (170) and is therefore a short term 
marker of oxidative stress.  
 
Hydration Status 
Biomarkers measured in spot urine samples must be adjusted for hydration status to prevent over or 
underestimating levels due to individual variation in urine concentration (171).  Osmolality, the measure 
of total solute concentration per kilogram of solution, is considered to be the gold standard for urine 
hydration but is not practical to measure.  Specific gravity (SG), the ratio of the density of urine to that of 
pure water at a constant temperature is a good approximation of osmolality.  SG can be approximately 




SG is influenced by the presence of large molecules so glucose or protein in the urine can lead to an 
overestimation of osmolality.  SG can be measured directly (gravitometry) by comparing the weights of 




refractometer or by measuring the change in pH of a polyelectrolyte in a reagent strip.  Gravitometry is 
the most accurate method of measuring SG but is impractical for routine use or for large samples.  
Refractometry measures the ratio of the velocity of light in air to light in a solution which is proportional 
to the concentration and type of solutes in solution.   Reagent strips are less accurate than refractometry 
but do not require calibration, are less influenced by temperature and glucose, and are disposable so there 
is no possibility of carryover from sample to sample.  Reagent strips do require milliliters of urine 
therefore are not practical for precious samples or high throughput analysis (172). 
 
Hydration status is also commonly adjusted for by measuring creatinine levels in urine.   Creatinine is a 
waste product from the degradation of creatine and creatine phosphate is steadily produced from muscle 
metabolism and is regularly excreted in the urine.  Approximately 2% of body creatine is converted to 
creatinine on a daily basis (171).  Creatinine contributes approximately 1.5% of total urine osmolality 
(172), and studies have demonstrated high correlation between urinary creatinine and specific gravity 
(173, 174).   However, creatinine, unlike specific gravity, is known to vary by gender, age, red meat 
intake, and season (171, 175) which can lead to inaccurate biomarker assessment and biased results.  For 
example mean creatinine levels have been found to be 25-30% higher in men than in women (175) which 
in the case of oxidative stress biomarkers, can lead to overestimating females’ levels of oxidative stress 
compared to men’s’.  Similarly, creatinine excretion decreases with age and explains why spot urine 
samples, adjusted for creatinine, showed oxidative stress increases with age whereas studies using 24hr 
urine samples (which do not require adjustment for hydration status) did not (151). 
 
SG may be more accurate over a broad range of urine dilutions than creatinine. In a 2009 study of drug 
concentrations in urine samples found that control levels adjusted for SG varied from 0.1% to 3% across a 






Oxidative Stress and Breast Cancer 
Oxidative stress may be of particular importance in the etiology of breast cancer (177-185). Oxidative 
stress underlies several risk factors for the disease including ionizing radiation to the chest, alcohol 
consumption, aging, and hormone exposure (91, 186, 187).  Alcohol consumption may result in increased 
levels of oxidative stress specifically in breast tissue because it expresses alcohol dehydrogenase (ADH) 
(188) and xanthine oxidoreductase (XOR). ADH reduces alcohol to acetaldehyde, a reactive intermediate. 
XOR can be reduced by NADH or through its metabolism of acetaldehyde. The re-oxidation of XOR by 
molecular oxygen generates ROS (189). The resulting superoxide anion and hydrogen peroxide can 
produce the hydroxyl radical, the primary ROS that yields 8-OxodG and subsequent mutations.   
 
 
Alcohol, Diet, Hormones and Aging on Oxidative Stress 
Oxidative stress may also have a role in hormone-related risk factors for breast cancer (190).  Risk factors 
such as HRT use, years between menarche and menopause, recent use of oral contraceptives, and even 
obesity, reflect increased exposure to reproductive hormones (37).  Metabolism of these hormones may 
produce substantial oxidative damage. In breast tissue, lactoperoxidase metabolism of estradiol and other 
estrogens with a phenoxy group, can generate superoxide radicals and hydrogen peroxide (42).  Estrogen 
metabolism via the CYP450 1B1 enzymatic reaction to quinones and semi-quinones also produces 
superoxide and hydrogen peroxide (41, 43). While hydrogen peroxide and superoxide are not capable of 
hydroxylating bases directly (191), they have a relatively long half-life, can cross membranes and 
participate in Fenton chemistry in the presence of iron or other transition metals, producing the highly 
reactive hydroxyl radical (162).  In vitro studies have demonstrated that superoxide, produced during 
redox cycling of estrogen quinone metabolites, can reduce ferritin-bound ferric iron (Fe3+) to ferrous iron 
(Fe2+) freeing it to react with hydrogen peroxide (40).   Finally, in vitro studies have demonstrated an 




even further (192).  Studies of oxidative stress have found that isoprostane levels correlated with estrogen 
level both pre- (193) and post-menopausally (190).  A 2002 study found that gender was a better predictor 
of lipid peroxidation than smoking status, with women having much higher plasma isoprostane levels 
than men (194) which could be due to increased levels of estrogen in women. 
 
In addition to increased exposure to oxidative stress, adult breast tissue may be more susceptible to 
oxidative damage than other organs as a result of monthly fluctuations in the growth of mammary ducts 
and lobules (12, 195).   Every month breast tissue responds to fluctuating levels of estrogen and 
progesterone, signaling proliferation of mammary ducts and differentiation of alveolar cells into secretory 
cells until menstruation when cellular activity regresses (7).  There is evidence that highly proliferative 
cells are more vulnerable to oxidative damage (196).  This recurrent cell proliferation limits the time 8-
OxodG repair enzymes can act before an 8-OxodG:A mismatch becomes a permanent and potentially 
carcinogenic mutation (197).  Given these breast-specific sources of oxidative stress and repeated periods 
of increased susceptibility to oxidative damage, we hypothesize that oxidative stress is a causal factor in 
breast cancer development and biomarkers of oxidative stress will be significantly elevated in urine prior 



















SIGNIFICANCE OF STUDY 
 
1. To ascertain if urinary biomarkers of oxidative stress can be used prospectively to identify 
women at risk of breast cancer in order to tailor screening and prevention efforts. 
2. To better understand the mechanisms leading to carcinogenesis by determining if established risk 
factors for breast cancer are potentially mediated by oxidative stress in order to identify avenues 
to reduce risk among women with a family history of breast cancer. 
3. To exam how pubertal development, a critical window of susceptibility, and a family history of 
breast cancer modifies oxidative stress levels. 
 
The current debate as to who will best benefit from mammography highlights the urgent need to improve 
breast cancer risk assessment.  Most screening guidelines for women at “average risk” are determined 
solely by age.  Family history is often used to distinguish high risk from average risk women but as 
discuss previously, family history is a complicated and often inaccurate risk factor.  There have been 
numerous models developed to identify an individual’s remaining lifetime risk or short term risk of breast 
cancer, but these models lack consensus and accuracy, and can vary by age, race or genetic influences 
which may or not be known (84).  An objective reliable marker of breast cancer risk would be of great 
benefit to all women but especially women ages 40-49 who are left on their own to make screening 
decisions. 
 
There is a clearly established link between the cancerous state and oxidative stress.   But given the 
multifaceted effects of ROS on DNA, signaling molecules, antioxidant expression, epigenetic regulation 
and cell cycle control, the role of oxidative stress in cancer initiation or progression is far from 
established.  By assessing biomarkers of oxidative stress prospectively in a cohort of high risk women it 
will be possible to determine how oxidative stress contributes to the risk incurred by family history and if 





The origins of breast cancer risk may be rooted in specific periods of susceptibility. Mounting evidence 
points to puberty as a critical window of vulnerability to carcinogenic insult.   Previous case control 
studies that have looked at early life risk factors are subject to recall bias.  Examining oxidative stress 
biomarkers cross-sectionally and longitudinally in young girls as they progress through puberty will 
clarify the influence developmental changes have on oxidative stress levels and if that change is modified 
by a family history of breast cancer. 
 
SPECIFIC AIMS 
Aim 1: To determine if biomarkers of whole-body oxidative stress can predict the onset of breast cancer, 
we aim to measure and compare levels of 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-OxodG) a product of 
oxidative stress on DNA and 15-isoprostane F2t (Isoprostane) a marker of lipid peroxidation, in 
prospectively collected urine from 73 women in the New York site of the Breast Cancer Family Registry 
(BCFR) who, within 17 years of follow-up, have since gone on to develop breast cancer and from 150 
unaffected control women.   
Hypothesis 1: Oxidative stress contributes to breast cancer development and biomarkers of 
oxidative stress will be significantly elevated in urine prior to breast cancer diagnosis. 
 
Aim 2: To determine if young girls with a family history of breast cancer have different levels of oxidative 
stress than girls without a family history, we aim to cross-sectionally measure and compare levels of 8-
OxodG and F2-Isoprostane in urine from 165 girls ages 6-13 from the New York site of the LEGACY 
cohort, comprised of 71 high risk girls with a family history of breast cancer identified through the BCFR 
and 86 low risk girls without a family history of breast cancer.  
Hypothesis 2a: Biomarkers of oxidative stress will be higher in girls with a family history 





Sub-Aim 2:  Puberty is a time of significant hormone exposure and mitogenic activity in breast tissue (5).  
How these changes influence oxidative stress levels is unknown.  We aim to determine if oxidative stress 
levels vary by stage of pubertal development by examining how the urinary biomarkers 8-OxodG and F2-
IsoP vary by changes in pubertal development, defined by Tanner Stage, both between girls cross-
sectionally and longitudinally within girls. We aim to pay particular attention to oxidative stress levels 
before and after the beginning of breast development, which occurs at Tanner stage 2. 
Hypothesis 2b: Biomarkers of oxidative stress will vary according to stages of pubertal 
development. 
Hypothesis 2c: Biomarkers of oxidative stress will increase in girls during breast 
development and this increase will be modified by a family history of breast cancer. 
 
Studies in adult women were carried out on a subset of participants in the New York Breast Cancer 
Family Registry (NYBCFR).  Adolescent girls were participants in the Lessons in Epidemiology and 





Chapter II: Urinary Oxidative Stress Biomarkers as Predictors of Breast Cancer Risk Among Women in the 




Breast cancer is the most frequently diagnosed cancer in women.  Identifying those most at risk is of great 
public health importance in order to target screening and prevention efforts to women who will benefit 
most while protecting low-risk women from the dangers of over-screening. Oxidative stress, an imbalance 
between reactive oxygen species (ROS) and antioxidant defenses, can lead to mutations and epigenetic 
misregulation that can lead to cancer.  Levels of whole-body oxidative stress can be measured 
inexpensively, reliably and noninvasively in urine (164, 198).  Elevated levels oxidative stress biomarkers 
have been found in breast tumors and in the urine or plasma of breast cancer patients (177, 180, 182, 183, 
185).  The causal relationship between these biomarkers and disease status is unclear from these studies 
since tumors and many cancer therapies are also sources of oxidative stress.  To determine if biomarkers 
of whole-body oxidative stress can predict the onset of breast cancer, we measured and compared levels 
of prospectively collected urinary 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-OxodG), a product of 
oxidative stress on DNA, and urinary 15-isoprostane F2t (F2-Isoprostane), a marker of lipid peroxidation, 
in a nested case control study of 219 women in the New York site of the Breast Cancer Family Registry. 
We found after adjusting for potential confounders or other predictors of breast cancer risk, both urinary 
8-OxodG and urinary F2-Isoprostane levels were significantly and inversely associated with breast cancer 
risk.  Further analysis revealed that the association for both biomarkers was limited to women who were 
under 50 at baseline or of average BMI.  There was also evidence that the relationship between urinary 
F2-Isoprostane levels and breast cancer was modified by a women’s age at menarche.  In a sub-analysis 
we looked at the relationship between urinary oxidative stress biomarkers and tumor characteristics 
among cases. Urinary 8-OxodG levels were significantly negatively associated with diagnosis of estrogen 
receptor negative breast cancer (β=-0.02, OR=0.98, CI 0.96-1.00) and women diagnosed with ER+ breast 
cancer had mean 8-OxodG levels that were 18% lower than women diagnosed with ER- breast cancer.  




between either urinary biomarker and PR status or tumor behavior (invasive vs in situ).  There was 
evidence that the urinary 8-OxodG levels were positively associated with HER2 status of tumor but that 




Recent changes to breast cancer screening recommendations have stressed the need to limit routine 
mammography for women under 50 to those at increased risk of breast cancer (29).  Those at “increased 
risk” are defined as women with either relatively rare genetic mutations (including in BRCA 1/2), prior 
exposure to chest radiation at a young age, a previous diagnosis of breast cancer, or a family history of 
breast cancer, especially in a first degree relative.  A family history of breast cancer does increase the risk 
of breast cancer 2-4 fold (12,13) but family history can be difficult to measure (199). Variation in family 
size means that family history cannot be measured equally between women. Family history may be 
limited by a small number of first-degree relatives or incomplete or inaccurate knowledge of relatives’ 
medical history.   Additionally, both the significance and likelihood of family history changes with age.  
Older women are more likely to have a family history of breast cancer but the risk it conveys is less than 
for a younger woman with the same family history (200, 201).  85% of women diagnosed with breast 
cancer do not have a family history (77). Even women with inherited BRCA1/2 mutations often have no 
family history of breast cancer in a first or second degree relative (202).  Relying on family history to 
determine who to target for additional screening would miss a substantial proportion of high risk women.  
Clearly, an alternative marker for breast cancer risk is needed. 
 
Underlying several known risk factors for breast cancer--including estrogen exposure, alcohol 
consumption, ionizing radiation, and aging--is oxidative stress. Oxidative stress reflects an imbalance 
between ROS and innate antioxidant defenses and can result in mutations, epigenetic misregulation (130), 




in tissue, blood, plasma and urine.  Two of the most validated oxidative stress biomarkers are F2-
Isoprostanes and 8-OxodG (154).  F2-Isoprostanes are produced solely through the free-radical oxidation 
of arachidonic acid, a ubiquitous polyunsaturated fatty acid.  They are rapidly and regularly excreted in 
the urine at levels that are easily detected (157, 203).  8-OxodG is a sensitive marker of oxidative stress 
on guanine either in DNA (Cooke 2005) or in the nucleotide pool (165).  Of all the nucleotide bases, 
guanine is the most vulnerable to oxidative stress due to its low redox potential (204) and can lead to 
point mutations (GCAT transversions).  Neither of these biomarkers is thought to be influenced by 
dietary sources or cell death (159, 164, 205), and both biomarkers can be easily and inexpensively 
measured using well-established ELISAs (198, 206). 
 
Numerous studies have found elevated levels of oxidative stress biomarkers in breast tumors and in the 
urine or plasma of breast cancer patients (177, 180, 182, 183, 185).  However, a major limitation of these 
studies is that they cannot establish if oxidative stress plays a causal role in the initiation or progression of 
breast cancer.  We aim to measure urinary F2-Isoprostane and 8-OxodG in women at high risk for breast 
cancer based on their family history, prior to cancer diagnosis and compare their levels with 2 healthy 
controls matched on age, race, menopausal status, and date of urine donation.  We will also prospectively 




Study Population and Design  
In 1995 the Breast Cancer Family Registry (BCFR) was established at 6 sites across the USA, Canada 
and Australia (Dr. Mary Beth Terry is PI of New York site).  Families were selected from either clinic or 
population based settings. The New York site is clinic-based and families were identified though six 
major New York-area medical centers (Columbia University Medical Center, Memorial Sloan-Kettering 
Cancer Center, Mount Sinai Medical Center, New York University Medical Center, Beth Israel Medical 




as first family member enrolled who may or may not have a personal history of breast cancer) was based 
on one or more of the following criteria: two or more 1st or 2nd relatives or three or more 1st, 2nd or 3rd 
degree relatives with a history of breast or ovarian cancer; a woman diagnosed with breast or ovarian 
cancer under 45 years of age; a woman with a history of both breast and ovarian cancer; an affected male; 
or known BRCA1 or BRCA2 mutation carriers. Special recruitment efforts were made to enroll Ashkenazi 
and minority families. All sites recorded family history data from probands and epidemiological and 
dietary information, and blood samples and/or other biospecimens from probands and selected relatives 
(207).  The NY BCFR was the only site to obtain spot urine samples and only from enrolled women 
between 1997 and 2000 (208).  Urine specimen containers were prepared with 150 mg sodium ascorbate 
as a preservative. Samples were kept chilled in Styrofoam containers, shipped overnight, aliquoted and 
frozen at –80oC in the Biomarkers Core Facility of the Herbert Irving Comprehensive Cancer Center of 
Columbia University, according to protocols established by the BCFR, which includes many “best 
practices” recommended for biospecimen repositories (207).   
  
Since the registry was started over 300 subjects who were unaffected at enrollment have since gone on to 
develop breast cancer.  This included, as of spring 2013, 101 subjects from the New York site, 73 of 
whom gave urine samples. These 73 breast cancer cases in the NY BCFR were individually matched with 
2 controls on:  Age at urine donation (±2 years); race/ethnicity; menopausal status; date of urine donation 
(±1 year).  Controls were alive and still enrolled in the registry at the time of case diagnosis, had not been 
diagnosed with any other cancer other than skin, and were not related to the cases. 
 
Laboratory Assays  
In this nested case-control study within the BCFR, frozen urine samples from 73 cases collected before 
diagnosis and 146 matched controls were used to measure levels of 8-OxodG and F2-IsoP using well-
established ELISAs. All samples were assayed in duplicate and blinded to disease status.  Quality control 




after relabeling to keep laboratory personnel blinded to sample identity.  Urinary biomarker levels were 
normalized for hydration status by measuring specific gravity, assayed using a handheld refractometer 
(TS 400, Reichert, Depew, NY).  Urinary biomarker levels were adjusted for specific gravity using the 
Levine Fahy equation (209): 
 
SG-Adjusted Biomarker (nmol/L*SG) = Biomarker (nmol/L) x [(overall mean SG -1)/ (sample SG -1)] 
 
Urinary F2-IsoP levels were measured using immunoassay kits from Oxford Biomedical Research 
(Product Number: EA85 Oxford, MI) according to the manufacture’s recommendations. Briefly, 100ul of 
diluted urine samples were treated with β-glucoronidase to release any isoprostane bound to glucuronic 
acids for 2hrs at 37oC.  Samples were mixed with a proprietary buffer to eliminate nonspecific binding. 
Samples and standards compete with horseradish peroxidase (HRP) conjugated-15-isoprostane F2t for 
binding to a polyclonal antibody bound to the microplate. The intensity of the color produced when HRP 
substrate is added is inversely proportional to the amount of unconjugated F2-IsoP in the samples or 
standards. F2-IsoP levels were expressed as nmol IsoP/L*Specific Gravity.  
 
For 8-OxodG measurement, urine samples were treated with 20 U/ml urase (Sigma-Aldrich, St. Louis, 
MO, USA) for 2hrs at 37oC to reduce non-specific binding as recommended (210). Urase treatment was 
stopped with N-ethylmaleimide to a final concentration of 4 mM for 5 min at room temperature.  The 
supernatant was removed after centrifugation and then used for Solid Phase Extraction (SPE) as described 
by Lam et al (211). Briefly, urease treated urine samples were passed through a hydroxylated polystyrene-
divinylbenzene sorbent column (Biotage  915-0050-P01) to isolate the polar 8-OxodG analyte from 
aqueous solutions.  The analyte was eluted from the column with 20% acetonitrile in 80% methanol, 





The eluted urine samples were then used in an in-house competitive ELISA.  96-well plates were coated 
with 10ng/well 8-OxoG-Bovine Serum Albumin (BSA) overnight and blocked with 1% fetal calf serum 
in 0.05% Tween in PBS.  25ul of the eluted urine analyte was added in duplicate to the plate along with 
serial dilutions of an 8-OxodG standard from Sigma. Sample and standards were incubated with 50ul 
(0.2ug/ml) anti-8-OxodG N45.1 antibody (Japanese Institute for the Control of Aging, Shizuoka, Japan) 
overnight at 4C. After plates were washed in PBS 0.05% Tween, an anti-mouse-Alkaline Phosphatase-
conjugated antiserum was used to detect antibody still bound to the coated plate. Color intensity is 
inversely proportional to 8-OxodG levels in the samples. Results were adjusted for specific gravity, a 
measure of hydration status of the urine, and reported as nmol 8-OxodG/L*Specific Gravity.  The 
significant processing required for the 8-OxodG ELISA increases the between plate variability.  To 
minimize this, matched case control pairs were run in the same SPE and ELISA plate. 
 
Statistical Analysis  
Baseline demographic covariates between cases and controls were evaluated for any potential 
confounding factors using chi square tests for categorical factors and t-test for normally distributed 
continuous variables.  Wilcoxon signed rank tests were used for continuous variables that were not 
normally distributed.  The distribution of urinary isoprostane and 8-oxodG levels was examined 
graphically to identify any potential outliers.  Outliers were traced back to their ELISA measurements to 
compare levels among duplicate sample to ensure they were comparable and to ensure they were within 
the limits of detection.  Characteristics of the outliers were inspected to determine if extreme biomarker 
levels were driven by a particular exposure or condition.   
 
Unpaired T-tests were used to compare the overall mean difference in urinary 8-oxodG levels and 
Wilcoxon rank-sum tests were used to compare the mean difference in urinary isoprostane levels which 




significant linear trend for ordinal categorical variables.  Conditional logistic regression was used to 
determine the effect estimate and OR of baseline oxidative stress biomarker levels on future diagnosis of 
breast cancer as both continuous and as categorical variables.  Cutoffs for tertiles of biomarker levels 
were based on its distribution among controls.  Models were adjusted for covariates that may influence 
both oxidative stress and breast cancer risk.  These included, a priori, average physical activity level, fruit 
and vegetable intake, alcohol intake, smoking history, body mass index (BMI), age at menarche, age at 
first birth, parity status at enrollment, oral contraceptive and hormone replacement therapy (HRT) use, 
BRCA1/2 mutation status, extent of family history of breast cancer, previous diagnosis of benign breast 
disease, and lifetime number of mammograms and chest x-rays.  Only covariates that changed the effect 
estimate of the biomarker level on disease outcome by >10% were included in the fully adjusted model.  
Linear regression was used to examine the relationship between the covariates that did change the effect 
estimate by more than 10% and oxidative stress to determine if they could be mediating the effect of 
oxidative stress and disease outcome.  
 
A sub-analysis of oxidative stress levels at baseline and outcomes among the 73 cases was also 
performed.  Unconditional logistic regression was used to examine oxidative stress and binary outcomes 
such as survival, behavior of tumor (invasive vs in situ) and estrogen/progesterone/Her2 receptor status of 
the tumor.  Linear regression was used to estimate the effect of oxidative stress biomarkers on continuous 
outcomes such as age at diagnosis and time to diagnosis from urine donation.  ROC curves were created 
to test the predictive value of adding tertiles of urinary oxidative stress biomarkers to the NCI’s Breast 
Cancer Risk Assessment Tool (212) and to our final model based on significant predictors of breast 
cancer risk in this cohort. All statistical tests were two-sided with a significance level of 0.05.   All 










Baseline Urinary Oxidative Stress Biomarkers and Breast Cancer Diagnosis 
Characteristics of Study Population 
Descriptive characteristics of our nested case control study population are shown in Table 1.  73 breast 
cancer cases were successfully matched to two controls on age at baseline (±2 years), menopausal status, 
race, and age of urine sample (±1 year).  Participants ranged in age from 24 to 83 with average age of 48.  
2.7% of the women identified as Hispanic or Latino and the rest were White.   Approximately 30% of the 
women had completed menopause at baseline.  There was no significant difference in age at menopause 
between cases and controls. 8% of the women were positive for a BRCA1 or BRCA2 mutation and 60% 
had a family history of breast cancer in a 1st or 2nd degree relative.  As previously reported (202) we found 
that almost half of the women with a BRCA1/2 mutation (8/17) reported no family history in a 1st or a 2nd 
degree relative.  Cases had fewer (1.4 vs 1.9) live births than controls (p=0.027) but were not statistically 
less likely to be parous than controls (p=0.33).  Cases were more likely to be positive for BRCA1 or 
BRCA2 mutations (p=0.0003).  Among modifiable covariates the only statistically significant differences 
between cases and controls were in hours of moderate exercise per week and BMI category.  Three F2-
Isoprostane outliers were identified and examined.  They were all within the limits of detection of the 
ELISA with good agreement between duplicates.  All three outliers were among current or former 
smokers who smoked for between 10-40 years, which we believe contributed to the high levels of F2-
Isoprostane. 
 
Urinary 8-OxodG and Breast Cancer:  
Overall we found a non-significant inverse association between urinary 8-OxodG levels and breast cancer 
risk using conditional logistic regression (Table 2). Controls had on average 9% higher levels of urinary 
8-OxodG than cases with mean level among controls of 87.6nmol/L*SG compared to 80.4nmol/L*SG 
among cases (Wilcoxon Mann Whitney test p=0.15).  This was in contrast to out hypothesis that cases 




logistic regression model (Table 4) we found that for every 10nmol/L*SG increase in 8-OxodG the odds 
of breast cancer decreased by 9% (β=-0.01, OR 0.99, CI 0.98-0.99 for 1-unit increase).   
 
Adjusting for all covariates that changed the crude effect estimate by 10% or more (BRCA1/2 Status, 
number of live births, time between menarche and parity or menopause, having a  2nd degree relative with 
breast cancer, season of urine collection, lifetime number of mammograms and category of fruit and 
vegetable intake) strengthened the inverse association.  In this fully adjusted model, only 8-OxodG and 
BRCA1/2 status remained significant predictors of breast cancer risk. In our univariate analysis (Table 2) 
we found that after urinary 8-OxodG was in the conditional logistic regression model, only number of live 
births, time between menarche and parity or menopause, BRCA1/2 status, and BMI remained significantly 
associated with the risk of breast cancer.   In our final parsimonious model adjusting for variables 
significantly predictive of breast cancer in our study population (8-OxodG, BRCA1/2 status, time between 
menarche and parity/menopause, and categorical BMI) we found that every 10nmol/L*SG increase in 8-
OxodG decreased the odds of breast cancer by 14% after other predictive variables were in the model (β= 
-0.014, OR=0.99, CI 0.97-1.00 for a 1-unit increase).   
 
Stratifying our conditional logistic regression analysis by age at baseline (women 50 and under/women 
over 50, Table 4) we found the inverse relationship between 8-OxodG and breast cancer risk was stronger 
in women under 50 than in the overall study population or in women over 50. There was no association 
between 8-OxodG and breast cancer in women 50 and older (β=0.0011, OR=1.00, CI 0.98-1.02) even 
after adjusting for potential confounders.  Likewise, stratifying the conditional logistic regression analysis 
by BMI category (average v overweight) we found the inverse association between 8-OxodG and breast 
cancer risk was limited to women who had an average BMI (<25) at baseline.  We found no discernable 





Urinary 8-OxodG levels were divided into tertiles according to their distribution among controls (Table 
5).  In our unadjusted conditional logistic regression model we found that women in the highest tertile of 
8-OxodG (>98.20nmol/L*SG) had a 40% reduction in the odds of developing breast cancer compared to 
women in the lowest tertile (<69.13nmol/L*SG) of 8-OxodG (β= -0.51, OR=0.60, CI 0.36-1.00).  
Adjusting for all covariates that changed the unadjusted effect estimate by 10% or more strengthened the 
inverse association (β= -0.85, OR=0.43, CI 0.23-0.80).  Our final parsimonious model, as above, was 
adjusted for BRCA1/2 status, time between menarche and parity or menopause and BMI category.   This 
final model also strengthened the association between urinary 8-OxodG and breast cancer diagnosis 
relative to the unadjusted model. Women in the highest tertile of 8-OxodG had less than half the odds of 
breast cancer compared to women in the lowest tertile of 8-OxodG after adjusting for significant risk 
factors for breast cancer (β= -0.79, OR=0.45, CI 0.253-0.831). In the final model, we observed a 
significant positive association between breast cancer risk for women in the middle tertile of 8-OxodG 
(β= 0.57, OR=1.76, CI 1.07-2.91), indicating that the relationship between 8-OxodG and breast cancer 
risk may be non-linear.  The positive association between breast cancer risk and 8-OxodG levels in the 
middle tertile (69.13-98.20nmol/L*SG) was particularly strong among women with an average BMI, non-
BRCA1/2 mutation carriers, or were over 50 at baseline. An examination of risk factor distribution by 
tertiles of 8-OxodG revealed older women were more likely to be in the middle tertile; 63% of the breast 
cancer cases in women over 50 had 8-OxodG levels that fell in the middle tertile, which may explain the 





Table 1 BCFR Baseline Covariates
Variable
n (%) Mean n (%) Mean p*
Matched Variables 73 146
Age at Baseline continuous 48.0 47.9
24-39 17 (23) 31 (21)
40-44 12 (16) 31 (21)
45-50 14 (19) 27 (18)
51-56 13 (18) 31 (21)
72-83 17 (23) 26 (18)
<50 40 (55) 83 (57)
50 or older 33 (45) 63 (43)
Race Hispanic/Latino 2 (3) 4 (3)
White/Caucasian 71 (97) 142 (97)
Age of Urine Sample continuous 14.9 14.8
11.8-14.2 years 20 (27) 35 (24)
14.3-14.9 years 13 (18) 39 (27)
15.0-15.4 years 19 (26) 36 (25)
15.4-16.6 years 21 (29) 36 (25)
Menopausal Status Not yet begun 35 (48) 80 (56)
Begun, not completed 6 (8) 14 (10)
Completed 24 (33) 43 (29)
Using HRT/Not Sure if Begun 8 (11) 9 (6)
continuous 15 46.9 34 47.6
Demographics
Highest Education Level HS Graduate or Less 8 (11) 16 (11)
Some Post HS Education 13 (18) 28 (19)
Bachelors Degree 28 (38) 51 (35)
Graduate Degree 24 (33) 51 (35)
Season of Collection Winter 22 (30) 40 (27)
Spring 17 (23) 39 (27)
Summer 17 (23) 44 (30)
Fall 17 (23) 23 (16)
Hormonal, FH and Reproductive Variables
Age at Menarche continuous 12.6 12.4
<12 years old 12 (16) 32 (22)
12-13 years old 46 (63) 88 (60)
>13 years old 15 (21) 26 (18)
Parity No 23 (32) 37 (25)
Yes 50 (68) 109 (75)
Yrs Btwn Menarche and Parity or 
Menopause continuous 19.7 17.2 0.05
Number of Live Births continuous 1.4 1.9 0.03
0 23 (32) 37 (26) 0.06
1 10 (14) 12 (8)
2 27 (37) 52 (36)
3 12 (16) 27 (18)
4 or more 1 (1) 18 (12)
Age at 1st Live Birth (among parous) continuous 27.7 26.3 0.05
<24 years old 7 (14) 36 (33) 0.04
24-28 years old 24 (48) 39 (36)
>28 years old 19 (38) 34 (31)
Breastfeeding History Never 37 (51) 77 (53)
Ever 36 (49) 69 (47)
Max Duration of BF Any Child None 37 (51) 78 (53)
<1 Month 5 (7) 7 (5)
1-5 Months 8 (11) 22 (15)
6-11 Months 10 (14) 22 (15)
12-24 Months 10 (14) 14 (10)
>24 Months 3 (4) 3 (2)
Current Hormonal Birth Control Use No 65 (89) 134 (92)
Yes 8 (11) 12 (8)
Current HRT No 62 (85) 121 (83)
Yes 11 (15) 25 (17)
Years on HRT None 56 (77) 113 (77)
1-10 years 13 (18) 30 (21)
More than 10 years 4 (5) 4 (3)
No 26 (36) 62 (42)
Yes 47 (64) 84 (58)
# 1st degree relatives with breast 
cancer 0 32 (44) 81 (55)
1 41 (56) 64 (44)
2 0 (0) 1 (0.68)
# 2nd degree relatives with breast 
cancer
0 46 (63) 107 (73.29)
1 24 (33) 36 (24.66)
2 3 (4) 3 (2.05)
BRCA1/2 Mutation Status Missing/Not Tested 26 (36) 53 (36.30) 0.0003
Negative 34 (47) 89 (60.96)
Positive 13 (18) 4 (2.74)
Benign Breast Disease No 51 (70) 110 (75)
Yes 22 (30) 36 (25)
*Chi-Squared Test on Categorical Variables, Wilcoxon Mann Whitney Test on continuous variables. 
Cases Controls
Age at Menopause (among 49 post-
menopausal women)
Family History of Breast Cancer in a 1st       






Table 1 BCFR Baseline Covariates (Continued)
Variable
n (%) Mean n (%) Mean p*
Modifiable Variables
Smoking Status Current 4 (5) 9 (6)
Former 30 (41) 49 (34)
Never 39 (53) 88 (60)
Years Smoking continuous 7.7 5.6
Fruit and Veg Intake (cups/day) continuous 8.8 8.7
Hours of Moderate Exercise/Week None 8 (11) 23 (16) 0.05
0.5-1hrs 6 (8) 26 (18)
1.5-2hrs 14 (19) 33 (23)
3hrs 19 (26) 21 (14)
4-6hrs 20 (27) 25 (17)
7 or more hrs 6 (8) 18 (12)
Hours of Strenuous Exercise/Week None 36 (49) 73 (50)
0.5-2hrs 14 (19) 34 (23)
3hrs 10 (14) 18 (12)
4 or more hrs 13 (18) 21 (14)
Frequency Moderate Exercise  never 7 (10) 26 (18)
1-6 times/month 9 (12) 28 (19)
7-9 times/month 14 (19) 18 (12)
10-12 times/month 43 (59) 74 (51)
Frequency Strenuous Exercise never 30 (41) 69 (47)
1-9 times/month 15 (21) 26 (18)
10-12 times/month 28 (38) 51 (35)
Ever Consume Alcoholic Beverages? No 33 (45) 73 (50)
Yes 40 (55) 73 (50)
Weekly Units of Wine 0 52 (71) 104 (71)
1-2 13 (18) 21 (14)
3-4 4 (5) 11 (8)
5-6 3 (4) 8 (5)
7 or more 1 (1) 2 (1)
Weekly Units of Beer 0 63 (86) 131 (90)
1-2 6 (8) 9 (6)
3 or more 4 (5) 6 (4)
Weekly Units of Hard Alcohol 0 62 (85) 131 (90)
1-2 7 (10) 8 (5)
3 or more 4 (5) 7 (5)
Lifetime # Mammograms continuous 9.1 7.7
<5 22 (30) 56 (38)
5-10 29 (40) 50 (34)
>10 22 (30) 40 (27)
Lifetime # Chest X-Rays continuous 10.0 17.0
BMI continuous 25.0 25.4
Underweight-Normal (<25) 40 (55) 88 (60) 0.02
Overweight (25-29) 27 (37) 32 (23)
Obese (30+) 6 (8) 26 (18)
Vitamin and Supplement Use
Stress Tabbs Type Vitamin No 67 (92) 134 (92)
Yes 6 (8) 12 (8)
Theraputic Type Vitamin No 61 (84) 132 (90)
Yes 12 (16) 14 (10)
One a Day Multivitamin No 44 (60) 92 (63)
Yes 29 (37) 54 (37)
Vitamin C Supplement No 38 (52) 87 (60)
Yes 35 (48) 59 (40)
Vitamin E Supplement No 42 (58) 92 (63)
Yes 31 (42) 54 (37)
Selenium Supplement No 66 (90) 134 (92)
Yes 7 (10) 12 (8)
β-Carotene Supplement No 69 (95) 135 (92)
Yes 4 (5) 11 (8)
Iron Supplement No 68 (93) 139 (95)
Yes 5 (7) 7 (5)
Calcium Supplement No 35 (48) 85 (58)
Yes 38 (52) 61 (42)





Urinary F2-Isoprostane and Breast Cancer   
As with our 8-OxodG biomarker, we found a negative association between urinary isoprostane levels and 
breast cancer risk (Tables 3 and 4), although it did not reach statistical significance in the unadjusted 
model (β= -0.04, OR=0.96, CI 0.93-1.01).  Controls had an average urinary F2-Isoprostane level of 
12.77nmol/L*SG while cases had a mean level of 7.93nmol/L*SG (Wilcoxon Mann Whitney Test: 
p=0.08).  Adjusting for all covariates that altered the unadjusted effect estimate by 10% or more 
(BRCA1/2 status, time between menarche and parity or menopause, duration of breast feeding, number of 
2nd degree relatives with breast cancer, season of urine collection) we found a statistically significant 49% 
decrease in risk for every 10-unit increase in urinary isoprostane (β= -0.07, OR=0.94 CI 0.89-0.99 for a 1-
unit increase).  Using a more parsimonious model that only included covariates that remained 
significantly associated with breast cancer diagnosis (BRCA1/2 status, time between menarche and parity 
or menopause and categorical BMI), F2-Isoprostane levels were still significantly inversely associated 
with breast cancer diagnosis (β= -0.05, OR=0.9559, CI 0.91-0.999 for a 1-unit increase). 
 
We examined the relationship between F2-Isoprostanes and breast cancer separately in women above and 
below 50 years of age and women who reached menarche at an early to normal age.  Limiting our 
conditional logistic regression to cases who were age of 50 at baseline and their matched controls, we 
found that unadjusted F2-Isoprostane levels were inversely associated with breast cancer diagnosis (β= -
0.022, OR=0.952, CI 0.911-0.995) and as with our results for 8-OxodG levels, there was no statistically 
significant association between F2-Isoprostane and breast cancer diagnosis in women 50 and older at 
baseline (Table 4).   
 
Examination of scatterplots of F2-Isoprostane levels and age at menarche by cases status showed a 
possible effect measure modification (Figure 1); women who reached menarche by the time they were 13, 
and later went on to develop breast cancer, appeared to have lower F2-Isoprostane levels than women 




Table 2: Univariate Analysis: Odds of Breast Cancer and  8oxodG (nmol/L*SG)
Variable Cases Controls β OR p
Overall 8oxodG (nmol/L*SG) 80.4 87.6 -0.01 0.99 0.98 1.00 0.10
80.4 87.6 0.15 *
Matched Variables






50 or older 84.8 87.2
Race Hispanic/Latino 104.8 71.4
White/Caucasian 79.7 88.1




Menopausal Status Not yet begun 74.4 85.9
Begun, not completed 67.6 95.5
Using HRT/Not Sure if Begun 88.0 74.7
Completed 89.9 91.0
Highest Education Level High School Graduate or Less 105.3 85.0 ref
Some Post High School Education 75.9 96.2 -0.05 0.95 0.53 1.72 0.88
Bachelors Degree 80.9 85.3 0.09 1.10 0.68 1.78 0.71
Graduate Degree 74.0 86.0 -0.03 0.97 0.59 1.59 0.91
Season of Urine Collection Winter 77.5 90.0 ref
Spring 80.7 84.7 -0.18 0.84 0.49 1.42 0.51
Summer 78.7 89.1 -0.31 0.73 0.45 1.20 0.21
Fall 85.6 85.4 0.45 1.57 0.89 2.77 0.12
Hormonal, FH and Reproductive Variables
Age at Menarche continuous 0.11 1.12 0.90 1.38 0.31
<12 82.9 82.1 -0.31 0.73 0.43 1.24 0.24
12 to 13 80.3 89.4 ref
>13 78.8 88.5 0.19 1.21 0.73 2.01 0.45
Younger than 40 (Assumed Premenopausal) No 82.4 88.5 ref
Yes 74.0 84.5 0.04 1.05 0.75 1.47 0.80
Parity (Any Live Births) No 70.6 85.8
Yes 85.0 88.2 -0.22 0.80 0.56 1.14 0.22
Time Btwn Menarche and Parity/Menopause continuous 0.04 1.04 1.00 1.07 0.03
# Live Births continuous -0.33 0.72 0.56 0.91 0.01
0 70.6 85.8 ref
1 73.4 78.5 0.79 2.19 0.94 5.11 0.07
2 85.8 84.7 0.38 1.47 0.79 2.72 0.22
3 93.7 96.2 0.18 1.20 0.58 2.47 0.62
4 or more 73.8 92.9 -2.05 0.13 0.02 0.70 0.02
Age at 1st Live Birth (Among All: Centered at 27 yrs) continuous 0.07 1.07 0.99 1.15 0.08
Age at 1st Live Birth (Among Parous Women) 16-24 85.6 95.3 ref
24-28 89.1 83.7 0.49 1.64 0.94 2.86 0.08
29-42 79.6 85.9 0.58 1.78 0.90 3.52 0.10
Breastfeeding History (Among All) Never 76.8 90.1 ref
Ever 84.2 84.8 0.03 1.03 0.70 1.50 0.85
Breastfeeding History (Among Parous Women) Never 86.6 93.4 ref
Ever 84.2 84.7 0.21 1.23 0.84 1.80 0.29
Max Time Nursing Any Child Nulliparous 70.2 85.8 0.19 1.21 0.71 2.06 0.49
<1 Month/Did Not Nurse 82.7 92.0 -0.46 0.63 0.36 1.12 0.11
1-11 Months 87.1 84.2 -0.25 0.78 0.47 1.27 0.31
>12 Months 85.3 87.2 ref
Current Hormonal Birth Control Use No 79.3 87.6 ref
Yes 89.7 87.4 0.28 1.33 0.75 2.34 0.33
Current HRT Use No 80.0 86.5 ref
Yes 83.0 92.8 -0.10 0.90 0.55 1.47 0.67
Family History in a 1st or 2nd Degree Relative Yes 77.6 85.8 ref
No 85.6 90.1 -0.16 0.85 0.64 1.15 0.30
# 1st degree relatives with breast cancer none 84.8 89.2 ref
1 or more 77.0 85.6 0.25 1.28 0.96 1.71 0.09
# 2nd degree relatives with breast cancer none 83.5 87.7 ref
1 or more 75.3 87.3 0.23 1.26 0.91 1.74 0.16
BRCA1/2 Status Missing/Not Tested 83.4 94.6 -0.57 0.56 0.33 0.97 0.04
Negative 74.4 82.5 ref
Positive 90.2 108.6 1.49 4.46 1.87 10.63 0.001
Benign Breast Disease No 83.7 88.2 ref
Yes 72.8 85.9 0.14 1.15 0.83 1.60 0.41










Table 2: Univariate Analysis: Odds of Breast Cancer 8oxodG (nmol/L*SG)
Variable Cases Controls β OR p
Modifiable Variables
Smoking Status Current 76.7 80.1 -0.06 0.94 0.41 2.15 0.89
Former 88.8 86.3 0.22 1.24 0.73 2.11 0.42
Never 74.3 89.1 ref
Fruit and Veg Intake (cups/day) very low (<4.7) 91.9 94.8 ref
low (4.7-6.4) 73.2 79.8 -0.01 0.99 0.57 1.74 0.98
average (6.4-8.5) 67.7 92.4 0.01 1.01 0.57 1.79 0.97
high (8.5-12.5) 87.9 83.0 0.23 1.26 0.74 2.16 0.40
very high (>12.5) 81.3 87.2 0.06 1.06 0.59 1.91 0.85
Hours of Moderate Exercise/Week None 100.1 73.6 ref
0.5-3hrs 76.3 88.1 0.04 1.04 0.69 1.57 0.86
4 or more hrs 80.6 94.3 0.36 1.43 0.86 2.37 0.16
Hours of Strenuous Exercise/Week None 81.2 85.9 ref
0.5-2hrs 83.2 95.4 -0.19 0.83 0.47 1.44 0.51
3hrs 78.3 90.6 0.12 1.13 0.58 2.21 0.72
4 or more hrs 76.9 78.4 0.13 1.14 0.64 2.04 0.65
Frequency Moderate Exercise  never 94.1 82.6 ref
1-9 times/month 77.9 94.0 0.19 1.21 0.77 1.91 0.41
10-12 times/month 79.6 85.4 0.36 1.44 0.92 2.25 0.11
Frequency Strenuous Exercise never 79.7 87.7 ref
1-9 times/month 76.1 88.3 0.13 1.13 0.70 1.83 0.61
10-12 times/month 83.6 87.2 0.08 1.08 0.73 1.61 0.69
Ever Consume Alcohol No 78.9 85.1 ref
Yes 81.7 90.1 0.11 1.11 0.85 1.45 0.42
Weekly Units of Wine None 82.9 89.0 ref
1-2 77.9 78.2 0.23 1.26 0.54 2.94 0.60
3-4 64.1 90.0 -0.30 0.74 0.25 2.25 0.60
5-6 81.6 82.6 -0.24 0.78 0.24 2.59 0.69
7 or more 46.8 123.3 0.22 1.25 0.17 9.26 0.83
Weekly Units of Beer None 81.3 88.1 ref
1-2 76.8 77.5 0.00 1.00 0.43 2.29 0.99
3 or more 72.5 92.8 0.18 1.20 0.46 3.13 0.71
Weekly Units of Hard Alcohol None 82.0 86.7 ref
1-2 75.2 94.8 0.31 1.37 0.63 2.99 0.43
3 or more 65.5 95.9 -0.05 0.95 0.39 2.29 0.91
Lifetime # Mammograms Low (<5) 76.7 87.1 ref
Med (5-10) 79.5 84.5 0.26 1.30 0.84 2.02 0.25
High (>10) 85.5 92.3 0.30 1.34 0.81 2.24 0.26
Lifetime # Chest X-Rays (Including Mammograms) Low (< 6) 80.3 87.7 ref
Medium (6-12) 74.0 79.7 -0.06 0.95 0.62 1.44 0.79
High (13-41) 87.9 96.6 0.03 1.03 0.64 1.65 0.90
BMI underweight-normal (>25) 71.2 90.5 ref
overweight (25-29) 93.5 84.8 0.68 1.98 1.20 3.27 0.01
obese (>29) 83.1 81.3 -0.69 0.50 0.26 0.96 0.04
Vitamin and Supplement Use
Stress Tabbs Type Vitamin No 81.4 87.1 ref
Yes 69.9 93.0 0.02 1.02 0.61 1.71 0.97
Theraputic Type Vitamin No 77.9 87.8 ref
Yes 93.5 86.3 0.68 1.98 1.29 3.03 0.12
One a Day Multivitamin No 82.6 86.4 ref
Yes 77.2 89.7 0.08 1.08 0.79 1.46 0.81
Vitamin C Supplement No 77.0 85.4 ref
Yes 84.1 90.9 0.38 1.47 1.08 1.99 0.22
Vitamin E Supplement No 78.4 88.7 ref
Yes 83.1 85.8 0.25 1.28 0.93 1.76 0.45
Selenium Supplement No 80.8 89.0 ref
Yes 76.8 72.3 0.14 1.15 0.69 1.93 0.79
β-Carotene Supplement No 79.7 88.1 ref
Yes 93.0 81.7 -0.31 0.73 0.40 1.32 0.60
Iron Supplement No 80.4 88.1 ref
Yes 81.6 77.2 0.40 1.49 0.82 2.72 0.51
Calcium Supplement No 86.4 89.7 ref











Table 3: Univariate Analysis: Odds of Breast Cancer and Isoprostane (nmol/L*SG)
Variable Cases Controls β OR p
Overall  Isoprostane (nmol/L*SG) 7.93 12.77 -0.04 0.96 0.93 1.01 0.09
7.93 12.77 0.08  + 
Matched Variables






50 or older 8.27 11.27
Race Hispanic/Latino 20.27 14.46
White/Caucasian 7.58 12.73




Menopausal Status Not yet begun 8.02 12.98
Begun, not completed 10.09 21.71
Using HRT/Not Sure if Begun 9.88 12.67
Completed 6.60 9.50
Highest Education Level High School Graduate or Less 8.48 6.83 ref
Some Post High School Education 6.76 13.65 0.01 1.01 0.56 1.83 0.97
Bachelors Degree 6.95 13.40 0.14 1.15 0.71 1.87 0.57
Graduate Degree 9.52 13.53 0.00 1.00 0.61 1.67 0.98
Season of Urine Collection Winter 8.43 9.25 ref
Spring 5.04 17.79 -0.20 0.82 0.48 1.41 0.47
Summer 8.61 11,94 -0.28 0.75 0.46 1.23 0.26
Fall 9.49 11.98 0.46 1.59 0.89 2.84 0.12
Hormonal, FH and Reproductive Variables
Age at Menarche continuous 0.13 1.14 0.92 1.42 0.23
<12 4.84 16.47 -0.28 0.76 0.45 1.29 0.31
12 to 13 7.33 11.59 ref
>13 12.22 12.23 0.27 1.31 0.78 2.21 0.31
Younger than 40 (Assumed Premenopausal) No 8.05 11.79 ref
Yes 7.53 16.43 0.08 1.08 0.77 1.52 0.66 ⁰
Parity (Any Live Births) No 9.51 22.06 ref
Yes 7.20 9.62 -0.21 0.81 0.57 1.16 0.25
Time Btwn Menarche and Parity or Menopause continuous 0.04 1.04 1.01 1.08 0.02
# of Live Births continuous -0.32 0.73 0.57 0.93 0.01
0 9.51 22.06 ref
1 7.67 11.82 0.79 2.21 0.94 5.16 0.07
2 6.28 9.97 0.34 1.40 0.77 2.55 0.27
3 8.53 7.00 0.09 1.10 0.54 2.23 0.79
4 or more 11.33 11.09 -1.83 0.16 0.03 0.82 0.03
Age at 1st Live Birth (Among All: Centered at 27 yrs) continuous 0.08 1.08 1.00 1.16 0.05
Age at 1st Live Birth (Among Parous Women) 16-23 11.43 8.71 ref
24-28 7.27 10.43 0.50 1.64 0.92 2.93 0.09
29-42 5.55 9.66 0.76 2.14 1.02 4.51 0.04
Breastfeeding History (Among All) Never 7.70 14.79 ref
Ever 8.16 10.52 0.04 1.04 0.79 1.37 0.77
Breastfeeding History (Among Parous Women) Never 6.28 8.62 ref
Ever 7.63 10.30 0.23 1.26 0.85 1.88 0.25
Max Time Nursing Any Child Nulliparous 8.56 22.06 0.17 1.19 0.69 2.04 0.53
<1 Month/Did Not Nurse 7.02 8.38 -0.47 0.62 0.35 1.11 0.11
1-11 Months 7.08 10.10 -0.30 0.74 0.45 1.21 0.23
>12 Months 9.61 12.64 ref
Current Hormonal Birth Control Use No 7.82 11.65 ref
Yes 8.80 25.29 0.27 1.31 0.76 2.25 0.33
Current HRT Use No 8.05 11.54 ref
Yes 7.24 18.76 -0.14 0.87 0.53 1.42 0.57
Family History in a 1st or 2nd Degree Relative Yes 7.85 14.50 ref
No 8.07 10.43 -0.14 0.87 0.64 1.17 0.34
# 1st degree relatives with breast cancer none 8.16 13.02 ref
1 or more 7.74 12.47 0.22 1.24 0.93 1.66 0.14
# 2nd degree relatives with breast cancer none 8.21 12.17 ref
1 or more 7.45 14.43 0.24 1.27 0.91 1.77 0.16
BRCA1/2 Status Missing/Not Tested 10.38 11.38 -0.56 0.57 0.33 0.98 0.04
Negative 6.78 13.46 ref
Positive 6.01 15.84 1.49 4.43 1.85 10.62 0.001
Benign Breast Disease No 7.39 12.17 ref
Yes 9.18 14.61 0.17 1.18 0.85 1.64 0.32
No 8.07 10.43 -0.14 0.87 0.64 1.17 0.34
+ Wilcoxon Man Whitney Test of Means
⁰ Unconditional Logistic Regression












Table 3: Univariate Analysis: Odds of Breast Cancer and Isoprostane (nmol/L*SG) 
Variable Cases Controls β OR p
Modifiable Variables
Smoking Status Current 19.70 31.11 0.01 1.01 0.43 2.39 0.97
Former 7.15 15.25 0.17 1.19 0.69 2.05 0.54
Never 7.32 9.52 ref
Fruit and Veg Intake (cups/day) 0.78-4.70 8.80 16.16 ref
4.71-6.43 6.70 9.40 -0.06 0.94 0.53 1.65 0.82
6.44-8.48 7.61 11.64 0.00 1.00 0.57 1.77 1.00
8.49-12.50 8.60 8.13 0.25 1.29 0.75 2.19 0.36
12.51-33.73 7.88 17.87 0.06 1.06 0.59 1.93 0.84
Hours of Moderate Exercise/Week None 4.88 13.96 ref
0.5-3hrs 8.36 11.80 0.02 1.02 0.67 1.54 0.93
4 or more 8.21 13.95 0.30 1.35 0.81 2.24 0.25
Hours of Strenuous Exercise/Week None 7.79 13.90 ref
0.5-2hrs 8.33 12.77 -0.20 0.82 0.47 1.44 0.48
3hrs 6.02 10.48 0.00 1.00 0.51 2.00 0.99
4 or more hrs 9.33 10.82 0.22 1.25 0.71 2.21 0.45
Frequency Moderate Exercise  never 5.41 13.47 ref
1-9 times/month 5.61 14.61 0.16 1.17 0.75 1.83 0.48
10-12 times/month 9.58 11.39 0.34 1.41 0.90 2.20 0.13
Frequency Strenuous Exercise never 7.97 14.35 ref
1-9 times/month 7.74 16.81 0.16 1.17 0.72 1.90 0.52
10-12 times/month 7.98 8.58 0.00 1.00 0.67 1.48 0.98
Ever Consume Alcohol Never 7.67 11.25 ref
Ever 8.14 14.30 0.08 1.09 0.84 1.41 0.52
Weekly Units of Wine None 7.37 12.88 ref
1-2 7.39 9.47 0.32 1.38 0.59 3.24 0.46
3-4 18.69 23.12 -0.10 0.90 0.30 2.70 0.86
5-6 7.14 7.04 -0.19 0.83 0.25 2.71 0.75
7 or more 3.02 7.93 -0.13 0.88 0.12 6.48 0.90
Weekly Units of Beer None 7.57 13.45 ref
1-2 13.06 6.33 0.06 1.07 0.46 2.47 0.88
3 or more 5.92 7.76 0.14 1.15 0.45 2.93 0.77
Weekly Units of Hard Alcohol None 7.45 13.23 ref
1-2 9.81 9.91 0.27 1.31 0.59 2.90 0.51
3 or more 11.95 7.43 0.00 1.00 0.41 2.42 1.00
Lifetime # Mammograms Low (<5) 8.83 13.41 ref
Med (5-10) 6.34 11.40 0.25 1.29 0.83 2.00 0.26
High (>10) 9.12 13.61 0.31 1.37 0.81 2.29 0.24
Lifetime Chest X-Rays (Including Mammograms) Low (< 6) 7.87 13.53 ref
Medium (6-12) 8.47 11.35 -0.03 0.97 0.63 1.48 0.89
High (13-41) 7.38 13.45 -0.02 0.98 0.61 1.57 0.93
BMI underweight-normal (18.5-24.99) 7.65 14.64 ref
overweight (25-29) 8.10 9.75 0.74 2.09 1.25 3.49 0.00
obese (>29) 8.97 10.17 -0.72 0.49 0.25 0.93 0.03
Vitamin and Supplement Use
Stress Tabbs Type Vitamin No 7.74 12.74 ref
Yes 10.00 13.16 -0.02 0.98 0.347 2.80 0.98
Theraputic Type Vitamin No 7.72 13.03 ref
Yes 9.00 10.35 0.62 1.86 0.801 4.33 0.15
One a Day Multivitamin No 7.67 14.15 ref
Yes 8.32 10.43 0.13 1.14 0.614 2.11 0.68
Vitamin C Supplement No 8.25 12.39 ref
Yes 7.58 13.33 0.33 1.39 0.745 2.59 0.30
Vitamin E Supplement No 7.52 13.33 ref
Yes 8.48 11.83 0.21 1.23 0.656 2.32 0.51
Selenium Supplement No 7.69 13.20 ref
Yes 10.13 7.97 0.10 1.11 0.394 3.12 0.85
β-Carotene Supplement No 7.93 12.93 ref
Yes 7.80 10.90 -0.29 0.75 0.23 2.42 0.63
Iron Supplement No 8.12 12.86 ref
Yes 5.35 11.11 0.45 1.56 0.463 5.26 0.47
Calcium Supplement No 7.42 13.23 ref
Yes 8.40 12.13 0.49 1.63 0.87 3.06 0.13







menarche at age 14 or above there was no obvious difference in F2-Isoprostane levels between cases and 
controls.    The interaction term between F2-Isoprostane and age at menarche was significant (p=0.036)  
Stratifying our conditional logistic regression analysis by age at menarche we found unadjusted urinary 
isoprostane levels were significantly inversely associated with breast cancer risk only among women who 
were under 14 at menarche (β= -0.05, OR=0.95, CI 0.90-1.00).  Adjusting for potential confounders 
strengthened this association (β= -0.08, p=0.03).  Among women who were 14 or older at menarche there 
was a non-significant positive association between urinary isoprostane and breast cancer risk.  This study 
likely lacked power to fully explore this relationship as we only had 15 cases who were 14 or older at 
menarche. 
 
Dividing isoprostane levels into tertiles based on its distribution among controls (Table 5) we found that 
women in the highest tertile of F2-Isoprostane (>10.14nmol/L*SG) had significantly reduced odds of 
breast cancer compared to women in the lowest quantile/tertile (<4.65nmol/L*SG).  The interaction term 
between continuous age at menarche and the highest tertile of F2-Isoprostane was also significant 
(p=0.01).   Adjusting for covariates that changed the unadjusted effect estimate of the highest tertile by 
10% or more (years between menarche and parity or menopause, season of urine collection, and 
categorical BMI) increased this association to a statistically significant 51% reduction in the odds of 
breast cancer for women with urinary levels F2-Isoprostanes greater than 10.14nmol/L*SG compared 
with those urinary levels were less than 4.65nmol/L*SG (β= -0.73, OR=0.48, CI 0.29-0.80).  The final 
parsimonious model also revealed a reduction in breast cancer risk with increasing F2-Isoprostane level 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 26 49 ref ref ref
2 (69.13-98.20 nmol/L SG) 31 47 0.35 0.10 1.42 0.93 2.16 0.21 0.60 1.24 0.56 2.76 0.57 0.03 1.76 1.07 2.91
3(>98.20 nmol/L SG) 16 50 -0.51 0.05 0.60 0.36 1.00 -1.08 0.03 0.34 0.12 0.93 -0.79 0.010 0.45 0.25 0.83
Mantel-Haenszel Chi-Square
p for trend
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 30 49 ref ref ref
2 (4.65-10.14 nmol/L SG) 28 48 0.17 0.45 1.18 0.77 1.82 0.24 0.32 1.27 0.80 2.02 0.15 0.54 1.17 0.71 1.91
3 (>10.14 nmol/L SG) 15 49 -0.46 0.04 0.63 0.41 0.99 -0.73 0.005 0.48 0.29 0.80 -0.67 0.010 0.51 0.30 0.85  +
Mantel-Haenszel Chi-Square
p for trend
 + interaction term Isoprostane Tertiles*Age at Menarche (cont) was significant p=0.02 in fully adjusted model.
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 21 35 ref ref ref
2 (69.13-98.20 nmol/L SG) 12 22 0.14 0.63 1.15 0.64 2.08 0.19 0.57 1.21 0.63 2.30 0.23 0.51 1.25 0.64 2.44
3(>98.20 nmol/L SG) 10 32 -0.60 0.09 0.55 0.27 1.11 -0.76 0.06 0.47 0.21 1.03 -0.73 0.07 0.48 0.22 1.07
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 18 25 ref ref ref
2 (4.65-10.14 nmol/L SG) 16 30 0.01 0.97 1.01 0.57 1.78 -0.12 0.71 0.89 0.47 1.67 -0.02 0.96 0.99 0.52 1.86
3 (>10.14 nmol/L SG) 9 34 -0.49 0.08 0.61 0.35 1.07 -0.60 0.07 0.55 0.29 1.05 -0.70 0.04 0.50 0.26 0.95
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR 95% CI
1 (<69.13 nmol/L SG) 5 14 ref ref ref
2 (69.13-98.20 nmol/L SG) 19 25 0.63 0.05 1.88 1.00 3.54 1.10 0.01 3.01 1.26 7.15 1.49 0.01 4.42 1.42 13.83
3(>98.20 nmol/L SG) 6 18 -0.30 0.44 0.74 0.35 1.59 -0.79 0.13 0.45 0.16 2.81 -0.82 0.14 0.44 0.15 1.31
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 12 24 ref ref ref
2 (4.65-10.14 nmol/L SG) 12 18 0.35 0.30 1.41751 0.73 2.75 0.75 0.13 2.11 0.81 5.54 0.37 0.37 1.45 0.64 3.31
3 (>10.14 nmol/L SG) 6 15 -0.41 0.29 0.66611 0.31 1.42 -0.81 0.15 0.45 0.15 1.32 -0.51 0.27 0.60 0.24 1.50
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 21 43 ref ref ref
2 (69.13-98.20 nmol/L SG) 25 36 0.37 0.12 1.45 0.91 2.29 0.52 0.05 1.68 0.99 2.83 0.49 0.07 1.64 0.96 2.78
3(>98.20 nmol/L SG) 12 41 -0.53 0.07 0.59 0.33 1.04 -0.80 0.02 0.45 0.23 0.87 -0.76 0.03 0.47 0.24 0.92
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 26 44 ref ref ref
2 (4.65-10.14 nmol/L SG) 25 40 0.44 0.09 1.55 0.93 2.58 0.45 0.10 1.56 0.91 2.68 0.32 0.27 1.37 0.79 2.40
3 (>10.14 nmol/L SG) 7 36 -0.83 0.004 0.43 0.24 0.77 -0.99 0.002 0.37 0.20 0.70 -1.00 0.002 0.37 0.20 0.69
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 5 6 ref ref ref
2 (69.13-98.20 nmol/L SG) 6 11 0.25 0.63 1.29 0.46 3.58 0.31 0.60 1.37 0.42 4.49 1.92 0.13 6.83 0.57 81.72
3(>98.20 nmol/L SG) 4 9 -0.41 0.46 0.66 0.22 1.99 -0.59 0.36 0.55 0.16 1.96 -1.62 0.13 0.20 0.02 1.65
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 4 5 ref ref ref
2 (4.65-10.14 nmol/L SG) 3 8 -0.77 0.19 0.46 0.15 1.46 0.00 0.00 0.00 0.00 0.00 5.03 1.00 152.99 0.00 #NUM!
3 (>10.14 nmol/L SG) 8 13 0.70 0.21 2.02 0.68 5.97 0.83 0.61 2.30 0.10 55.22 5.98 0.996 394.97 0.00 #NUM!
Total Strata # too few subjects, over paramatization in these models.
Full Adjustment
* 8-OxodG Tertiles Adjusted for: time btwn menarche and parity, BRCA1/2 status. 
* Isoprostane Tertiles Adjusted for Age at Menarche, Season of Urine Collection, Time btwn Menarche and Parity/Menopause, BMI (cat).
Final Model








Fully Adjusted*# Significant Predictors#: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
15.00
58.00





Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI 95% CI
Table 5e: Conditional Logistic Regression: Tertiles of Urinary Biomarkers of Oxidative Stress 
and Odds of Breast Cancer AMONG WITH OLDER AGE AT MENARCHE (≥14)
Table 5b: Conditional Logistic Regression: Tertiles of Urinary Biomarkers of Oxidative Stress 
and Odds of Breast Cancer AMONG WOMEN 50 AND UNDER AT BASELINE
30.00







Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
Table 5c: Conditional Logistic Regression: Tertiles of Urinary Biomarkers of Oxidative Stress 
and Odds of Breast Cancer AMONG WOMEN OVER 50 AT BASELINE
Table 5d: Conditional Logistic Regression: Tertiles of Urinary Biomarkers of Oxidative Stress 
and Odds of Breast Cancer AMONG WOMEN WITH AVERAGE AGE AT MENARCHE (<14)
Table 5a: Conditional Logistic Regression:  Tertiles of Urinary Biomarkers of 
Oxidative Stress and Odds of Breast Cancer for ENTIRE BCFR COHORT Final Model
n
Crude/Unadjusted 
Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI
95% CI
95% CI 95% CI 95% CI
p=0.21
95% CI 95% CI 95% CI
95% CI 95% CI
43.00





Fully Adjusted* Significant Predictors: BRCA, Time Btwn 





   
(Continued)
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 6 18 ref ref ref
2 (69.13-98.20 nmol/L SG) 11 25 0.04 0.91 1.04 0.53 2.05 0.01 0.98 1.01 0.49 2.09 0.01 0.98 1.01 0.49 2.09
3(>98.20 nmol/L SG) 10 15 -0.13 0.72 0.87 0.42 1.80 -0.30 0.46 0.74 0.33 1.65 -0.30 0.46 0.74 0.33 1.65
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 11 21 ref ref ref
2 (4.65-10.14 nmol/L SG) 9 17 -0.17 0.63 0.84 0.41 1.71 -0.11 0.78 0.90 0.43 1.89 -0.18 0.64 0.83 0.39 1.80
3 (>10.14 nmol/L SG) 7 20 0.01 0.98 1.01 0.44 2.32 -0.15 0.76 0.86 0.32 2.29 -0.29 0.64 0.75 0.29 1.94
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 17 31 ref ref ref
2 (69.13-98.20 nmol/L SG) 18 22 0.80 0.02 2.21 1.14 4.32 1.07 0.01 2.93 1.29 6.63 1.07 0.01 2.93 1.29 6.63
3(>98.20 nmol/L SG) 5 35 -0.98 0.02 0.38 0.16 0.88 -1.43 0.009 0.24 0.08 0.71 -1.43 0.009 0.24 0.08 0.71
Total Strata
Urinary Isoprostane Tertiles Cases Controls β p OR β p OR β p OR
1(<4.65 nmol/L SG) 17 28 ref ref ref
2 (4.65-10.14 nmol/L SG) 16 31 0.27 0.40 1.31 0.71 2.41 0.36 0.28 1.44 0.74 2.79 0.43 0.21 1.54 0.78 3.03
3 (>10.14 nmol/L SG) 7 29 -0.66 0.03 0.52 0.29 0.94 -0.73 0.03 0.48 0.25 0.91 -0.83 0.01 0.44 0.23 0.83
Total Strata
Full Adjustment
* 8-OxodG Tertiles Adjusted for: time btwn menarche and parity, BRCA1/2 status. 
* Isoprostane Tertiles Adjusted for Age at Menarche, Season of Urine Collection, Time btwn Menarche and Parity/Menopause, BMI (cat).
Final Model
All models adjusted for time between menarche and parity or menopause, BMI (cat), and BRCA1/2 Status (except where stratified on)
95% CI 95% CI 95% CI
40.00
Final Model





Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI
Table 5f: Conditional Logistic Regression: Tertiles of Urinary Biomarkers of Oxidative Stress 
and Odds of Breast Cancer AMONG WOMEN OVERWEIGHT AT BASELINE
95% CI
27.00
95% CI 95% CI 95% CI
n
Crude/Unadjusted 
Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
Table 5g: Conditional Logistic Regression: Tertiles of Urinary Biomarkers of Oxidative Stress 
and Odds of Breast Cancer AMONG WOMEN WITH NORMAL BMI AT BASELINE
Figure 1: Interaction between Isoprostane and Age at Menarche








































Predictive Value of Urinary Biomarkers of Oxidative Stress: Receiver Operator Curves 
In order to quantitatively measure the potential screening value of urinary oxidative stress biomarkers, we 
measured the change in the Area Under the Curve (AUC) in Receiver Operator Curves (ROC) when we 
added tertiles of oxidative stress biomarkers to our final parsimonious model and to the NCI’s Breast 
Cancer Risk Assessment Tool (BCRAT) using our study population with the variables we had available 
(Figure 2).  We limited subjects in our study population to those with an average BMI where our results 
indicated both biomarkers were most predictive. The BCRAT, which is based on the Gail Model, has 
been validated in White and Asian female populations and is commonly used to assess short-term breast 
cancer risk based on the following risk factors: 1. Prior diagnosis of breast cancer, BRCA1/2 mutation 
status, Age, Age at Menarche, Age at 1st Live Births, Number of 1st degree Relatives with Breast Cancer, 
Number of Prior Breast Biopsies, and Race (213-216).    
 
We did not have information on number of prior breast biopsies, and none of our study subjects had been 
diagnosed with cancer, other than skin.  We also removed Race from the model as our study population 
was almost entirely White/Caucasian. With those modification we found the BCRAT could correctly 
identify a randomly selected case based on the pre-diagnostic characteristics in the model 69% of the time 
(measured by AUC=0.687).  Adding tertiles of 8-OxodG to the model improved the probability of 
identifying a case to 77% which was an almost statistically significant improvement (p=0.058).  Our final 
parsimonious model (BRCA1/2 mutation status, time between menarche and parity or menopause, and 
matched variables, age and menopausal status) without information on oxidative stress biomarkers, and 
tested in average BMI women in our study population, would correctly identify a case prospectively 68% 
of the time.  Adding tertiles of 8-OxodG to the model significantly improved the probability to 78% 
(p=0.03).  F2-Isoprostane tertiles were not as valuable in predicting breast cancer risk in these models.  
Adding F2-Isoprostane tertiles to the BCRAT as above only increased prediction by 1.4% (p=0.46).  
Adding F2-Isoprostane tertiles to our final model improved prediction by 5.7% which was not a 










8-OxodG Model vs. 
Gail Model Alone
0.0821 0.0433 -0.0027 0.1669 3.6029 0.058
8-OxodG Model vs. 
Final Model Alone
0.0959 0.043 0.0115 0.1802 4.9626 0.026
Std Std
Error Error
IsoP Model vs. Gail 
Model Alone
0.0176 0.024 -0.0293 0.0646 0.5404 0.462
IsoP Model vs. Final 
Model Alone














  Figure 2: ROC Curves with and without Oxidative Stress Biomarkers in the Models
Gail Model: Our Final Model:
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Urinary Oxidative Stress Biomarkers and Breast Cancer Tumor Characteristics 
 
 
Characteristics of Cases and Tumors  
Cases ranged in age at diagnosis from 34 to 79 with a median at age at diagnosis of 55 (Supplemental 
Table 1).  Time to diagnosis was on average 6.7 years, but ranged from 0 to 15 years after baseline 
interview.  To make sure our results were not influenced by the presence of undiagnosed cancer at 
baseline we examined the relationship between our oxidative stress biomarker levels and time to 
diagnosis using linear regression (Figure 3).  There was no linear relationship between either urinary ln 8-
OxodG (R2=0.025 p=0.18) or ln F2-Isoprostane (R2=0.0018 p=0.72) and time to diagnosis, although 8-
OxodG levels appear to be trending positive (ANOVA for continuous Ln 8-OxodG and categorical time 
to diagnosis and Mantel-Hanzel Chi-Square Test for tertiles of 8-OxodG both non-significant, 
Supplemental Table 3).  Looking at odds of diagnosis of breast cancer within a specific time from 
baseline we observed that 8-OxodG was significantly positively associated with breast cancer diagnosis 
only after 10 years since baseline (Table 6).  F2-Isoprostane levels remained flat regardless of how many 
years samples were taken prior to diagnosis and are still lower than control levels (mean = 
12.77nmol/L*SG).  Of the cases, 45% had estrogen receptor positive (ER+) breast cancer, 16% had ER- 
breast cancer and the rest were unknown; 38% were progesterone receptor positive (PR+), 22% were PR- 
and the rest were unknown; only 5% of the cases were known to be HER2 positive (HER2+). Of the 73 
cases, we had information on tumor behavior for only 29; 11 of these were in situ, 18 were invasive.  As 
of April 2014, 8 of the 73 cases had died (Supplemental Table 1).  
 
Oxidative Stress Biomarkers and Tumor Characteristics 
Women diagnosed with ER- tumors had significantly higher levels of urinary 8-OxodG than women 
diagnosed with ER+ breast cancer (85.6nmol/L*SG vs 69.9nmol/L SG, p=0.013, Table 7). Using 
unconditional logistic regression, we found a significant negative association between urinary 8-OxodG 




adjusting for age at baseline, age of urine sample, menopausal status, BMI, time between menarche and 
parity or menopause, BRCA1/2 status, and time to diagnosis. F2-Isoprostane levels were not associated 
with ER status.  There was also some evidence of a positive association between F2-Isoprostane and 
diagnosis of HER2+ breast cancer (β=0.11, p=0.05) but this was only based on 4 HER2+ cases.   There 
was no significant association between either oxidative stress biomarker and PR status, mortality, or 








Intercept 4.192 0.099 42.52 <.0001 4.00 4.39 Intercept 1.871 0.176 10.66 <.0001 1.52 2.22
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95% Prediction Limits95% Confidence LimitsFit
Fit Plot for lnOxo_SG
N Mean β p-value Mean β p-value
18 73.9 -0.014 0.21 8.69 0.021 0.67
16 71.6 -0.014 0.23 7.24 -0.01 0.79
13 79.9 -0.004 0.67 9.69 0.072 0.16
17 85.6 0.006 0.48 6.28 -0.08 0.19
9 100.1 0.034 0.02 8.19 0.01 0.85















β p OR β p OR
-0.02 0.02 0.98 0.96 1.00 -0.03 0.01 0.97 0.95 0.99
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Here we show that relatively high levels of whole body oxidative stress as measured by two well 
established urinary biomarkers are associated with protection against breast cancer in a cohort of high risk 
women.  This result was somewhat unexpected given the large body of epidemiological evidence (148, 
179-182, 184, 185, 217, 218) linking high levels of oxidative stress with cancer and laboratory studies 
(Reviewed in (127)) that demonstrate the mutagenic potential of ROS.  However these prior studies are 
limited in that they do not study the effect of oxidative stress prior to cancer diagnosis or they are in vitro 
studies that cannot accurately capture the exquisitely complicated interplay of oxidative stress, 
antioxidant regulation, DNA repair, and cell cycle regulation.   
 
To our knowledge there have been only two prior studies that have prospectively looked at the same 
urinary biomarkers of oxidative stress and breast cancer.  These studies support our findings.  A nested 
case control study in the Shanghai Women’s Health Study (152) found among women with an average 
BMI, breast cancer risk was reduced with increasing levels of F2-Isoprostane in a dose-response manner 
(p for trend =0.006) with an OR of 0.46 (95% CI, 0.26 to 0.80) for the highest tertile compared to the 
lowest. Our study also found that the inverse association between urinary isoprostane levels was limited 
to women with an average BMI.  As in our study, the significant inverse relationship between F2-
Isoprostane tertiles and breast cancer was limited to younger women (OR=0.58, p=0.04, for the highest 
tertile) in the Shanghai Women’s Health Study; among older, postmenopausal women there was a non-
significant positive association (OR=1.33, p=0.23).  A 2013 Danish nested case control study by Loft et 
al. also found a non-significant positive association between urinary 8-OxodG and breast cancer diagnosis 
among of 336 postmenopausal (ages 50-64) women after 3-7 years of follow-up (151). That same study 
did find that 8-oxodG levels were positively associated with diagnosis of ER+ breast cancer which is 
opposite of what this study found.  However, we note that 14 of our 19 ER+ cases among women over 50 
at baseline had 8-OxodG levels between 69.13-98.20 nmol/L SG, the tertile where we found a significant 




study subjects only reach to the middle tertile of 8-OxodG in our study.  We are unable to compare 
directly since the Loft study presents 8-OxodG levels adjusted for creatinine and levels were assessed 
using HPLC with electrochemical detection which gives 8-OxodG levels lower than ELISA does. 
 
Other studies have demonstrated that several protective factors for breast cancer (parity, exercise, pre-
eclampsia) are associated with higher levels of oxidative stress (219).  We did not find increased F2-
Isoprostane or 8-OxodG levels were associated with parity or exercise level and we did not have 
information on pre-eclampsia for our subjects. We did find that oxidative stress levels increased with 
older age at menarche, but we did not find that age at menarche alone was a significant predictor of breast 
cancer risk. 
 
Several large RCTs among populations at high risk of cancer have demonstrated that use of antioxidants, 
which may lower whole body levels of oxidative stress, can significantly increase the risk of cancer.  The 
Alpha Tocopherol Beta Carotene Cancer Prevention Study, a randomized placebo-controlled trial that 
assigned 30,000 Finnish smokers to receive antioxidant supplements-either beta-carotene, alpha 
tocopherol, both or placebo, found that after 5-8 years of follow up, smokers who had received beta 
carotene supplements had an 18% higher incidence of lung cancer (220).  No reduction of lung cancer 
was observed among those who receive alpha tocopherol supplements.  In 1996 the Beta Carotene and 
Retinol Efficacy Trail (CARET) reported more lung cancer cases among subjects who had been randomly 
assigned to receive both beta-carotene and retinol (RR=1.28 95% CI 1.04-1.57) (221).   And finally, the 
SELECT study assigned 35,000 men aged 50 or older to receive vitamin E, selenium, both or placebo.  
After 5-12 years of follow-up men who received vitamin E had an increased risk (IRR 1.17, p=0.008) of 
prostate cancer than men who received placebo (222).   These studies did not measure whether or not the 
antioxidant supplements altered levels of oxidative stress relative to placebo and the mechanism by which 





No cell is free from the damaging effect of even low levels of ROS.  Approximately 20,000 bases of 
DNA are modified daily by endogenous levels of ROS (223).  Restricting the growth of cells with 
oxidative damage is an unsustainable defense strategy.  Senescence and apoptotic pathways are reserved 
for the most damaged cells.  It may be that in the earliest stages of cancer progression the cells with low 
to moderate levels of oxidative stress are able to fly “under the radar” of cancer defense mechanisms and 
are ultimately the main source of cancerous lesion.  The results of our study may reflect a protective 
effect of high levels of whole body oxidative stress if it prevents the growth of precancerous cells more 
efficiently than in women with low levels of oxidative stress.  The positive association seen among 
women in the middle tertile of 8-OxodG may be due to an increased mutation rate relative to those in the 
lowest tertile but with 8-OxodG levels not high enough to trigger anti-cancer defense. 
 
Low levels of whole body oxidative stress may result in increased cancer risk if it allows precancerous 
cells to evade the body’s most important anti-cancer defense, namely p53 activation. P53 is a tumor 
suppressor that regulates cell fate. P53 recognizes damaged or stressed cells and triggers expression of 
other genes that will either lead to repair and survival, growth arrest, senescence or apoptosis.  The trigger 
for survival vs apoptosis depends on the cell type, the level of p53 expression and extent of damage to the 
cell (141, 224). Many of the genes induced by p53 are related to oxidative stress generation or response 
(57). Under moderate to low levels of oxidative stress, p53 is expressed at relatively low levels and 
triggers expression of antioxidant genes which continue to reduce ROS allowing the cell to continue 
growing. Moderate to low levels of oxidative stress can also promote cell growth through their role as 
signaling molecules.  ROS can trigger growth and survival by stimulating the phosphorylation of 
mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) and JUN N-
terminal kinase (JNK) (48).   
 
When oxidative stress levels rise to potentially dangerous levels, p53 expression increases and favors pro-




expression of Bax and PUMA which allow the release of ROS and cytochrome c from the mitochondria 
which then induces apoptosis (225).  Apoptosis is a form of programmed cell death that results in cell  
 
Figure 4: Oxidative Stress Modulation of p53 Response 
 
Adapted from Vurusander 2012 (224) 
 
shrinkage, chromatin condensation and eventual fragmentation and death of the cell through “budding” 
while maintaining the integrity of the cell membrane.  Apoptosis is distinct from necrosis because it is 
controlled by the cell itself and does not result in an inflammatory response (226).  Apoptosis is a normal 
part of aging and development.  Breast tissue in particular goes through regular cycles of apoptosis in 
infancy, after each pregnancy and during menopause (5).  Apoptosis is also a means to protect against 






Several studies have demonstrated that antioxidants, either dietary or endogenous, may reduce the 
protective apoptotic response via p53 activation, and promote continued cell growth in cells with 
oncogenic mutations.  In a mouse lung tumor model, dietary antioxidant supplementation increased 
proliferation of lung tumors by decreasing expression of p53 via reduced oxidative stress.  This reduction 
in p53 expression was replicated in human lung cells after exposure to antioxidants (58).  Recent studies 
have shown that cells with oncogenic mutations in Kras, Braf or Myc may exploit endogenous antioxidant 
pathways to their advantage.  Primary murine cells with endogenous Kras, Braf or Myc mutations were 
found to increase levels of Nrf2, a transcription factor responsible for activating endogenous antioxidants 
including NAD(P)H quinone oxidoreductase 1 (Nqo1), haem oxygenase (HMOX1),  and genes 
responsible for GSH production and regeneration (227).  The resulting reduction in ROS allowed these 
cells to avoid apoptosis and promoted tumorigenesis (228).  Our results may signify a similar condition in 
our subjects, whereby low levels of oxidative stress are allowing tumor progression more than high levels. 
 
The antioxidant response of Nrf2 may play a role in the tissue specificity of BRCA1-related cancers.  
BRCA1 interacts with Nrf2 and promotes its activation and stability.  Mutations in BRCA1 result in 
impaired Nrf2 antioxidant response.  In premalignant mammary epithelial cells this leads to increased 
levels of oxidative stress which impairs survival.  Estrogen restored Nrf2 back to levels found in WT 
BRCA1 and by reducing levels of oxidative stress and promoted cell survival despite BRCA1-related 
DNA repair deficiencies. It may be that high levels of oxidative stress due to BRCA1 mutations may 
block tumor progression all other tissues other than breast and ovarian cells which are estrogen responsive 
(48). 
 
It has been hypothesized that the effect of ROS levels may depend on tissue type (219).  In 
undifferentiated, highly proliferative tissue—such as premenopausal breast tissue, low levels of oxidative 
stress would further promote growth while high levels of oxidative stress would trigger apoptosis and 




and a subset of breast cancer stem cells were found to have reduced levels of ROS due to increased 
expression of antioxidant pathways, particularly genes responsible for GSH biosynthesis.  The reduced 
levels of ROS protected these stem cells from DNA damage and provided resistance to radiation therapy 
(229).  In terminally differentiated cells, which have limited ability to proliferate, high levels of ROS lead 
to apoptosis and degenerative diseases from the loss of healthy tissue.   High levels of oxidative stress in 
both undifferentiated and differentiated cells could also lead to cancer but only if the cells can accumulate 
enough DNA damage before being targeted for apoptosis.   
 
This may help explain why this study and the Shanghai Women’s Health study (152) found an inverse 
association between oxidative stress level and cancer risk only among women under 50 and why our 
study found that women who reached menarche at an earlier age were more vulnerable to low levels of 
oxidative stress. Younger women have more active, proliferative breast tissue than older women, 
especially women who have reached menopause.  Women who reached menarche early had 
undifferentiated breast tissue for a longer time than women who reached menarche at age 14 or older 
which may increase their vulnerability to mutagenic changes that may initiate tumors.  Lower levels of 
oxidative stress later in life, or after initiation, may aid in tumor progression. 
 
We tried to validate this hypothesis using our study results.  If low levels of oxidative stress acted to 
promote tumor growth we would expect to see lower levels of oxidative stress and the negative 
association between oxidative stress levels and breast cancer diagnosis to be strongest among those 
diagnosed closer to baseline.  High levels of oxidative stress would act more as a cancer initiator years 
prior to diagnosis so we would expect to see higher levels of oxidative stress and a positive relationship 
between oxidative stress and cancer risk in women diagnosed further from baseline.  For F2-Isoprostane 
there was no significant change in urinary levels or in association with breast cancer risk with quintile of 
time to diagnosis (Table 6).  Mean 8-OxodG levels did seem to increase with quintile of time to diagnosis 




significant (Figure 3 and Supplemental Table 3)).  However, we did find a significant positive 
relationship between 8-OxodG and breast cancer risk limited to 9 cases diagnosed more than 10 years 
from baseline, indicating that high levels of 8-OxodG may contribute to the earlier steps in cancer 
progression. 
 
It seems likely that the protective effect of relatively high levels of oxidative stress in our study are a 
potential trigger of apoptosis and not the result of it.  Studies of 8-OxodG following chemotherapy 
induced cytotoxicity did not show any significant increases in urinary levels.  Additionally, several 
studies of patients with high levels of apoptosis due to lupus found no increases in urinary 8-OxodG 
(reviewed (168)).  Lower levels of oxidative stress among our cases may reflect an impaired ability to 
increase levels of oxidative stress in response to cellular stressors perhaps due to over active antioxidant 
defenses or poor pro-oxidant response. 
 
We found a significant negative association between 8-OxodG levels and diagnosis of ER+ breast cancer 
among cases using logistic regression.  As this analysis--limited to cases only--broke our matching, we 
adjusted for all previously matched variables (age at baseline, menopausal status, date of urine donation 
and race) and known predictors of breast cancer risk (BRCA1/2 status, categorical BMI, time between 
menarche and parity or menopause, number of live births, and time to diagnosis from baseline).  The 
results were still significant (β= -0.0274 p=0.0124).   This finding was also unexpected.  Other studies 
that have looked at oxidative stress levels in tumors directly have generally found higher levels of 8-
OxodG in ER+ tumors compared to ER- tumors (177, 230) and a study that looked at blood levels of ROS 
at time of breast cancer diagnosis found higher ROS levels in women with ER+ breast cancer than in 
women with ER- breast cancer (231). The only other study (Loft 2013 (151)) to look at urinary 8-OxodG 
and breast cancer prospectively found a positive association between 8-OxodG and diagnosis of ER+ 
breast cancer (IRR=1.11, 1.06-1.37 per 1-unit increase in 8-OxodG nmol/mmol creatinine).  The 




our study, or because the Loft study was limited to postmenopausal women, where we found no 
association between either oxidative stress biomarker and breast cancer diagnosis.  As stated previously, 
we found that 14 of our 19 ER+ cases among women over 50 at baseline had 8-OxodG levels between 
69.13-98.20 nmol/L*SG.  Interestingly, 11 of the 14 ER+ cases among women under 50 fell into the 
lowest tertile of 8-OxodG (<69.13 nmol/L*SG). It may be that oxidative stress, as measured by 8-OxodG 
levels acts differently in the progression of ER+ cancer depending on age or menopausal status.   
 
Our study had several limitations.  While approximately 30% of the NY BCFR as a whole is comprised of 
participants who identified as Hispanic/Latino, Black or Asian, our case control study was 
overwhelmingly (97%) composed of White/Caucasian women.   This may be due in part to our use of 
urine samples which were only collected from participants who enrolled between 1997 and 2000, while 
enrollment continued exclusively for minorities until 2005.  This may also be due in part to increased 
rates of breast cancer incidence among white women and the proportion of high risk Ashkenazi Jewish 
women in the cohort.  The generalizability of our results may be limited to white women at high risk of 
breast cancer.  We did not have specific genetic information on our participants other than BRCA1/2 
status.  Other studies however, (148, 232-234) have looked at genetic factors within the NY Registry but 
none of the genes examined in these studies seem likely modifiers of oxidative stress and breast cancer 
risk.  It is possible that the increased risk of breast cancer associated with 8-OxodG levels could be due to 
poor DNA repair leading to oxidized bases remaining in cellular DNA instead of being removed and 
released into urine.   A prospective study of 8-OxodG and lung cancer risk found no change in urinary 8-
OxodG levels with variations in OGG1 genotype (150).  Previous studies in our lab in this same study 
population found that variations in double strand break repair (234) NER (Kappil, M. et al, unpublished) 
did not increase breast cancer risk.  We also lacked information about breast density and had only limited 
information on prognostic characteristics of tumors among cases.  Sample size limitations prevented us 





While 8-OxodG and F2-Isoprostanes are well established biomarkers of whole body oxidative stress, 
measurement methods other than ELISA, such as MS/CG or HPLC may be more accurate.  ELISA is 
known to give results significantly higher than MS methods for reasons not completely understood (235). 
This limits our ability to quantitatively compare our results to the results of other studies or to categorize 
oxidative stress levels in absolute terms.  For example our 8-OxodG means were approximately 6 times 
higher than the means found in Loft 2013.  However, this study was interested in measuring relative and 
not absolute levels of oxidative stress between subjects and because we made efforts to reduce potential 
sources of non-specific binding in the 8-OxodG ELISA, there should be high correlation between ELISA 
and GC/MS methods (210, 236).   There was considerable intra-day assay variation in our 8-OxodG 
ELISA but in this study we were comparing differences between cases and matched controls which were 
run on the same plate on the same day which minimized variation considerably (CV <15%).   
 
F2-Isoprostane levels are known to vary with monthly hormone fluctuations and this is uncontrolled for in 
our sampling.  Variance in isoprostane levels peaks mid-follicular stage and is smallest post-ovulation.  
However, the maximal mean difference between isoprostane levels during these two stages is reported to 
be less than 10% (237).  Finally, our study measured only a single time point spot urine sample from each 
participant which may not be an accurate representation of long term individual average levels of 
oxidative stress, or of levels in breast tissue. 
 
The major strength of this study was its prospective nested case-control design within a well-defined 
cohort with a clear/clinically defined end point.  This is only the third study we know of that has 
prospectively examined urinary biomarkers of oxidative stress and diagnosis of breast cancer and is the 
first to measure multiple biomarkers using ELISA which is well suited for economical, high throughput 
screening.  The matched case control design minimized potential confounding and allowed for efficient 
analysis.  Detailed questionnaire data allowed us to control for many important risk factors or potential 




reproductive factors.  We adopted improvements to the 8-OxodG ELISA that have been reported to 
increase its correlation to GC/MS methods (236).  Namely, our urine samples were treated with urase and 
cleaned by solid phase extraction before overnight incubation of the sample with antibody at 4⁰C to 
minimize reported cross reactivity of the 8-OxodG antibody with urea. This extra processing does results 
in loss of some of our sample (SPE estimated 80% recovery (211)) and increased variation between SPE 
runs.  Finally, we believe that adjusting our urinary biomarkers for specific gravity rather than creatinine 
as a marker of hydration status helped reduce confounding as creatinine is known to correlate with age, 
BMI and hormonal factors (171, 175) whereas specific gravity does not. 
 
Our results highlight the complexity of oxidative stress and indicate that while elevated levels of ROS are 
associated with disease status and are a significant source of potentially carcinogenic mutations, oxidative 
stress may also provide a means of cancer prevention by activating tumor suppressor genes and triggering 
apoptosis in the most damaged cells.  Future studies should examine how expression of genes regulating 
endogenous antioxidants, DNA repair, and cell cycle regulation varies in this population and if these 
variations are driving risk and oxidative stress levels. 
 
Reducing the risk of breast cancer, especially among women with a family history of the disease is of 
critical importance.  Whether or not whole body oxidative stress levels are easily modifiable is a question 
still up for debate.  Exposures known to increase levels of oxidative stress such as cigarette smoke, 
pollution, radiation, certain chemicals and drugs, are harmful and should be avoided.  While there is 
evidence that dietary antioxidants can reliably reduce ROS in vitro and in animal studies, in human 
studies the evidence is mixed at best.  A review of 33 studies that looked at how antioxidant supplements 
altered F2-Isoprostane levels in human subjects found that only 12 showed that dietary antioxidants could 
reduce oxidative stress levels and those studies were limited to populations with a disease or exposure 
associated with high levels of oxidative stress (diabetes, high cholesterol, smokers) (238).  Antioxidant 




antioxidant supplement use and markers of oxidative DNA damage (including 8-OxodG) largely found 
null results (239). In this study we did not find that supplement use or fruit and vegetable intake 
significantly altered either of our oxidative stress biomarkers which is in agreement with several other 
studies (151, 185, 240). Despite the lack of strong evidence that antioxidant supplement use in healthy, 
non-deficient populations can reduce oxidative stress, approximately 45-80% of breast cancer patients use 
antioxidant supplements after diagnosis or during treatment (241) as did at least 40% of the women in this 
study. Our results, and the results of RCTs of antioxidant supplementation in populations at high risk of 
cancer, suggest caution in the casual use of antioxidant supplements especially for younger women at 





BCFR SUPPLEMENTAL TABLES 
 
  
Supplemental Table 1: Case Characteristics
Variable N Mean
Age at Diagnosis 73 54.7
Time to Diagnosis 73 6.7
Estrogen Receptor Status N Percent Mean 8-OxodG Mean IsoP
NULL 18 24.66 90.19 8.63
Negative 12 16.44 85.61 8.29
Positive 33 45.21 69.86 8.35
Unknown 10 13.7 91.54 4.84
HER2-Neu Receptor Status N Percent Mean 8-OxodG Mean IsoP
Borderline/Equivocal 2 2.74 42.68 3.94
NULL 43 58.9 83.6 7.01
Negative 17 23.29 77.53 9.37
Positive 4 5.48 81.5 15.13
Unknown 7 9.59 78.2 7.06
Progesterone Receptor Status N Percent Mean 8-OxodG Mean IsoP
Borderline 1 1.37 79.26 9.33
NULL 18 24.66 90.19 8.63
Negative 16 21.92 75.65 7.98
Positive 28 38.36 72.96 8.5
Unknown 10 13.7 91.54 4.84
Breast Cancer Behavior N Percent Mean 8-OxodG Mean IsoP
In situ 11 15.07 94.68 8.1
Invasive 18 24.66 82.18 10.13
NULL 40 54.79 76.29 6.91
Unknown 4 5.48 74.74 7.73
Vital Status N Percent Mean 8-OxodG Mean IsoP
Alive 65 89.04 79.27 8.17






Supplemental Table 2: Unconditional Logistic Regression Among Cases
β p OR
0.006 0.54 1.01 0.99 1.02
0.010 0.83 1.01 0.92 1.11
β p OR
-0.01 0.13 0.99 0.97 1.00
0.02 0.56 1.02 0.95 1.10
β p OR
0.001 0.95 1.00 0.97 1.03
0.11 0.05 1.12 1.00 1.25
β p OR
-0.02 0.19 0.98 0.94 1.01
0.03 0.52 1.03 0.94 1.14
β p OR
0.009 0.39 1.01 0.99 1.03




Invasive Breast Cancer 95% CI
8-OxodG (nmol/L SG)
Isoprostane (nmol/L SG)
Vital Status 95% CI
8-OxodG (nmol/L SG)
Isoprostane (nmol/L SG)
HER2+ Breast Cancer 95% CI
8-OxodG (nmol/L SG)
Isoprostane (nmol/L SG)
ER- Breast Cancer 95% CI
8-OxodG (nmol/L SG)
Isoprostane (nmol/L SG)











7 7 4 6 2 26
9.59 9.59 5.48 8.22 2.74 35.62
26.92 26.92 15.38 23.08 7.69
38.89 43.75 30.77 35.29 22.22
8 8 6 6 3 31
10.96 10.96 8.22 8.22 4.11 42.47
25.81 25.81 19.35 19.35 9.68
44.44 50 46.15 35.29 33.33
3 1 3 5 4 16
4.11 1.37 4.11 6.85 5.48 21.92
18.75 6.25 18.75 31.25 25
16.67 6.25 23.08 29.41 44.44
18 16 13 17 9 73











            ANOVA and Fisher's Exact Test: 8-OxodG and Time to Diagnosis
Fisher's Exact Test
Supplemental Table 3: 
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Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 4 0 ref ref ref
2 (69.13-98.20 nmol/L SG) 5 1 -0.06 0.90 0.95 0.38 2.34 -0.06 0.90 0.95 0.38 2.36 -0.02 0.97 0.98 0.37 2.59
3(>98.20 nmol/L SG) 4 3 0.34 0.56 1.40 0.45 4.42 0.34 0.53 1.40 0.44 4.43 0.43 0.47 1.54 0.48 5.00
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 7 1 ref ref ref
2 (4.65-10.14 nmol/L SG) 5 1 0.65 0.32 1.91 0.54 6.84 0.35 0.68 1.42 0.27 7.44 0.57 0.46 1.77 0.58 5.38
3 (>10.14 nmol/L SG) 1 2 -0.82 0.31 0.44 0.09 2.14 -0.85 0.36 0.43 0.07 2.67 -0.79 0.38 0.45 0.08 2.67
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 22 49 ref ref ref
2 (69.13-98.20 nmol/L SG) 26 46 0.53 0.04 1.69 1.03 2.79 0.61 0.02 1.84 1.08 3.12 0.71 0.01 2.04 1.17 3.55
3(>98.20 nmol/L SG) 12 47 -0.76 0.02 0.47 0.25 0.87 -0.89 0.007 0.41 0.21 0.78 -0.92 0.01 0.40 0.20 0.79
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 23 48 ref ref ref
2 (4.65-10.14 nmol/L SG) 23 47 0.10 0.69 1.10 0.69 1.75 0.19 0.49 1.21 0.71 2.06 0.16 0.53 1.17 0.71 1.93
3 (>10.14 nmol/L SG) 14 47 -0.43 0.07 0.65 0.41 1.04 -0.79 0.006 0.45 0.26 0.80 -0.62 0.02 0.54 0.32 0.91
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 15 35 ref ref ref
2 (69.13-98.20 nmol/L SG) 23 37 0.39 0.14 1.48 0.88 2.49 0.58 0.06 1.78 0.97 3.26 0.64 0.05 1.90 0.99 3.65
3(>98.20 nmol/L SG) 12 37 -0.53 0.07 0.59 0.33 1.05 -0.83 0.02 0.44 0.22 0.89 -0.87 0.02 0.42 0.20 0.85
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 23 38 ref ref ref
2 (4.65-10.14 nmol/L SG) 19 37 0.44 0.11 1.55 0.90 2.68 0.51 0.11 1.66 0.90 3.07 0.52 0.12 1.69 0.87 3.27
3 (>10.14 nmol/L SG) 8 34 -0.73 0.02 0.48 0.26 0.88 -0.88 0.01 0.41 0.20 0.84 -0.99 0.007 0.37 0.18 0.76
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 11 14 ref ref ref
2 (69.13-98.20 nmol/L SG) 8 10 0.23 0.56 1.26 0.57 2.79 0.74 0.26 2.10 0.58 7.62 0.24 0.54 1.27 0.58 2.79
3(>98.20 nmol/L SG) 4 13 -0.38 0.48 0.68 0.24 1.96 -0.86 0.33 0.42 0.07 2.38 -0.31 0.58 0.74 0.25 2.17
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 7 11 ref ref ref
2 (4.65-10.14 nmol/L SG) 9 11 -0.32 0.43 0.72 0.33 1.61 1.35 0.34 3.86 0.23 63.36 -0.38 0.35 0.68 0.30 1.54
3 (>10.14 nmol/L SG) 7 15 -0.13 0.72 0.88 0.44 1.76 -2.01 0.08 0.13 0.01 1.23 -0.20 0.59 0.82 0.40 1.69
Total Strata
Full Adjustment
* 8-OxodG Tertiles Adjusted for: time btwn menarche and parity, BRCA1/2 status. 
* Isoprostane Tertiles Adjusted for Age at Menarche, Season of Urine Collection, Time btwn Menarche and Parity/Menopause, BMI (cat).
Final Model
All models adjusted for time between menarche and parity or menopause, BMI (cat), and BRCA1/2 Status (except when stratified on).








Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI 95% CI
50.00
95% CI 95% CI 95% CI
50.00
Supplemental Table 5k: Conditional Logistic Regression: Categories of Urinary 




Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI 95% CI
60.00
95% CI 95% CI 95% CI
60.00
Supplemental Table 5j: Conditional Logistic Regression: Categories of Urinary 




Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI
13.00
95% CI 95% CI 95% CI
13.00
Supplemental Table 5i: Conditional Logistic Regression: Categories of Urinary 
Biomarkers and Odds of Breast Cancer AMONG NON-CARRIERS
Supplemental Table 5h: Conditional Logistic Regression: Categories of Urinary 




Fully Adjusted* Significant Predictors: BRCA, Time Btwn 






Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 14 ref ref ref
2 (69.13-98.20 nmol/L SG) 6 0.37 0.41 1.45 0.60 3.55 0.27 0.59 1.30 0.50 3.40 0.12 0.81 1.13 0.42 3.05
3(>98.20 nmol/L SG) 4 -0.82 0.13 0.44 0.15 1.27 -0.84 0.14 0.43 0.14 1.34 -0.68 0.24 0.51 0.16 1.57
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 11 ref ref ref
2 (4.65-10.14 nmol/L SG) 9 0.10 0.80 1.10 0.53 2.31 -0.18 0.67 0.83 0.36 1.93 0.17 0.69 1.18 0.52 2.70
3 (>10.14 nmol/L SG) 4 -0.74 0.07 0.48 0.22 1.05 -0.69 0.15 0.50 0.20 1.27 -0.83 0.06 0.44 0.18 1.04
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 12 ref ref ref
2 (69.13-98.20 nmol/L SG) 25 0.39 0.12 1.47 0.90 2.40 0.77 0.02 2.15 1.15 4.03 1.03 0.01 2.81 1.34 5.90
3(>98.20 nmol/L SG) 12 -0.34 0.27 0.71 0.39 1.30 -0.73 0.06 0.48 0.23 1.03 -0.78 0.05 0.46 0.21 1.01
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 19 ref ref ref
2 (4.65-10.14 nmol/L SG) 19 0.21 0.45 1.23 0.72 2.10 0.43 0.18 1.54 0.82 2.89 0.15 0.64 1.16 0.62 2.17
3 (>10.14 nmol/L SG) 11 -0.30 0.29 0.74 0.43 1.29 -0.64 0.06 0.52 0.27 1.04 -0.53 0.12 0.59 0.30 1.14
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 20 30 ref ref ref
2 (69.13-98.20 nmol/L SG) 17 25 0.41 0.16 1.51 0.85 2.67 0.52 0.12 1.68 0.88 3.20 0.46 0.20 1.58 0.79 3.15
3(>98.20 nmol/L SG) 10 29 -0.82 0.03 0.44 0.21 0.93 -1.04 0.02 0.35 0.15 0.84 -0.96 0.03 0.38 0.16 0.91
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 17 22 ref ref ref
2 (4.65-10.14 nmol/L SG) 21 33 0.31 0.25 1.36 0.81 2.28 0.41 0.16 1.51 0.85 2.67 0.28 0.38 1.32 0.71 2.45
3 (>10.14 nmol/L SG) 9 29 -0.60 0.04 0.55 0.31 0.98 -0.96 0.008 0.38 0.19 0.78 -1.08 0.004 0.34 0.16 0.71
Total Strata
Cases Controls
Urinary 8oxodG Tertiles β p OR β p OR β p OR
1 (<69.13 nmol/L SG) 6 19 ref ref ref
2 (69.13-98.20 nmol/L SG) 14 22 0.41 0.24 1.51 0.77 2.97 0.65 0.11 1.91 0.87 4.24 0.86 0.05 2.37 0.99 5.67
3(>98.20 nmol/L SG) 6 21 -0.09 0.81 0.91 0.44 1.91 -0.51 0.26 0.60 0.24 1.47 -0.54 0.25 0.58 0.23 1.47
Total Strata
Urinary Isoprostane Tertiles β p OR β p OR β p OR
1(<4.65 nmol/L SG) 13 27 ref ref ref
2 (4.65-10.14 nmol/L SG) 7 15 -0.18 0.67 0.84 0.37 1.89 -0.25 0.65 0.78 0.27 2.27 -0.14 0.78 0.87 0.32 2.34
3 (>10.14 nmol/L SG) 6 20 -0.17 0.64 0.84 0.40 1.75 -0.25 0.59 0.78 0.31 1.94 -0.23 0.598 0.79 0.33 1.89
Total Strata
Full Adjustment
* 8-OxodG Tertiles Adjusted for: time btwn menarche and parity, BRCA1/2 status. 
* Isoprostane Tertiles Adjusted for Age at Menarche, Season of Urine Collection, Time btwn Menarche and Parity/Menopause, BMI (cat).
Final Model
All models adjusted for time between menarche and parity or menopause, BMI (cat), and BRCA1/2 Status (except when stratified on).
26.00
95% CI 95% CI 95% CI
26.00
95% CI 95% CI 95% CI
47.00
Supplemental Table 5o: Conditional Logistic Regression: Categories of Urinary 




Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI 95% CI
47.00




Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
49.00
95% CI 95% CI 95% CI
49.00
Supplemental Table 5n: Conditional Logistic Regression: Categories of Urinary 
Biomarkers and Odds of Breast Cancer in Women WITH A FAMILY HISTORY
n
Crude
Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI 95% CI
24.00
95% CI 95% CI 95% CI
24.00
Supplemental Table 5m: Conditional Logistic Regression: Categories of Urinary 




Fully Adjusted* Significant Predictors: BRCA, Time Btwn 
Menarche and Parity/Menopause, BMIEverything Changed Crude β 10%
95% CI 95% CI 95% CI
Supplemental Table 5l: Conditional Logistic Regression: Categories of Urinary 






Chapter III: Influence of Pubertal Development and Family History on Urinary Oxidative Stress Biomarkers 




Oxidative stress, an imbalance between reactive oxygen species (ROS) and antioxidant defenses can 
cause mutations and epigenetic modifications (130, 242, 243) and has been associated with breast cancer 
(179, 180, 182, 185, 244).  Many risk factors of breast cancer are known to be strongest when they occur 
early in life (109, 113, 186, 245-248). Puberty is a time of intense growth and differentiation of breast 
tissue.  How oxidative stress levels change during breast development in adolescent girls is not known. 
We measured urinary biomarkers of whole body oxidative stress (F2-Isoprostane and 8-OxodG) by 
ELISA in a cohort of adolescent girls with and without a family history of breast cancer (BCFH) from the 
New York site of the LEGACY cohort (Lessons in Epidemiology and Genetics in Adults Cancer from 
Youth).  We aimed to understand how oxidative stress levels differ between girls with and without a 
family history of breast cancer accounting for differences in pubertal growth and development, both 
cross-sectionally at baseline and longitudinally over an 18-month follow up period.   
 
In our cross-sectional baseline analysis, we found no difference in mean F2-Isoprostane or 8-OxodG 
levels in girls with or without a family history of breast cancer.  F2-Isoprostane levels significantly 
increased as girls began breast development (thelarche) and there was a significant association between 
increasing tertiles of F2-Isoprostane and a positive family history of breast cancer.  We found no 
significant association between 8-OxodG levels in girls and breast Tanner Stage or other markers of 
pubertal development at baseline.  At baseline neither oxidative stress biomarker was significantly 
associated with age, race, age-specific BMI category, or having reached menarche.   
 
In our longitudinal analysis we found that urinary 8-OxodG levels rose significantly higher over follow-




significant difference in 8-OxodG levels over follow up time by Breast Tanner Stage, age-specific BMI 
category, race or age category.  F2-Isoprostane levels rose significantly over follow-up among all girls 




Despite decades of investigation and billions of dollars spent on breast cancer research, few modifiable 
risk factors for breast cancer have been identified. Not surprisingly, the incident rate of breast cancer has 
not appreciably decreased.  Growing evidence indicates that puberty may be a key period of vulnerability 
to carcinogens and other risk factors that may lead to breast cancer.  Yet, very few studies have looked at 
breast cancer risk factors from a life stage approach.  A recent report by the Interagency Breast Cancer 
and Environmental Research Coordinating Committee noted that most breast cancer studies have 
investigated environmental exposures at or around the time of diagnosis and have failed to examine how 
environmental exposures interact with sensitive developmental periods such as puberty (249). 
Understanding early life risk factors for breast cancer may be critical not just for understanding the 
etiology of the disease but also for identifying opportunities to reduce risk and would be of great benefit 
to public health. 
 
Elevated levels of oxidative stress have been observed in women diagnosed with breast cancer (179, 180, 
182, 185, 244).  Oxidative stress is also associated with several risk factors for breast cancer including 
radiation exposure, alcohol metabolism, low fruit and vegetable consumption, and estrogen levels (64, 
126, 189, 250-255).  It is not known how or if oxidative stress levels change with pubertal development.  
A previous study in adult women has shown that oxidative stress levels vary with monthly hormonal 
changes (237) and several studies (124, 194, 218) have found higher levels of oxidative stress in women 
than in men which may be due in part to hormone fluctuations.  There have been very few studies looking 
at oxidative stress in children over puberty and the results are not consistent.  A 1998 study of children 




antioxidant enzyme superoxide dismutase as puberty progressed, suggesting that increasing levels of 
oxidative stress during pubertal development may be depleting the enzyme (256). Conversely, a 2000 
study of age related changes in antioxidant levels found that subjects aged 12-24 had higher catalase 
levels in erythrocytes than subjects 2-11 indicating antioxidant capacity increased though adolescence.  
That study also found differences by sex with prepubescent girls having higher catalase levels than boys 
the same age (257). 
 
As puberty is a stage where breast tissue undergoes increased exposure to hormones, extreme 
proliferation and development, the metabolic needs of breast tissue will increase.  This could increase 
mitochondrial oxidative phosphorylation and as a result, we hypothesize that endogenous oxidative stress 
levels are likely to rise.  We also hypothesize that a family history of breast cancer may be associated with 
higher levels of oxidative stress and that oxidative stress levels would increase at a greater rate over the 
follow up period in girls with a family history of breast cancer.  Knowing how oxidative stress changes 
during this period could help identify appropriate timing of interventions that may reduce damage caused 
by oxidative stress. It may also improve the validity of future studies of oxidative stress in young girls by 
allowing investigators to control for bias due to variations in pubertal status. A relationship between 
family history of breast cancer and oxidative stress levels during puberty would highlight environmental 




Study Population and Design 
 
The LEGACY cohort (Lessons in Epidemiology and Genetics of Adult Cancer from Youth, PI Dr. Mary 
Beth Terry) is following 533 BCFH+ girls ages 6-13 from the families in the 5 North American sites of 
the BCFR.   An additional 507 girls without a family history of breast cancer in a 1st or 2nd degree relative 




without a family history were frequency matched on age and race/ethnicity to BCFH+ girls at each site. 
Informed consent was obtained from parental guardians of the minors in the study.  Epidemiological, 
behavioral and developmental questionnaires were administered at baseline in the first year and then 
every 6-months for the next four years of follow-up. Tanner stage was assessed by girls and their mothers 
via questionnaire, and by a study nurse at the clinical site. Age-specific BMI was calculated based on 
CDC cutoffs by age for average BMI (<85%), overweight BMI (85%-90%) and obese (>90%) (258).  
Biospecimens (urine, blood and/or saliva) were collected at baseline and then at 6-month intervals, up to 
18 months in this study but will continue over 5 years of follow up. Baseline enrollment began in August 
2011 and continued through early 2014.  First morning urine samples were used from girls with and 
without a family history of breast cancer to assess levels of oxidative stress (259). 
 
Laboratory Assays  
Frozen urine samples from 71 girls with a family history of breast cancer and 85 girls without a family 
history from the New York site of LEGACY were used to measure levels of 8-OxodG and F2-Isoprostane 
using well-established ELISAs. All samples were assayed in duplicate and blinded to disease status.  
Quality control included analysis of a pooled urine sample with each batch of test samples and 5% 
duplication of samples after relabeling to keep laboratory personnel blinded to sample identity.  Urinary 
biomarker levels were normalized for hydration status by measuring specific gravity, assayed using a 
handheld refractometer (TS 400, Reichert, Depew, NY).  Urinary biomarker levels were adjusted for 
specific gravity using the Levine Fahy equation (209): 
 
SG-Adjusted Biomarker (nmol/L*SG) = Biomarker (nmol/L) x [(overall mean SG -1)/(sample SG -1)] 
 
 
Urinary F2-Isoprostane levels were measured using immunoassay kits from Oxford Biomedical Research 
(Product Number: EA85 Oxford, MI) according to the manufacture’s recommendations. Briefly, 100ul of 
diluted urine samples were treated with β-glucoronidase to release any isoprostane bound to glucuronic 




Samples and standards compete with horseradish peroxidase (HRP) conjugated-15-isoprostane F2t for 
binding to a polyclonal antibody bound to the microplate. The intensity of the color produced when HRP 
substrate is added is inversely proportional to the amount of unconjugated F2-IsoP in the samples or 
standards. F2-Isopostane levels were expressed as nmol F2-Isoprostane/L*Specific Gravity.  
 
For 8-OxodG measurement, urine samples were treated with 20 U/ml urase (Sigma-Aldrich, St. Louis, 
MO, USA) for 2hrs at 37oC to reduce non-specific binding as recommended (210). Urase treatment was 
stopped with N-ethylmaleimide to a final concentration of 4 mM for 5 min at room temperature.  The 
supernatant was removed after centrifugation and then used for Solid Phase Extraction (SPE) as described 
by Lam et al. (211).  Briefly, urease treated urine samples were passed through a hydroxylated 
polystyrene-divinylbenzene sorbent column (Biotage 915-0050-P01) to isolate the polar 8-OxodG analyte 
from aqueous solutions.  The analyte was eluted from the column with 20% acetonitrile in 80% methanol, 
dried, and resuspended in 200ul PBS.    
 
The eluted urine samples were then used in an in-house competitive ELISA.  96-well plates were coated 
with 10ng/well 8-OxoG-Bovine Serum Albumin (BSA) overnight and blocked with 1% fetal calf serum 
in 0.05% Tween in PBS.  25ul of the eluted urine analyte was added in duplicate to the plate along with 
serial dilutions of an 8-OxodG standard from Sigma. Sample and standards were incubated with 50ul 
(0.2ug/ml) anti-8-OxodG N45.1 antibody (Japanese Institute for the Control of Aging, Shizuoka, Japan) 
overnight at 4C. After plates were washed in PBS 0.05% Tween, an anti-mouse-Alkaline Phosphatase-
conjugated antiserum was used to detect antibody still bound to the coated plate. Color intensity is 
inversely proportional to 8-OxodG levels in the samples. Results were adjusted for specific gravity, a 
measure of hydration status of the urine, and reported as nmol 8-OxodG/L*Specific Gravity.  The 
significant processing required for the 8-OxodG ELISA increases the between plate variability.  To 






Baseline demographic covariates between cases and controls were evaluated for any potential 
confounding factors using Pearson’s chi square tests for categorical factors and Student’s t-test for 
normally distributed continuous variables.  Wilcoxon signed rank tests were used for continuous variables 
that were not normally distributed.  The distribution of urinary F2-Isoprostane and 8-oxodG levels was 
examined graphically to identify any potential outliers.  As neither 8-OxodG nor Isoprostane levels were 
normally distributed, Wilcoxon Mann Whitney tests were used to compare the overall mean difference in 
urinary 8-oxodG and F2-Isoprostane levels between girls with and without a family history of breast 
cancer.  Cutoffs for tertiles of 8-OxodG and Isoprostane were based on the biomarker distribution among 
control girls.  The Mantel-Haenszel chi-square test was used to determine if there was a significant linear 
trend for ordinal tertiles of oxidative stress biomarkers.  
 
Linear regression methods were used for the cross sectional baseline analysis to test the relationship 
between family history, age, race, Tanner Stage of breast development, and biomarker level as a 
continuous variable, Ln transformed to meet assumptions for linear regression.  Dummy variables were 
created to test for interactions between family history and measures of pubertal breast development, age 
and race, also using linear regression.  Chi square tests were used to identify any potential confounders of 
a significant relationship between our oxidative stress biomarkers and other covariates. General linear 
models were used to model urinary oxidative stress biomarker levels and family history (any/none), BMI 
(continuous and dichotomously: average/overweight obese), race (all race categories or limited to 
Hispanic/Latino or White), and dichotomous Tanner Breast Stage (Tan2B) defined as Tanner Breast 
Stage 1 or Tanner Stage ≥2.  More parsimonious models were compared to the “Max Model” using a 
combination of Mallow’s Cp, F-values, and R2 values where for the parsimonious model (p, p=# 


















Repeated measures ANOVA using mixed effects models were used to examine the change in oxidative 
stress levels within girls longitudinally, accounting for within-subject co-variability.  Different 
variance/covariance structures were tested and the optimal one was determined by comparing the -2 Log 
likelihood of each model structure compared to that of the autoregressive model. Our models assumed 
equal time between biomarker measurements in an unbalanced design since subjects were at different 
stages of follow-up at the time urine samples were analyzed or because urine was not available from 
every follow-up visit.  The univariate longitudinal analysis determined how family history, age-specific 
BMI category, Tan2B, and race individually were associated with urinary oxidative stress levels over 
time.   Our final longitudinal analysis compared how oxidative stress levels changed over follow up time 
within girls and between girls with and without a family history of breast cancer controlling for potential 
confounders. If Yi,j is the continuous outcome of 8-OxodG or F2-Isoprostane levels of the i-th girl at 
collection point j, let Xi,j represent the vector of environmental and epidemiologic exposures such as 
Tanner stage (our primary interest), BMI, age or race (our secondary interests) at the same timepoint,  Zi 
is the binary indicator for higher risk group (FHBC versus no FHBC), Ti,j. represents the vector of family 
and subject level effects which will be included as random effects. We assume that, conditional on the 
subject level effects, that the outcome Yi,j is associated with Xi,j and Zi through the following model: 
 

Yij  ij  1X
i1
ij










Baseline Urinary Oxidative Stress Biomarkers During Adolescence 
 
Characteristics of Study Population 
Characteristics of our nested case control study population are shown in Table 1.  We had urine samples 
from 85 control girls of average risk of breast cancer (BCFH-) and 71 high risk girls (BCFH+) based on 
their family history. Among BCFH+ girls, 31% had a family history in a first degree relative; 69% had a 
family history only in a second degree relative. At baseline LEGACY girls ranged in age from 5.8 to 
almost 14. Girls with and without a family history were similar in mean age, race and age-specific BMI 
category.  At baseline, BCFH+ girls had a higher mean BMI (19.5 vs 17.4, p=0.0004 Wilcoxon Mann 
Whitney Test), were more likely to have reached menarche (12% vs 6%, p=0.007 χ2), and were more 
likely to be at Tanner breast stage 2 or above (52% vs 31%, p=0.008 χ2) than BCFH- girls. 
 
Urinary Oxidative Stress Biomarkers and Family History at Baseline  
We found no significant difference in mean 8-OxodG or mean F2-Isoprostane levels between girls with or 
without a family history of breast cancer at baseline and there was no significant relationship between 
girls’ tertile of 8-OxodG family history (Table 2). At baseline BCFH+ girls had a mean urinary 8-OxodG 
level of 120.61nmol/L*SG and BCFH- girls had a mean level of 122.32nmol/L*SG.  Mean urinary F2-
Isoprostane levels between BCFH+/- girls were 8.66nmol/L*SG and 7.76nmol/L*SG respectively.  We 
did find a significant difference and a significant trend in tertiles of F2-Isoprostane by family history (MH 
chi square p=0.01, Pearson’s chi square=0.04) noting that 50% of girls with a family history were in the 






Table 1:Distribution of Baseline Covariates Among Girls at the New York Site of the LEGACY Study
Variable Category n (%) Mean n (%) Mean p-value*
Family History No Family History 86 (55)
Family History 71 (45)
In a 2nd Degree Relative 49 (32)
In a 1st Degree Relative 22 (14)
Demographics
Age continuous 9.9 9.3 0.15
5-7 years old 21 (30) 27 (31)
8-10 years old 17 (24) 26 (30)
11-14 years old 33 (47) 33 (38)
Race Black/African American 5 (7) 13 (15) 0.47
Hispanic/Latino 24 (34) 28 (33)
White/Caucasian 37 (52) 37 (43)
Asian 4 (6) 5 (6)
Other 1 (1) 3 (3)
Pubertal/Hormonal Variables
1 31 (48) 58 (70) 0.008
2+ 34 (52) 26 (31)
1 31 (48) 58 (69) 0.02
2 10 (15) 10 (12)
3 10 (15) 8 (10)
4 9 (14) 8 (10)
5 5 (8) 0 (0)
Reached Menarche? no 50 (72) 76 (89) 0.007
yes 19 (28) 9 (11)
Modifiable Covariates
BMI continuous 19.5 17.4 0.0004
Age-Specific BMI Category <85% (Normal) 39 (61) 62 (76) 0.15
85-94% (Overweight) 11 (17) 10 (12)
95+%  (Obese) 14 (22) 10 (12)
*Chi square test for categorical variables, Wilcoxon Mann Whitney test for continuous variables.
BCFH- (n=86)BCFH+ (n=71)
Dichotomous Tanner Breast  Stage 
(baseline gardian-reported)






<94.99 30 (35) 27 (38) 7 (32) 20 (41)
94.99-127.82 28 (33) 17 (24) 7 (32) 10 (20)
>127.82 28 (33) 27 (38) 8 (36) 19 (39)
MH Chi-Square for Trend
Chi-Square
<5.20 30 (35) 14 (20) 6 (27) 8 (16)
5.20-7.65 28 (33) 21 (30) 5 (23) 16 (33)
>7.64 28 (33) 36 (51) 11 (50) 25 (51)
MH Chi-Square for Trend
Chi-Square
Baseline Urinary Biomarkers as Continuous Variables
Baseline Urinary Biomarkers as Categorical Variables

















N BCFH- (%) N BCFH+ (%)
p=0.49
FH in 1st 
Deg. Rel
FH in 2nd 
Deg Rel
p=0.55
FH in 1st 
Deg. Rel













Urinary Oxidative Stress Biomarkers and Pubertal Development and Growth at Baseline  
Girls who were are Tanner Stage 2 or above had 23% higher urinary Isoprostane levels (Wilcoxon Mann 
Whitney test p=0.005) than girls classified as pre-pubescent at Tanner Stage 1 (Table 3).  Using 
univariate linear regression methods we found urinary F2-Isoprostane levels (Ln transformed for 
normality) were  associated with Tanner Stage of breast development using both dichotomous Tanner 
Breast Staging (Tan2B) comparing girls pre- and post-initiation of breast development (T2+: β=0.23, 
p=0.01) and full Tanner Breast Staging (T2: β=0.34, p=0.01; T3: β=0.11, p=0.40; T4: β=0.40, p=0.01 T5; 
β=-0.03, p=0.89).  Consistent with our hypothesis, F2-Isoprostane levels increased as girls initiated breast 
development at stage 2 (Figure 1).   
 
There was a statistically significant association between 8-OxodG level and reaching full breast 
development at Tanner stage 5 (β=0.5, p=0.01); however this finding is based only on five girls, all of 
whom who had a family history of breast cancer.  Otherwise, we found no association between urinary 8-
OxodG levels and pubertal development as measured by Tanner Stages 1-4 or dichotomous for breast 
development (stage 1 vs 2+) or having reached menarche.   
 
Modeling Urinary Oxidative Stress Biomarkers During Pubertal Development in Girls with and without a 
Family History of Breast Cancer  
In our univariate linear regression analysis, 8-OxodG (Table 4a) was not associated with girl’s age, race, 
BMI or age-specific BMI category.  There was a statistically significant increase in 8-OxodG with BMI 
only among girls with a family history of breast cancer and the interaction term in the linear regression 
model (BMI*BCFH) was significant.  This interaction was not seen with age-specific BMI category 
(average BMI vs overweight/obese) and indicating that this result may be due to confounding with age 
(R2 age and BMI =0.23, p<0001).  Yet adding age or race into the linear regression model did not change 







β p β p
1 (N=89) ref ref ref ref
2 (N=19) 0.16 0.14 0.34 0.01
3 (N=18) -0.01 0.89 0.11 0.40
4 (N=17) 0.06 0.58 0.40 0.005
5   (N=5) 0.51 0.01 -0.03 0.89
ANOVA (TanB1-5/TanB1-4)
β p β p
1 (N=89) ref ref ref ref
2 or Higher (N=59) 0.11 0.11 0.23 0.01
ANOVA
* Wilcoxon Mann Whitney p=0.005
β p β p
No (N=125) ref ref ref ref







Table 3: ANOVA and Linear Regression-Baseline Oxidative Stress Biomarker Levels 
and Markers of Pubertal Development















Baseline Urinary Biomarker Mean









Baseline Urinary Biomarker Mean

























F2-Isoprostane levels (Table 4b) as noted previously, were positively associated with girls’ Tanner breast 
stage.  F2-Isoprostane levels were not associated with girls’ age, race, age-specific BMI category, or 
having reached menarche.  BMI as a continuous variable was associated with F2-Isoprostane levels 
(β=0.022, p=0.05) and BMI was also associated with Tan2B (Supplemental Table 1) making BMI a 
potential confounder of the relationship between Tanner breast stage and Isoprostane levels.  Adding 
continuous BMI and an interaction term (BMI*Tanner Breast Stage 2+) into the general linear regression 
model of F2-Isoprostane and Tan2B showed a statistically significant interaction between BMI and 
dichotomous Tanner Breast Stage.  Stratifying the relationship between Ln Isoprostane and BMI by 
dichotomous Tanner Breast Stage using linear regression revealed that BMI was positively associated 
with F2-Isoprostane levels only among pre-adolescent girls (T1: β=0.05, R2=0.05, p=0.03).  Among girls 
who had begun breast development (N=52), BMI had no significant effect on Isoprostane levels (T2+: β= 
-0.01, R2=0.008, p=0.52) (Figure 3).  Therefore we concluded that BMI was not likely a confounder of 
the observed increase in F2-Isoprostane levels in girls at Tanner Breast Stage 2 or above.  Additionally, 
we found that race was associated with BMI (Supplemental Table 1).  Further tabular examination of this 
relationship revealed that it was largely driven by girls who identified as Hispanic/Latino.  31% of the 
Hispanic girls in this cohort were obese compared to only 16% of the girls overall, and Hispanic girls 
made up 66% of the obese subjects in this study.  Girls who identified as White or Asian were less likely 
to be obese.  Obesity overall was associated with dichotomous Tanner Breast Stage (χ2=0.03) but 
Hispanic race was not (χ2=0.39). 
 
In the linear model of F2-Isoprostane and race, the interaction term for family history and all other 
covariates was non-significant except for race=Asian/Other (p=0.01).   However, this was based on only 5 
BCFH+ girls in this race category. We did not find that the statistically significant positive association of 
F2-Isoprostane levels with breast development, measured cross-sectionally, was modified by a family 










BC risk based on family history any 121 (71) 122 (85) -0.02 0.72
1st Degree Relative 125 (22) 0.02 0.81
Demographics
Age continuous 0.02 0.22 0.06
5-7 107 (21) 128 (27) reference
8-10 115 (17) 114 (26) -0.04 0.68 0.56
11-13 133 (33) 124 (33) 0.04 0.59 0.16
Race Hispanic/Latino 116 (24) 129 (28) -0.02 0.83 0.68
Black/African American 154 (5) 119 (13) -0.04 0.76 0.21
White/Caucasian 121 (37) 120 (37) reference
Asian/Other 112 (5) 113 (8) -0.25 0.14 0.89
Pubertal Development
Tanner Breast Stage 1 105 (31) 119 (58) reference
2 129 (10) 168 (9) 0.16 0.14 0.70
3 105 (10) 118 (8) -0.01 0.89 0.81
4 140 (9) 99.6 (8) 0.06 0.58 0.08
5 197 (5) NA 0.51 0.01 NA
Tan2B: Tanner Breast Stage 1 105 (31) 119 (58) reference
2 or higher 135 (34) 130 (25) 0.11 0.11 0.25
Reached Menarche no 111 (50) 123 (75) reference
yes 145 (19) 112 (9) 0.14 0.11 0.12
Modifiable Variables
BMI continuous 0.006 0.51 0.02
Stratified by BCFH BCFH- -0.01 0.28
BCFH+ 0.03 0.04
Stratified by Tan2B 1 -0.01 0.57 0.07
2 or higher -0.001 0.95 0.46
Age-Specific BMI Category <85% for age (Average) 118 (39) 125 (62) reference
85-94% for age (Overweight) 98.6 (11) 126 (10) -0.05 0.61 0.46
>=95% for age (Obese) 147 (14) 106 (14) 0.02 0.83 0.23
BMI cat: 
 Tanner Stage 1 <85% for age (Average) 101 (23) 121 (53) reference
> 85% for age (Overweight/Obese) 121 (6) 95.0 (3) -0.03 0.85 0.33
 Tanner Stage 2+ <85% for age (Average) 129 (22) 137 (18) reference
> 85% for age (Overweight/Obese) 164 (7) 119 (6) 0.03 0.84 0.67
BMI cat: 
No BCFH <85% for age (Average) 125 (62) reference
> 85% for age (Overweight/Obese) 116 (20) -0.04 0.72
With a BCFH <85% for age (Average) 118 (39) reference
> 85% for age (Overweight/Obese) 126 (25) 0.02 0.87
8-OxodG (nmol/L*SG) Linear Regression (Ln 8-OxodG)
Variable Category





Figure 2: Ln 8-OxodG and BMI Stratified by BCFH or 
Tanner Breast Stage (1 vs 2+)
Stratified by BCFH
Stratified Tan2B






















Ln 8-OxodG and BMI at Baseline Visit





















Tanner Stage 2+Tanner Stage 1Tanner Breast Stage












BC risk based on family history any 8.66 (71) 7.67 (85) 0.12 0.16
1st degree relative 7.48 (22) -0.10 0.44
Demographics
Age continuous 0.02 0.30 0.74
5-7 9.11 (21) 6.95 (27) reference
8-10 8.65 (17) 6.85 (26) 0.01 0.93 0.68
11-13 8.38 (33) 8.93 (33) 0.11 0.30 0.28
Race Hispanic/Latino 9.63 (24) 7.19 (28) -0.02 0.83 1.00
Black/African American 7.13 (5) 8.81 (13) -0.04 0.76 0.23
White/Caucasian 8.79 (37) 7.28 (37) reference
Asian/Other 4.61(5) 9.2(8) -0.25 0.14 0.02
Pubertal Development
Tanner Breast Stage 1 9.08 (31) 6.74 (58) reference
2 8.90 (10) 13.04 (9) 0.34 0.01 0.16
3 8.22(10) 6.79 (8) 0.11 0.40 0.77
4 9.89(9) 10.30 (8) 0.40 0.01 0.65
5 7.11(5) NA (0) -0.03 0.89 NA
Tan2B: Tanner Breast Stage 1 9.08(31) 6.74(58) reference
2 or higher 8.70(34) 10.16(25) 0.23 0.01 0.22
Reached menarche no 8.57(50) 7.50 (75) reference
yes 8.86(19) 9.62(9) 0.19 0.09 0.71
Modifiable Variables
BMI continuous 0.02 0.05 0.75
Stratified by BCFH BCFH- 0.01 0.35
BCFH+ 0.02 0.22
Stratified by Tan2B Tanner Breast Stage 1 0.05 0.03 0.29
2 or higher -0.01 0.52 0.59
Age-Specific BMI <85% for age (Average) 7.66 (46) 7.82 (62) reference
85-94% for age (Overweight) 9.11 (11) 7.52 (10) 0.19 0.14 0.58
>=95% for age (Obese) 10.49 (14) 6.83 (10) 0.19 0.11 0.13
Age-Specific BMI
Tanner Stage 1 <85% for age (Average) 7.45 (23) 6.89 (53) reference
> 85% for age (Overweight/Obese) 16.66 (6) 5.32 (3) 0.47 0.01 0.01
Tanner Stage 2+ <85% for age (Average) 9.35 (22) 9.13 (18) reference
> 85% for age (Overweight/Obese) 7.25 (7) 8.04 (6) -0.20 0.18 0.49
Isoprostane (nmol/L*SG)
Table 4b: Cross Sectional Analysis of Baseline Variables and Urinary Oxidative Stress Biomarkers using Linear Regression
Linear Regression (Ln Isoprostane)
Variable Category
Figure 3: Ln Isoprostane and BMI Stratified by BCFH or Tanner Breast Stage (1 vs 2+)
Stratified by BCFH Stratified Tan2B





























Ln Isoprostane and BMI at Baseline Visit




























Tanner Stage 2+Tanner Stage 1Tanner Breast Stage




To select the best linear regression model for predicting F2-Isoprostane levels we started with a maximum 
model that included dichotomous Tanner breast stage, age-specific BMI category (normal vs. 
overweight/obese), BCFH, race (Hispanic/Latino or White/Caucasian), and interaction terms among 
predictors. We then ran 5 other more parsimonious models (Supplemental Table 2) and selected the best 
regression models based on optimization of Mallow’s Cp, F-values, and R2 values (Table 5a).    A final 
conservative model for predicting F2-Isoprostane levels included Tanner breast stage, age-specific BMI 
category, BCFH, Hispanic race, White race, and an interaction term between Tanner breast stage and age-
specific BMI category (R2=0.11, p=0.02).  A more parsimonious model was limited to just Tanner breast 
stage, age-specific BMI category and the interaction term between the two ((R2=0.09, p=0.006).  
Following the same method to select a model for explaining 8-OxodG levels, we were unable to find a 
model that significantly explained the variance of 8-OxodG levels with the variables we had (Table 5b).  
The best model of those we examined included BCFH, continuous BMI and the interaction term between 




Model A: BCFH, BMI and Interaction Term
Ln 8-OxodG= β0 +  β1(BCFH) +β2(BMI) + β3(BMI*BCFH)
Ln 8-OxodG= 4.9619 - 0.8190(BCFH) -0.0141(BMI) +  0.0425(BMI*BCFH)
R-Square F Value Pr > F
Model A: 0.041 2.00 0.12
Standard
Error
Intercept 4.962 0.231 21.45 <.0001 4.505 5.419
BCFH  Yes -0.819 0.348 -2.35 0.020 -1.507 -0.131
BCFH No ref . . . . .
bmi -0.0141 0.013 -1.08 0.28 -0.040 0.012
bmi*BCFH Yes 0.0425 0.018 2.3 0.023 0.006 0.079
bmi*BCFH No ref . . . . .










Table 5: Baseline Models of Oxidative Stress Levels using General Linear Models
F2-ISOPROSTANE LEVELS
Model A: BCFH and Hispanic or White Race Included
Ln Isoprostane=     β0 +  β1(Tan2B) +β2(BMI >85%) + β3(BCFH) +β4(Hispanic) +β5(White) +β6(Tan2B*BMI>85%)
Ln Isoprostane= 
R-Square F Value Pr > F
Model A: 0.111 2.7 0.0167
Standard
Error
Intercept 1.695 0.108 15.62 <.0001 1.480 1.910
TAN2B                                                    
Tanner Stage 2+
0.278 0.103 2.69 0.0081 0.073 0.482
TAN2B                                                   
Tanner Stage 1
ref . . . . .
BMI                                                     
Overweight/Obese
0.447 0.186 2.41 0.0174 0.080 0.814
BMI                             
Average
ref . . . . .
BCFH Yes 0.0893 0.0926 0.96 0.34 -0.094 0.272
BCFH No ref . . . . .
Hispanic  Yes 0.106 0.126 0.84 0.40 -0.142 0.354
Hispanic No ref . . . . .
White  Yes 0.155 0.121 1.28 0.20 -0.084 0.395
White  No ref . . . . .
TAN2B*BMI                      
Tanner Stage 2+ 
Overweight/Obese
-0.643 0.244 -2.63 0.0095 -1.126 -0.160
TAN2B*BMI                         
Tanner Stage 2+             
Average BMI
ref . . . . .
TAN2B*BMI                          
Tanner Stage 1 
Overweight/Obese
ref . . . . .
TAN2B*BMI                                     
Tanner Stage 1              
Average BMI
ref . . . . .
1.6949 +  0.2779(Tan2B) + 0.4468(BMI >85%) +  0.0892(BCFH) + 
0.1060(Hispanic) + 0.1553(White) - 0.6432(Tan2B*BMI >85%)







Longitudinal Analysis of Urinary Oxidative Stress Biomarkers in Adolescent Girls with and 
without a Family History of Breast Cancer 
 
Characteristics of Study Population over Follow-Up Period 
The number of participants in our nested case control study population are shown in Table 6. The 
decrease in participants with each follow up visit is not due to loss-to-follow-up, but the fact that urine 
samples were analyzed while follow-up was ongoing; baseline enrollment was complete, and the majority 
of girls had reached the 6-month follow-up visit but only the girls who had joined the study early had 
reached the 12-month or 18-month follow-up visit.  There were no significant differences in follow-up by 
fixed variables such as race or family history (data not shown). 
(Continued)
Table 5: Baseline Models of Oxidative Stress Levels using General Linear Models
Model B: Parsimonious-Tan2B, BMI >85%, Interaction
Ln Isoprostane= β0 +  β1Tan2B +β2BMI >85% +β3Tan2B*BMI>85%
Ln Isoprostane= 1.8343 +  0.2918(Tan2B) + 0.4720(BMI >85%) - 0.6765(Tan2B*BMI >85%)
R-Square F Value Pr > F
Model B: 0.090 4.37 0.0057
Standard
Error
Intercept 1.834 0.058 31.53 <.0001 1.719 1.949
TAN2B                                                  
Tanner Stage 2+
0.292 0.100 2.92 0.0041 0.094 0.489
TAN2B                                              
Tanner Stage 1
ref . . . . .
BMI  Overweight/Obese 0.472 0.179 2.64 0.0093 0.118 0.826
BMI Average ref . . . . .
TAN2B*BMI                                  
Tanner Stage 2+ 
Overweight/Obese
-0.677 0.242 -2.80 0.0059 -1.154 -0.199
TAN2B*BMI                      
Tanner Stage 2+                                                   
Average BMI
ref . . . . .
TAN2B*BMI                      
Tanner Stage 1 
Overweight/Obese
ref . . . . .
TAN2B*BMI                      
Tanner Stage 1                
Average BMI
ref . . . . .







Repeated Measures Analysis of Urinary Oxidative Stress Biomarkers over 18-Month Follow-Up 
In the univariate longitudinal analysis 8-OxodG levels did not change significantly by follow-up visit 
overall (Table 7).  However when we stratified by BCFH, we found that 8-OxodG levels rose 
significantly higher over follow up time in girls with a family history of breast cancer.  There was no 
difference in the change in 8-oxodG levels over time when we stratified by age category, race, tanner 
breast stage, or age-specific BMI.  The difference in 8-OxodG levels over time by BCFH remained 
significant after adding age category, age-specific BMI category, Tanner breast stage and interaction 
between age-specific BMI category and BCFH to the model (Table 9). This result was unchanged when 
we limited our model to the first year of follow-up. 
BCFH Baseline 6 month 12 Month 18 month
BCFH- 86 74 45 26
BCFH+ 71 60 45 21
Total 157 134 90 47
% of Base 100 85 57 30
BCFH Baseline 6 month 12 Month 18 month
BCFH- 7.67 8.78 10.78 8.29
BCFH+ 8.66 11.04 18.03 7.77
WMW p>|Z| 0.07 0.31 0.41 0.69
BCFH Baseline 6 month 12 Month 18 month
BCFH- 122 125 112 113
BCFH+ 121 137 140 171
WMW p>|Z| 0.69 0.30 0.02 0.12
No. Participants at Follow Up
Table 6: Longitudinal Analysis-Participants by Follow-
Up Visit and Urinary Biomarker Levels in High and Low 
Risk girls over Follow-Up
Mean at Follow Up Visit
F2-Isoprostane (nmol/L*SG)






In the univariate longitudinal analysis F2-Isoprostane levels rose significantly over follow-up time among 
all girls but there was no significant difference longitudinally in F2-Isoprostane levels by BCFH (Table 
7). There was no difference in the change in F2-Isoprostane levels over follow-up by age, race or tanner 
breast stage.   
 
We did find a significant difference in F2-Isoprostane levels when stratifying by age-specific BMI 
category. This change appeared non-linear with the greatest difference occurring at the 6-month follow-up 
visit but the levels were almost identical at the 12-month and 18-month visits.   The change in F2-
Isoprostane levels over follow-up was no longer significant when age category, age-specific BMI 
category and Tanner breast stage were added to the model, but the difference in F2-Isoprostane levels 










Table 7: Univariate Repeated Measures Analysis of Urinary 8-OxodG Levels Over Time
Ln 8-OxodG Over Follow Up
Effect Num DF Den DF F Value Pr > F
Follow-Up Visit 3 164 1.61 0.19
Follow Up Visit
Effect Num DF Den DF F Value Pr > F
BCFH 1 156 2.18 0.14
Follow-Up Visit 3 156 1.8 0.15
BCFH*Follow-Up Visit 3 156 3.15 0.03
BMI: Average v Overweight/Obese
Effect Num DF Den DF F Value Pr > F
BMI Category 1 152 0.27 0.61
Follow-Up Visit 3 152 1.58 0.20
BMI Cat*Follow-Up Visit 3 152 0.05 0.99
8-OxodG Type 3 Tests of Fixed Effects (N=165)
8-OxodG Type 3 Tests of Fixed Effects (N=158)
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0 6mo 1yr 1.5yr
Ln 8-OxodG Means Over Follow Up by Age-Specific BMI Category
Unadjusted





















0 6mo 1yr 1.5yr
Ln 8-OxodG Means Over Follow Up
Unadjusted






Table 7 (continued): Univariate Repeated Measures Analysis of Urinary 8-OxodG Levels Over Time
Tanner Breast Stage
Effect Num DF Den DF F Value Pr > F
Tan2B 1 161 1.19 0.28
Follow-Up Visit 3 161 1.77 0.16
Tan2B*Follow-Up Visit 3 161 0.39 0.76
Race*
Effect Num DF Den DF F Value Pr > F
Race/Ethnicity 4 153 0.37 0.83
Follow-Up Visit 3 153 0.4 0.75
Race*Follow-Up Visit 12 153 0.48 0.92
* All 5 race categories used for test of fixed effects.  Graphed only 3.
Age Category
Effect Num DF Den DF F Value Pr > F
Age tertile 2 164 0.27 0.76
Follow-Up Visit 3 164 1.26 0.29
Age Tertile*Follow-Up Visit 6 164 0.64 0.70
8-OxodG Type 3 Tests of Fixed Effects (N=162)
8-OxodG Type 3 Tests of Fixed Effects





















0 6mo 1yr 1.5yr
Ln 8-OxodG Means Over Follow Up by Breast Development
Unadjusted





















0 6mo 1yr 1.5yr
Ln 8-OxodG Means Over Follow Up by Race/Ethnicity
Unadjusted





















0 6mo 1yr 1.5yr
Ln 8-OxodG Means Over Follow Up by Age Category
Unadjusted







Table 8: Univariate Mixed Models Analysis of Urinary F2-Isoprostane Levels Over Time
Ln Isoprostane Over Follow Up Time
Effect Num DF Den DF F Value Pr > F
Follow-Up Visit 3 164 3.43 0.02
Family History
Effect Num DF Den DF F Value Pr > F
BCFH 1 156 0.39 0.54
Follow-Up Visit 3 156 3.21 0.02
BCFH*Follow-Up Visit 3 156 0.92 0.43
BMI: Average v Overweight/Obese
Effect Num DF Den DF F Value Pr > F
BMI Category 1 147 3.02 0.08
Follow Up Visit 3 147 2.71 0.05
BMI Cat*Follow-Up Visit 3 147 3.62 0.01
F2-Isoprostane Type 3 Tests of Fixed Effects (N=158)
F2-Isoprostane Type 3 Tests of Fixed Effects (N=165)
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0 6mo 1yr 1.5yr
Ln Isoprostane Means Over Follow Up
Unadjusted




























0 6mo 1yr 1.5yr
Ln Isoprostane Means Over Follow Up by BMI
Unadjusted









Table 8 (continued): Univariate Mixed Models Analysis of Urinary F2-Isoprostane Levels Over Time
Tanner Breast Stage
Effect Num DF Den DF F Value Pr > F
Tan2B 1 156 1.7 0.19
Follow Up Visit 3 156 2.56 0.06
Tan2B*Follow-Up Visit 3 156 1.03 0.38
Race* 
Effect Num DF Den DF F Value Pr > F
Race/Ethnicity 4 152 1.46 0.22
Follow Up Visit 3 152 2.26 0.08
Race*Follow-Up Visit 12 152 0.86 0.59
* All 5 race categories used for test of fixed effects.  Graphed only 3.
Age Category
Effect Num DF Den DF F Value Pr > F
Age Category 2 164 2.96 0.05
Follow Up 3 164 2.22 0.09
Age Category*Follow Up 6 164 0.58 0.75
F2-Isoprostane Type 3 Tests of Fixed Effects (N=158)
F2-Isoprostane Type 3 Tests of Fixed Effects (N=157)


























0 6mo 1yr 1.5yr
Ln Isoprostane Means Over Follow Up by Breast Development
Unadjusted


























0Baseline 6mo 1yr 1.5yr
Ln Isoprostane Means Over Follow Up by Race/Ethnicity
Unadjusted




























0 6mo 1yr 1.5yr
Ln Isoprostane Means Over Follow Up by Age Category
Unadjusted












Our cross-sectional results indicate that there is a relationship between breast development and oxidative 
stress as measured by urinary F2-Isoprostane levels.  This relationship was independent of age, age-
specific BMI, onset of menarche, and race.  It was also independent of family history of breast cancer so 
its significance in future risk of breast cancer is unknown. However we did find that BCFH+ girls were 
more likely than BCFH- girls to be in the highest tertile of urinary Isoprostane (51% vs 33%). F2-
Isoprostane levels changed over follow-up time among all girls but this increase was not related to family 
history and may be driven by BMI.  We did not see a significant change difference in F2-Isoprostane 
levels by Tanner breast stage over the 18-month follow up period as we did at baseline.  However, over 
the follow-up period the number of girls at T1 are decreasing as they age and begin breast development 
Table 9: Longitudinal Multivate Analysis using Mixed Models, Oxidaitve Stress Biomarker Levels over Follow-Up 
Effect Num DF Den DF F Value Pr > F Effect Num DF Den DF F Value Pr > F
Family History 1 144 2.25 0.14 Family History 1 143 1.65 0.20
Age Tertile 2 144 0.06 0.94 Age Tertile 2 143 0.69 0.51
BMI Category 1 144 0 0.98 BMI Category 1 143 0.35 0.56
Tan2B 1 144 0.06 0.81 Tan2B 1 143 2.67 0.10
Follow Up 3 144 1.79 0.15 Follow Up 2 143 2.5 0.09
FH*Follow Up 3 144 2.99 0.03 FH*Follow Up 2 143 4.13 0.02
Age Tertile*Follow Up 6 144 0.71 0.64 Age Tertile*Follow Up 4 143 0.02 1.00
BMI Category*Follow Up 3 144 0.22 0.88 BMI Category*Follow Up 2 143 0.09 0.91
Tan2B*Follow Up 3 144 1.24 0.30 Tan2B*Follow Up 2 143 0.97 0.38
FH*BMI*Follow Up 4 144 0.03 1.00 FH*BMI*Follow Up 3 143 0.04 0.99
Effect Num DF Den DF F Value Pr > F Effect Num DF Den DF F Value Pr > F
Family History 1 144 0.07 0.79 Family History 1 143 0.03 0.87
Age Tertile 2 144 1.82 0.17 Age Tertile 2 143 1.13 0.33
BMI Category 1 144 0.93 0.34 BMI Category 1 143 3.91 0.05
Tan2B 1 144 0.04 0.85 Tan2B 1 143 0.62 0.43
Follow Up 3 144 1.98 0.12 Follow Up 2 143 1.75 0.18
FH*Follow Up 3 144 0.64 0.59 FH*Follow Up 2 143 1.13 0.33
Age Tertile*Follow Up 6 144 0.64 0.70 Age Tertile*Follow Up 4 143 1.14 0.34
BMI Category*Follow Up 3 144 3.56 0.02 BMI Category*Follow Up 2 143 3.8 0.02
Tan2B*Follow Up 3 144 0.46 0.71 Tan2B*Follow Up 2 143 1.29 0.28
Tan2B*Follow Up*BMI Cat 4 144 1.54 0.19 Tan2B*Follow Up*BMI Cat 3 143 2.25 0.08
All Follow-Up Visits (18-months) First 3 Follow-Up Visits (12-months)
Model ln 8-OxodG= FH Age(cat) BMI(cat) Tanner Stage Follow-Up  (FH*Follow-Up) (Age*Follow-Up) (BMI*Follow-Up) (Tanner Stage*Follow-Up) 
(BCFH*BMIcat*Follow-Up) 
All Follow-Up Visits (18-months)
Model ln F2-Isoprostane= FH Age(cat) BMI(cat) Tanner Stage Follow-Up  (FH*Follow-Up) (Age*Follow-Up) (BMI*Follow-Up) (Tanner Stage*Follow-
Up) (Tanner*BMIcat*Follow-Up) 




and enter stages 2 and above.  It’s possible this study was too small and the analysis too simplistic to 
account for this crossover.  The significantly higher levels of F2-Isoprostane at baseline do appear to be 
maintained through the 6-month follow up visit (Table 8).      
 
At baseline we found no significant difference in DNA oxidation, as measured by 8-OxodG, and BCFH 
or pubertal development. In our longitudinal analysis we observed that 8-OxodG levels significantly 
increased only in girls with a family history of breast cancer.  Whether or not this increase is a reflection 
of their family history, or is a contributor to their risk is not known.  The increase in 8-OxodG among 
BCFH+ girls does not seem to be driven by differences in BMI, or whether or not breast development had 
begun.  The disparity in results between baseline and follow-up with regards to differences in family 
history may be due to poor %CV of the 8-OxodG ELISA which involves significant sample processing.  
In our cross sectional baseline analysis we compared differences between girls whose samples were run 
on different plates and days with different SPE runs. This maximized the variation between samples. 
Assuming variation in 8-OxodG levels is non-differential in regards to family history then we would 
expect a bias towards the null.  In our longitudinal analysis of 8-OxodG levels, repeated urine samples 
from the same girl were run on the same ELISA plate on the same day, purified by the same SPE run, 
reducing the variability to more acceptable levels (<15%).        
 
In both our baseline biomarker results we observed an intriguing effect modification with BMI.  BMI has 
been associated with both oxidative stress (231, 260, 261) and breast cancer risk (72, 262).  It is also one 
of the few risk factors for breast cancer that is modifiable.  We observed that baseline F2-Isoprostane 
levels significantly increased with BMI (continuous or age-specific category) but only among pre-
pubescent girls. This interaction was still apparent over the first year of follow-up.  Similarly, baseline 8-
OxodG levels increased significantly with continuous BMI only among BCFH+ girls.  These interactions 
with BMI hint at a possible role for hormonal regulation of oxidative stress levels.  If estrogen acts as an 




marker of pubertal development and hormonal changes, oxidative stress levels would cease to rise with 
increasing BMI.  Similar results have been observed in studies of adult women.  A 2008 study found that 
F2-Isoprostane levels were associated with estrogen only in post-menopausal women after adjusting for 
BMI (190).  A more recent study found the risk of postmenopausal breast cancer was higher in obese 
women with genetically impaired antioxidant response relative to postmenopausal obese women without 
an oxidative stress phenotype (266).  We note that in our previous study in the BCFR we did not find a 
significant interaction between oxidative stress, levels BMI and menopausal status (data not shown).  
However, the discrepancy may be because all women in that study have a family history of breast cancer.  
Similarly, the observed 8-OxodG increases with BMI only among girls with a BCFH elicits the 
possibility that their antioxidant capacity, hormonally mediated or otherwise, is somehow impaired.  If so, 
the increased levels of DNA oxidation in girls with a high BMI and a family history of breast cancer may 
contribute their increased risk of breast cancer.  Future studies should examine genetic interplay between 
antioxidant genes such as Nrf2, Keap1, or SOD, estrogen, progesterone and/or insulin levels, and BMI.        
 
At baseline we did not observe a significant relationship overall between either of the oxidative stress 
biomarkers and BCFH.  The genetic or environmental factors that put these families are increased risk 
may not work through mechanisms that alter oxidative stress.  It may be that this study suffers from a 
form of misclassification bias in using breast cancer family history as a surrogate for breast cancer risk.  
A family history of breast cancer is an imperfect measure of breast cancer risk.  It can change over time 
and the risk it imparts decreases with age (200, 201).  It varies by family size.  It may be that BCFH- girls 
will change status over time and do harbor genetic or environmental risk factors that put them at 
significantly increased risk of breast cancer. Similarly some BCFH+ girls, especially those with a family 
history in a 2nd degree relative only, may not be at increased risk.  This scenario would bias our results 





A family history in a first degree relative by age 20 is a strong risk factor for breast cancer (201).  
However, we still did not find a significant difference in mean oxidative stress levels at baseline when we 
limited our analysis to the 22 girls with a family history in a first degree relative compared to girls 
without a family history in a first degree relative or to girls with no family history at all (Tables 2 and 4), 
but this may be due to lack of power given the small number of subjects with a family history of breast 
cancer in a first degree relative.  Future studies of breast cancer risk in adolescent girls may want to focus 
solely on girls with a family history in a first degree relative where the risk more definitive.  While there 
may be more significant genetic biomarkers breast cancer risk, such as BRCA1/2 mutations, the 
American Academy of Pediatrics discourages genetic testing in children for adult-onset diseases (267), 
leaving family history one of the few meaningful risk factors for breast cancer that are manifest in 
childhood.   
 
This highlights the importance of this study in trying to validate oxidative stress as an easily measurable 
and potential modifiable risk factor for breast cancer among adolescent girls.  There have been very few 
studies looking at oxidative stress levels in healthy children.  A 2014 study in 159 healthy Italian children 
5-11 years old found that urinary 8-OxodG levels decreased with increasing BMI (268); however urine 
hydration status was adjusted for by creatinine and creatinine is known to increase with BMI so adjusting 
by creatinine would artificially deflate 8-OxodG levels by BMI.  Other studies (257, 269) have shown 
contradictory changes in antioxidant enzyme levels by age. 
 
Results between F2-Isoprostane and 8-OxodG were not exactly consistent.  This was not unexpected 
(154, 270).  Our biomarkers are measuring two different forms of oxidative stress that may be subject to 
different sources of ROS both spatially and temporally.  Levels of oxidative stress can vary within the 
same biomarker depending on the biospecimen used (271). Lipids may be more sensitive or have greater 
exposure to oxidative stress than DNA.  In a test of various biomarkers of oxidative stress to exposure to 




(158).  In our previous study of oxidative stress in adult women from the BCFR we found smoking 
significantly influenced isoprostane levels whereas smoking had no significant effect on 8-OxodG levels.  
Other studies (272-275) have also found that smoking does not alter 8-OxodG levels.  Among these 
studies Sakano et al., also measured isoprostane levels and similarly found an increase in isoprostane 
levels among smokers without a concomitant increase in 8-OxodG. The fact that 8-OxodG levels are also 
influenced by DNA repair rates also complicates its interpretation. It may be possible that rapid cell 
division during breast development limits the repair mechanisms that excise 8-OxodG from DNA and 
would increase levels excreted in urine. 
 
To our knowledge, this is the first study to look at oxidative stress levels in a cohort of young girls with a 
family history of breast cancer.  It is also the first study to examine oxidative stress levels in girls at high 
risk for breast cancer at various stages of pubertal development and over time.  Comparing changes in 
oxidative stress levels within girls over follow-up reduced variation and gave our analysis greater power 
to detect small changes. Our use of repeated urinary measures over an 18-month period enabled us to look 
at long term averages of oxidative stress and is a major improvement over most studies that use single 
spot urine samples.  Previous studies that have looked at early life exposures often try to measure these 
exposures as recalled from adulthood and may be subject to recall bias (276-279).  Studies that have tried 
to determine the role pubertal development has on breast cancer risk are limited by the ability of adult 
women to accurately recall specific developmental milestones.  The LEGACY study’s prospective 
collection of pubertal development using Tanner staging allows for more a more accurate analysis of the 
relationship between FH, oxidative stress and pubertal development. 
 
The LEGACY study benefits from well documented family histories collected from parent/guardian 
questionnaires that recorded cancer events and types in daughters 1st, 2nd and 3rd degree relatives, their 




variety of racial and ethnic backgrounds. At baseline girls were at a wide range of ages and stages of 
pubertal development which allowed us to make comparisons between groups. 
 
Urinary oxidative stress levels were measured using well established biomarkers by ELISA which is well 
suited for studies of large populations.  Hydration status was adjusted for using specific gravity rather 
than creatinine in order to reduce biases due to age, diet and body composition that can influence 
creatinine excretion.  In this study we found that creatinine levels were significantly correlated to girls’ 
age, BMI, Tanner stage, and reaching menarche whereas specific gravity was not significantly associated 
with any of these variables (data not shown).  We believe that adjusting for hydration status using specific 
gravity instead of creatinine is a significant improvement over other studies. 
 
This study does have some limitations.  There may be misclassification bias for the control girls who 
currently do not have a family history but may actually be at high risk of familial breast cancer if their 1st 
or 2nd degree relatives develop cancer later.  Those girls may share similar genetic or environmental 
exposures as the girls in the BCFH+ group and would bias our results towards the null. 
 
Breast Tanner staging is based on the outward appearance of breasts.  We do not know exactly what 
internal changes to breast and/or mammary tissue are occurring at each tanner stage beyond that at tanner 
stage 2 mammary glands are present.  What specific additional changes occur to mammary tissue between 
stages 2 and 5 are not known due to the unavailability of human breast tissue from healthy adolescent 
girls.  Our results revealed significant increases in isoprostane levels at Tanner stages 2 and 4.  Whether 
or not the non-significant change at Tanner stage 3 has a physiological basis is not known.  Most of what 
is known about mammary gland development comes from mouse studies and as mice do not produce 
outward breasts, it is impossible to connect mouse mammary gland development to human Tanner stage.  




non-invasively measure breast tissue density and can be used in future studies to connect tanner staging 
with internal changes in breast tissue (259). 
 
Finally, spot urine samples only provide a short term measure of oxidative stress, though we did collect 
them repeatedly at 6-month intervals. Blood samples were collected from girls in this study however girls, 
especially young girls, were much more likely to donate urine (98% at baseline) than blood samples (41% 
at baseline) so relying on blood samples would reduce our sample size and power considerably and could 
have biased out results. 
 
Oxidative stress has been used as a biomarker in studies of children with diabetes, hypertension, lead 
poisoning, etc.  It is important to know how or if pubertal development influences oxidative stress levels 
so that future studies can adjust for these fluctuations accordingly. 
 
The results of our study indicate that lipid peroxidation may increase over pubertal development 
corresponding to the initiation of breast development.  The initiation of breast development also modified 
the effect of BMI on lipid peroxidation, with increases with BMI limited to girls who had not yet begun 
breast development.  We also demonstrated that DNA oxidation increases during adolescence only in 
girls at higher risk of breast cancer due to their family history.  Teasing out the individual effects of age, 
BMI, and pubertal development is difficult as they are all so interconnected.  Still, we were able to show 
distinct and meaningful effects of these characteristics on oxidative stress levels. Data from the full 5-year 
follow-up period of the LEGACY study will increase our capacity to understand these relationships. 
 
These results add to the evidence that puberty is a critical phase that may significantly influence breast 
cancer risk.  Breasts may be as susceptible to oxidative stress induced mutations during puberty as other 
organs are during fetal development given their still undifferentiated state. Several animal studies support 




during puberty—and specifically breast development—may produce high levels of endogenous oxidative 
stress. This may contribute to girls’ breast cancer risk. Small amounts of unrepaired DNA damage in 
precursor breast cells, so called stem cells, may give rise to mutations throughout mature breast tissue (17, 
280). Even slight increases in oxidative stress may lead to a significant increase in mutation rates over 
time.  As our study is measuring oxidative stress levels years if not decades before cancer may develop in 



































Tanner Breast Stage and Isoprostane Tertiles
<5.20 32 (36) 8 (13)
5.20-7.65 28 (31) 19 (32)
>7.64 29 (33) 33 (55)
MH Chi-Square for Trend
Chi-Square
Tanner Breast Stage and BMI category
1   (PrePubertal) 63 (66) 13 (62) 9 (41)
2+ (Begun Breast Develop) 32 (34) 8 (38) 13 (59)
MH Chi-Square for Trend
Chi-Square
Tanner Breast Stage and Obesity
1   (PrePubertal) 76 (66) 9  (41)
2+ (Begun Breast Develop) 40 (34) 13 (59)
MH Chi-Square for Trend
Chi-Square
Isoprostane Tertile and BMI category
<5.20 33 (33) 2 (10) 5 (21)
5.20-7.65 30 (30) 8 (38) 7 (29)
>7.64 38 (38) 11 (52) 12 (50)
MH Chi-Square for Trend
Chi-Square
Isoprostane Tertile and Obesity
<5.20 35 (29) 5  (20.83)
5.20-7.65 38 (31) 7  (29.17)
>7.64 49 (40) 12 (50.00)
MH Chi-Square for Trend
Chi-Square
Isoprostane Tertile and Overweight/Obesity
<5.20 33 (32.67) 7 (16)
5.20-7.65 30 (29.70) 15 (33)
>7.64 38 (37.62) 23 (51)
MH Chi-Square for Trend for final analyis cat BMI as normal v overweight/obese
Chi-Square
Tertile Isoprostane             




Tertile Isoprostane             
(nmol/L SG) Tanner 1 Tanner 2+
0.001
0.004
Tertile Isoprostane             
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(nmol/L SG) Normal/Overweight Obese











Tanner Breast Stage Normal/Overweight Obese
Supplemental Table 1: Is the relationship between Tanner Breast Stage and 






Tanner Breast Stage and Race
1   (PrePubertal) 28 (55) 10 (59) 45 (64) 4 (57) 2 (50)
2+ (Begun Breast Develop) 23 (45) 7 (41) 25 (36) 3 (43) 2 (50)
MH Chi-Square for Trend
Chi-Square
Isoprostane Tertile and Race
<5.20 15 (29) 5 (28) 18 (24) 5 (56) 1 (25)
5.20-7.65 13 (25) 5 (27) 28 (38) 2 (22) 1 (25)
>7.64 24 (46) 8 (44) 28 (38) 2 (22) 2 (50)
MH Chi-Square for Trend
Chi-Square
BMI category and Race
Normal 29 (57) 12 (67) 51 (77) 7  (100) 2 (50)
Overweight 6  (12) 2 (11) 11 (17) 0 2 (50)
Obese 16* (31) 4 (22) 4  (6) 0 0
MH Chi-Square for Trend
Chi-Square
* 66% of obese girls were Hispanic/Latino
BMI category and Race: Chi Square for Individual Race Groups
Normal 29 (57) 72 (75.79) 12 (67) 89 (70) 51 (77) 50 (63)
Overweight 6  (12) 15 (15.79) 2  (11) 19 (15) 11 (17) 10 (13)
Obese 16 (31) 8  (8.42) 4  (22) 20 (16) 4   (6) 20 (25)
MH Chi-Square for Trend
Chi-Square
Obesity and Race: Chi Square for Individual Race Groups
Normal/Overweight 35 (69) 87 (92) 14 (78) 108 (84) 62 (94) 60 (75)
Obese 16 (31) 8   (8) 4  (22) 20   (16) 4   (6) 20 (25)
MH Chi-Square for Trend
Chi-Square
Tanner Breast Stage and Race: Chi Square for Individual Race Groups
1   (PrePubertal) 28 (55) 61 (62) 10 (59) 79 (60) 45 (64) 44 (56)
2+ (Begun Breast Develop) 23 (45) 37 (38) 7   (41) 53 (40) 25 (36) 35 (44)
MH Chi-Square for Trend
Chi-Square
Isoprostane Tertiles and Obesity, Stratified by Hispanic Race
AMONG ALL GIRLS AMONG HISPANIC/LATINO GIRLS ONLY
<5.20 35 (29) 5  (21) 10 (29) 4 (25)
5.20-7.65 38 (31) 7  (29) 9  (26) 4 (25)
>7.64 49 (40.16) 12 (50) 16 (46) 8 (50)
MH Chi-Square for Trend
Chi-Square
Tanner Breast Stage and Obesity, Stratified by Hispanic Race
AMONG ALL GIRLS AMONG HISPANIC/LATINO GIRLS ONLY
1   (PrePubertal) 76 (66) 9  (41) 22 (63) 6 (40)
2+ (Begun Breast Develop) 40 (34) 13 (59) 13 (37) 9 (60)
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RACE N (%) RACE N (%)
Supplemental Table 1: Is the relationship between Tanner Breast Stage and 
Isoprostane Tertiles confounded by Race or BMI?













Tertile Isoprostane             







Supplemental Table 2a: LEGACY Baseline Isoprostane Model Selection
Model # Variables Variables F value Pr > F SSE MSE n Mallow's Cp (# Va+1)-Cp Fmodel R
2
Notes


































6 3 Tan2B 4.27 0.006 34.21 0.26 137 3.59 0.41 0.96 0.09
adj_BMI2
Tan2B*Adj_BMI2
Cp=SSE(model)/MSE(max model)-[n-2(#variables in model+1)]
Fmodel=[SSE(model)-SSE(max model)]/(# var in max model)-(# variables in model)/MSE(max model)
Max Model, all possible significant variables and potential 
confounders
Removed non-significant interaction terms.                                                         
Significant model and Cp very close to # variables in the model.  
This and #6 are the best
Switched dichotmous age-specific BMI (Obese/Not-Obese) for 
continuous BMI, which 2 race categories (which were associated 
with BMI) for all 5. Overall non-signficant
As Above but without BCFH*BMI interaction term.                                                                                                                                                                         
Model much less significant without interaction term.
Model #2 wihout any race variable.    Good, but not as signficant 
as same model without family history 
Model # 5 without BCFH. Signficant, parsimonious, Cp close to 
# variables in model.  Might be the best.  R
2
 higher in #2 but that 




Supplemental Table 2b: LEGACY Baseline 8-OxodG Model Selection
Model # Variables Variables F value Pr > F SSE MSE n Mallow's Cp (# Va+1)-Cp Fmodel R
2
Notes


































6 3 Tan2B 0.95 0.42 24.58 0.18 137 3.48 0.52 0.95 0.02
adj_BMI2
Tan2B*Adj_BMI2





8 3 age 1.34 0.26 25.57 0.18 145 0.79 3.21 1.48 0.03
bmi
age*bmi
9 3 bmi 2.00 0.12 25.23 0.18 145 -1.05 5.05 1.29 0.04
Family History
bmi*FH
10 3 adj_BMI2 0.08 0.97 26.26 0.19 145 4.49 -0.49 1.85 0.002
Family History
Adj_BMI2*FH




Cp=SSE(model)/MSE(max model)-[n-2(#variables in model+1)]
Fmodel=[SSE(model)-SSE(max model)]/(# variables in max model)-(# variables in model)/MSE(max model)
As above (#9) but changed continuous bmi to categorical 
(average bmi vs overweight/obese).   Interaction term with 
categorical bmi non-significant.                                                                                                                                                                   
As #9 but adjusting for age.  Family history and interaction terms 
still significant when age in the model
Above but remove FH
Just what was significant from the unvariate  analysis.  Highest F-
value of all the models. Explains as much of the variation as 
models #3 and #4 which have more variables
Significant from univariate, plus potential confounder.  Worst 
model?
Model # 5 without BCFH. 
Max Model, all possible significant variables and potential 
confounders
removed non-significant interaction terms.                                                      
switch dichotmous age-specific BMI (Obese/Not-Obese) for 
continuous BMI, which 2 race categories (which were associated 
with BMI) for all 5.                                                     
As Above but without BCFH*BMI interaction term.                                                                                                                                                                      







Supplemental Table 3: Effect Estimates for Change in Ln 8-OxodG Over 12-Month Follow-Up 
Effect BCFH Tan2B BMI cat
Follow Up 
Visit
Age Category Estimate Pr > |t|
BCFH*Follow-Up Yes 1 0.132 0.17 -0.057 0.321
BCFH*Follow-Up Yes 2 0.236 0.02 0.045 0.427
BCFH*Follow-Up Yes 0 0.000 . . .
BCFH*Follow-Up No 1 0.000 . . .
BCFH*Follow-Up No 2 0.000 . . .
BCFH*Follow-Up No 0 0.000 . . .
Age Cat*Follow-Up 1 8.5-11 years old 0.010 0.92 -0.196 0.217
Age Cat*Follow-Up 1 >11 years old -0.001 0.99 -0.287 0.284
Age Cat*Follow-Up 1 <8.5 years old 0.000 . . .
Age Cat*Follow-Up 2 8.5-11 years old -0.012 0.92 -0.242 0.218
Age Cat*Follow-Up 2 >11 years old 0.002 0.99 -0.299 0.302
Age Cat*Follow-Up 2 <8.5 years old 0.000 . . .
Age Cat*Follow-Up 0 8.5-11 years old 0.000 . . .
Age Cat*Follow-Up 0 >11 years old 0.000 . . .
Age Cat*Follow-Up 0 <8.5 years old 0.000 . . .
BMI cat* Follow-Up Overweight/Obese 1 -0.047 0.68 -0.270 0.177
BMI cat* Follow-Up Overweight/Obese 2 0.023 0.85 -0.215 0.262
BMI cat* Follow-Up Overweight/Obese 0 0.000 . . .
BMI cat* Follow-Up Average 1 0.000 . . .
BMI cat* Follow-Up Average 2 0.000 . . .
BMI cat* Follow-Up Average 0 0.000 . . .
Tan2B*Follow-Up Tanner Stage 2+ 1 0.005 0.97 -0.250 0.260
Tan2B*Follow-Up Tanner Stage 2+ 2 -0.156 0.25 -0.422 0.111
Tan2B*Follow-Up Tanner Stage 2+ 0 0.000 . . .
Tan2B*Follow-Up Tanner Stage 1 1 0.000 . . .
Tan2B*Follow-Up Tanner Stage 1 2 0.000 . . .
Tan2B*Follow-Up Tanner Stage 1 0 0.000 . . .
BCFH*BMI*Follow-Up Yes Overweight/Obese 1 0.022 0.88 -0.276 0.320
BCFH*BMI*Follow-Up Yes Overweight/Obese 2 -0.034 0.83 -0.348 0.279
BCFH*BMI*Follow-Up Yes Overweight/Obese 0 -0.024 0.86 -0.301 0.252
BCFH*BMI*Follow-Up Yes Average 1 0.000 . . .
BCFH*BMI*Follow-Up Yes Average 2 0.000 . . .
BCFH*BMI*Follow-Up Yes Average 0 0.000 . . .
BCFH*BMI*Follow-Up No Overweight/Obese 1 0.000 . . .
BCFH*BMI*Follow-Up No Overweight/Obese 2 0.000 . . .
BCFH*BMI*Follow-Up No Overweight/Obese 0 0.000 . . .
BCFH*BMI*Follow-Up No Average 1 0.000 . . .
BCFH*BMI*Follow-Up No Average 2 0.000 . . .
BCFH*BMI*Follow-Up No Average 0 0.000 . . .
95% CI





Supplemental Table 4: Effect Estimate for Change in Ln F2-Isoprostane Over 12-Month Follow-Up 
Effect BCFH Tan2B BMI cat
Follow Up 
Visit
Age Category Estimate Pr > |t|
BCFH*Follow-Up Yes 1 -0.060 0.61 -0.295 0.174
BCFH*Follow-Up Yes 2 -0.234 0.16 -0.558 0.090
BCFH*Follow-Up Yes 0 0.000 . . .
BCFH*Follow-Up No 1 0.000 . . .
BCFH*Follow-Up No 2 0.000 . . .
BCFH*Follow-Up No 0 0.000 . . .
Age Cat*Follow-Up 1 8.5-11 years old -0.099 0.54 -0.418 0.221
Age Cat*Follow-Up 1 >11 years old -0.153 0.48 -0.576 0.270
Age Cat*Follow-Up 1 <8.5 years old 0.000 . . .
Age Cat*Follow-Up 2 8.5-11 years old 0.109 0.64 -0.354 0.572
Age Cat*Follow-Up 2 >11 years old 0.462 0.11 -0.104 1.028
Age Cat*Follow-Up 2 <8.5 years old 0.000 . . .
Age Cat*Follow-Up 0 8.5-11 years old 0.000 . . .
Age Cat*Follow-Up 0 >11 years old 0.000 . . .
Age Cat*Follow-Up 0 <8.5 years old 0.000 . . .
BMI cat* Follow-Up Overweight/Obese 1 0.402 0.04 0.025 0.778
BMI cat* Follow-Up Overweight/Obese 2 -0.418 0.23 -1.097 0.261
BMI cat* Follow-Up Overweight/Obese 0 0.000 . . .
BMI cat* Follow-Up Average 1 0.000 . . .
BMI cat* Follow-Up Average 2 0.000 . . .
BMI cat* Follow-Up Average 0 0.000 . . .
Tan2B*Follow-Up Tanner Stage 2+ 1 0.137 0.51 -0.276 0.551
Tan2B*Follow-Up Tanner Stage 2+ 2 -0.614 0.02 -1.138 -0.090
Tan2B*Follow-Up Tanner Stage 2+ 0 0.000 . . .
Tan2B*Follow-Up Tanner Stage 1 1 0.000 . . .
Tan2B*Follow-Up Tanner Stage 1 2 0.000 . . .
Tan2B*Follow-Up Tanner Stage 1 0 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 2+ Overweight/Obese 1 -0.474 0.05 -0.942 -0.006
Tan2B*BMI*Follow-Up Tanner Stage 2+ Overweight/Obese 2 0.158 0.69 -0.624 0.940
Tan2B*BMI*Follow-Up Tanner Stage 2+ Overweight/Obese 0 -0.354 0.05 -0.713 0.005
Tan2B*BMI*Follow-Up Tanner Stage 2+ Average 1 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 2+ Average 2 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 2+ Average 0 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 1 Overweight/Obese 1 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 1 Overweight/Obese 2 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 1 Overweight/Obese 0 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 1 Average 1 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 1 Average 2 0.000 . . .
Tan2B*BMI*Follow-Up Tanner Stage 1 Average 0 0.000 . . .







Change in 8-OxodG by BCFH Over Follow-Up Stratified by BMI Category
Effect Num DF Den DF F Value Pr > F
BCFH 1 146 2.25 0.14
BMI category 1 146 0.02 0.90
BCFH*BMI category 1 146 0.07 0.79
Follow Up Visit 3 146 1.85 0.14
BCFH*Follow-Up 3 146 2.04 0.11
BMI cat*Follow-Up 3 146 0.06 0.98
BCFH*BMI cat*FollowUp 3 146 0.18 0.91
Average BMI: Overweight/Obese:
Change in 8-OxodG by BCFH Over Follow-Up Stratified by Tan2B
Effect Num DF Den DF F Value Pr > F
BCFH 1 155 2.39 0.12
Tan2B 1 155 1.33 0.25
Follow-Up 3 155 2.75 0.04
BCFH*Tan2B 1 155 0.45 0.50
BCFH*Follow Up 3 155 3.81 0.01
Tan2B*Follow-Up 3 155 0.76 0.52
BCFH*Tan2B*Follow-Up 3 155 1.14 0.34
8-OxodG Type 3 Tests of Fixed Effects
8-OxodG Type 3 Tests of Fixed Effects
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Change in F2-Isoprostane and BCFH Over Follow-Up Stratified by BMI Category
Effect Num DF Den DF F Value Pr > F
BCFH 1 146 0.13 0.72
BMI category 1 146 1.87 0.17
Follow-Up Visit 3 146 2.82 0.04
BCFH*BMI cat 1 146 0.36 0.55
BCFH*Follow-Up 3 146 1.07 0.36
BMI cat*Follow_Up 3 146 3.51 0.02
BCFH*BMI cat*Follow-Up 3 146 2.53 0.06
Average BMI Overweight/Obese:
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Chapter IV: Conclusions and Future Directions 
 
 
The studies presented here, examining the role of oxidative stress and breast cancer risk in adult women 
and adolescent girls, aimed to achieve three major objectives.  First, to ascertain if urinary biomarkers of 
oxidative stress can be used prospectively to identify women at risk of breast cancer.  In this effort, 
presented in Chapter II, we largely succeeded.  We found, contrary to our hypothesis, that high levels of 
oxidative stress were actually associated with reduced risk of breast cancer and it was women with low 
levels who were at increased risk. This result was strongest in women under 50 with an average BMI, 
women who, other than their family history, would otherwise be considered at low risk for breast cancer.  
Even after knowing information on BRCA1/2 mutation status, time between menarche and 
parity/menopause, age and menopausal status, adding information on a women’s relative level of 8-
OxodG significantly improved prediction of breast cancer risk.   
 
These results can help tailor screening and prevention efforts to women most at risk.  Limiting screening 
will be of value to all women.  High risk women will benefit from screening and low risk women can 
avoid the harmful effects of unnecessary screening that can lead to overdiagnosis. 
 
Our efforts in Chapter III towards this end were not as fruitful.  Overall we found no statistically 
significant difference in oxidative stress levels between girls with and without a family history of breast 
cancer.  This is unfortunate because there are very few known risk factors for breast cancer that are 
evident during adolescence.  Identifying easily measured and reliable risk factors at a young age could be 
of great public health benefit if could lead to interventions that could prevent cancer initiation or 






This brings us to our second objective: To better understand the mechanisms leading to carcinogenesis by 
determining if established risk factors for breast cancer are potentially mediated by oxidative stress in 
order to identify avenues to reduce risk among women with a family history of breast cancer.  In Chapter 
II our negative association between oxidative stress and breast cancer risk caused us to rethink the 
assumption that high levels of oxidative stress are always advancing cancer risk.  Redox reactions control 
some of the most fundamental elements of homeostasis and years of evolution have created a very tightly 
regulated cellular environment that balances ROS, DNA repair, cell cycle control, antioxidant and pro-
oxidant responses.  It is not as simple as oxidative stress—bad, antioxidants—good.   
 
Recent studies have demonstrated that oxidative stress is a critical trigger of DNA repair and cell cycle 
checkpoint controls.  We believe our results demonstrate that high levels of oxidative stress after tumor 
initiation may block tumor promotion by triggering senescence or apoptosis.  Future laboratory or animal 
studies should focus on understanding how/if cells control ROS in response to carcinogenic insults, how 
that response alters expression or activity of tumor suppressor genes, including p53 and BRCA1/2, and if 
that response alters growth of early neoplasms. Within the BCFR itself this study could be expanded to 
the other sites and available blood samples could be utilized to examine if mutations, SNPs or 
methylation differences in antioxidant genes are driving oxidative stress levels down in our cases.  
 
Other labs have found that BRCA1 is important in activating anti-oxidant responses.  We only had 17 
BRCA1/2 mutation positive women in our cohort and all but 4 were cases so we lacked sufficient power 
in our study to examine the relationship between oxidative stress, BRCA1/2 status and cancer risk.    
Future population studies could replicate our investigation in a larger population of BRCA1/2 carriers.     
 
As our results seem to be limited to women with an average BMI and in women under 50, the roles of 
ovarian and adipose hormones should also be considered.  The significant interaction between age at 




The relationship between age at menarche and oxidative stress is interesting because urinary biomarkers 
are short-term markers of oxidative stress.  Here we found a significant relationship between case status, 
F2-Isoprostane levels, and an event that occurred years if not decades prior to urine donation. We also 
observed that parous women had significantly lower levels of oxidative stress (Supplemental Table 5a), 
again a past event.  This makes us wonder is there an underlying mechanism regulating both menarche 
and oxidative stress? Do hormones change antioxidant response?  Do parity induced changes to breast 
tissue alter cellular metabolism and reduce oxidative stress?  
 
While we found that oxidative stress levels may contribute to breast cancer risk, we found very few 
modifiable factors that altered oxidative stress levels. Other than hours of moderate exercise and smoking, 
only age and hormone/parity related variables (Supplemental Table 5) were significantly associated with 
oxidative stress and largely only with F2-Isoprostane levels.  This is not surprising given the critical role 
of redox reactions in maintaining normal cell functions.   It seems likely that the observed differences in 
oxidative stress between cases and controls are driven by genetics and not environmental exposures. 
 
Finally, our third aim was to examine how pubertal development, a critical window of susceptibility, and 
a family history of breast cancer modify oxidative stress levels.  As this was the first study to examine 
how oxidative stress levels vary during puberty in girls at high risk of breast cancer, all our significant 
findings are an important contribution to understanding adolescent health.   Results for the LEGACY 
study detailed in Chapter III demonstrated that F2-Isoprostane levels increased as girls began breast 
development at Tanner breast stage 2. Furthermore, F2-Isoprostane levels also increased with BMI but 
only in prepubescent girls.  Oxidative stress has been associated with obesity in adolescent populations 
(261) but whether or not pubertal hormones modify this association is not known.  Estrogen has been 
reported be both an antioxidant acting through the ER on specific cells and target genes (48, 192, 264, 
282) and a source of oxidative stress via its metabolism by Cyp450 enzymes or lactoperoxidase (41, 42, 




estrogen on whole body oxidative stress levels needs clarification. The roles of progesterone and insulin 
on oxidative stress levels individually and in concert with estrogen also needs further research.  Future 
studies, which could be done within this same cohort using collected blood samples, should examine the 
role pubertal hormones play in modifying oxidative stress levels during pubertal development with 
special attention paid to how BMI may modify any relationship. 
 
While we were able to show 8-OxodG levels rose significantly over follow-up in BCFR+ girls, we were 
limited in power to fully adjust our longitudinal analysis for all relevant covariates.  Expanding this study 
to the full five year follow-up period will increase the power to model change in oxidative stress levels 
over time adjusting for differences age, race, BMI, and markers of pubertal development. 
 
We compared oxidative stress levels between the women in the BCFR study and the girls in the 
LEGACY study.  We found that girls had significant higher levels of 8-OxodG than the adult women but 
that F2-Isoprostane levels were similar (Table 1). 8-OxodG levels in adult women may be lower if DNA 
repair efficiency declines with age or if nuclear sources of ROS are higher in childhood than adulthood.  
It would be interesting to know how oxidative stress levels vary throughout the entire lifecourse of an 
individual and if this is related to breast cancer risk. There was some evidence in our adult study that 
hormone-related life events such as menarche, parity, breastfeeding, and menopause can alter ROS levels.  
It may be that women at high risk of breast cancer have an impaired response to such events and that high 
levels associated with breast cancer risk in adolescence are reduced in adulthood allowing for cancer 
progression.  However, these results comparing oxidative stress levels between the two studies, should be 
interpreted with extreme caution.  ELISA based methods are best for determining relative levels of 
oxidative stress and are not reliable for determining absolute levels.  It may not be appropriate to compare 
results across studies, especially given the high variability of repeated measures between ELISA plates 
and different SPE. This limits our ability to put our results in context with other studies that have looked 




BCFR are different than in the LEGACY study or equivalent to averages found in other populations.  Our 
results should be validated using more quantitative methods such as HLPC GC/MS. 
 
There is still much to be understood about temporal and spatial contributions to urinary levels of 
oxidative stress biomarkers.  It is not known how oxidative stress levels vary between organs or 
how much influence a single tissue type or organ can have on levels of “whole body” oxidative 
stress.  It is not completely understood why one biomarker changes in response to exposures 
while the others don’t, or what influences levels of ROS in cytosol compared to the nucleus.  8-
OxodG levels are reported to be a result of DNA repair of nuclear DNA and oxidative stress on 
the nucleotide pool. The relative contribution of these sources to overall 8-OxodG levels is 





The duality of oxidative stress in cancer initiation/progression, combined with the reportedly high intra-
person variation of the biomarker levels and variety of sources of oxidative stress, limits the utility of 8-
OxodG or Isoprostane as practical screening biomarkers.  Nevertheless, results of our ROC comparisons 
demonstrate the potential value of characterizing the mechanisms underlying oxidative stress levels in 
identifying those at risk for breast cancer in the short term.  In our study population of women with a 
Wilcoxon Mann 
Whitney Test
N Mean N Mean Two-Sided Pr > |Z|
8-OxodG (nmol/L*SG) 219 85.2 158 122 <.0001
F2-Isoprostane (nmol/L*SG) 219 11.2 158 8.10 0.47
Raw 8-OxodG (nmol/L) 219 82.9 158 115 <.0001
Raw F2-Isoprostane (nmol/L) 219 13.7 158 8.55 0.38
Specific Gravity 219 1.018 158 1.021 <.0001
Levine-Fahy SG Ratio 219 1.336 158 1.137 0.56
Creatinine (mmol/L) 219 9.32 158 11.3 <.0001
BCFR Adults LEGACY Girls
Variable




family history of breast cancer, the oxidative stress biomarkers were most significant in younger women 
who were not obese or overweight.  These are the women who have the least clarity on mammographic 
screening decisions.  A biomarker that could improve their risk assessment would be invaluable.  The 
identification of an underlying mechanism which reduced levels of oxidative stress while increasing 
cancer risk-especially one that may be modifiable-would be a major achievement. 
 
Similarly, for young girls with a family history of breast cancer, clarity on what specifically is 
contributing to their risk would be a major benefit to them personally and to public health.  If the years 
before parity are indeed a critical window for reducing breast cancer risk (11), then understanding how 
specific differences in breast development and oxidative stress in high risk girls contribute to mutagenesis 
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